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Abstract 
 
The Matrix Metalloproteinase (MMP) family are conventionally considered as 
key enzymes contributing to cancer-cell invasion through remodelling of the 
extracellular matrix (ECM). In contrast, MMP-8 has been shown to exert an 
anti-cancer role. In normal breast, MMP-8 expression is restricted to tumour 
suppressor myoepithelial cells (MECs), which form the interface between 
glandular epithelium and the ECM. In ductal carcinoma in situ (DCIS), MECs 
are altered; a consistent change is up-regulation of αvβ6-integrin, which is 
associated with loss of suppressor activity. Preliminary observations 
indicated that there is also loss of MMP-8 expression in DCIS-MEC. The aim 
of this study is to investigate the impact of loss of MEC derived MMP-8 on 
MEC function and how this might modulate tumour progression. 
To generate a model of DCIS MEC, an αvβ6 over-expressing cell line (Myo-
β6) was generated from normal MECs (Myo-Puro). These cells were found to 
lose MMP-8 expression. To dissect gain-of-function effect, MMP-8 was re-
introduced into Myo-β6 (MMP-8 WT). A proteolytic inactive form of MMP-8 
was used to dissect the dependence of function on proteolysis.  
In-vitro analysis demonstrated that MMP-8 WT but not inactive MMP-8 
significantly up-regulates MEC adhesion (p=0.0001) and spread (p=0.0003) 
on ECM, but reduces migration towards ECM proteins including Collagen-I 
(p=0.006) and fibronectin (p=0.01). Furthermore MMP-8 WT results in 
reduced numbers of filopodia/retraction fibres (p=0.01) and reduced 
protrusion length (p=0.0001) on MEC cell surface. MMP-8 promotes the 
localisation of α6β4-integrin to hemidesmosomal adhesive structures 
(p=0.003), and inhibits MEC gelatinase (p=0.002) and TGF-β activity. 
Conversely, knock-down of endogenous MMP-8 in Myo-Puro MECs 
promotes migration and filopodia/retraction fibre formation (p=0.05), 
increases gelatinase activity (p=0.007) and TGF-β signalling. 
To analyse the paracrine effect of MEC-derived MMP-8 on breast cancer cell 
invasion, MDA MB 231 or SUM159 cells were co-cultured with modified Myo-
β6 cells in Boyden chamber invasion assays. A significant reduction in breast 
cancer cell invasion was observed only in the presence of MMP-8 WT 
(p=0.004) but not with inactive MMP-8. In contrast, MMP-8 knock-down in 
Myo-Puro MECs significantly enhanced breast cancer cell invasion 
(p=0.001). In order to recapitulate the DCIS stromal micro-ecology, 3D-
organotypic cultures were constructed. In these systems there was a 
significant reduction in invasion only in the presence of MMP-8 WT MECs 
(p<0.001). Conversely, in the absence of Myo-Puro-derived MMP-8 breast 
cancer cell invasion was significantly up-regulated (p=0.007).    
These results suggest that MMP-8 does contribute to MEC tumour 
suppressor function via mechanisms dependent upon its proteolytic activity. 
These data support the hypothesis that loss of MMP-8 may contribute to the 
progression of DCIS to invasive disease.  
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1 Introduction 
 
1.1 Breast Cancer Incidence 
 
1.1.1 Incidence of Ductal Carcinoma in situ 
 
The frequency of detection of in situ breast cancer has increased 
dramatically in the last two decades (Figure 1-1) (CRUK Statistics 2010). 
This increase is concomitant with the advent of the National Health Service 
Breast Screening Programme (NHSBSP) which was introduced in 1988. 
According to NHSBSP, women aged between 50 and 70 are invited for 
mammographic screening every three years. A recent trial is ongoing to 
extend breast screening to 47-73 age limits (CRUK Statistics 2010).  
 
Figure 1-1: In situ breast carcinoma age-standardised incidence rates 
between 1979 and 2010. The rates were substantially increased after 
NHSBSP introduced in 1988-1989 financial year (Figure extracted from 
www.cancerresearchuk.org).    
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Ductal carcinoma in situ (DCIS) forms the majority of in situ breast carcinoma 
cases with 90% of detected in situ breast carcinomas diagnosed as DCIS  
and 10% as lobular carcinoma in situ (LCIS). The incidence of DCIS is higher 
in women aged 50-69 which also corresponds to the screening strategy 
(Figure 1-2) (CRUK Statistics 2010).  
 
Figure 1-2: Distribution of average number of new cases per year and 
incidence of in situ breast cancer according to age group and 
histological type (2008-2010). The highest incidence rate of in situ breast 
carcinoma is in women in 50s and 60s. DCIS has an approximately 9 times 
higher incidence rate than that of LCIS (Figure extracted from 
www.cancerresearchuk.org).  
   
Women diagnosed with in situ breast cancer have twice the risk of 
developing invasive breast cancer when compared to women with no in situ 
breast cancer history [1]. In 2010 83% of total diagnosed in situ breast 
cancer cases and 20% (3100 cases) of total breast cancer cases in women 
were DCIS (CRUK Statistics 2010).    
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1.1.2 Invasive Breast Carcinoma Incidence 
 
Breast cancer is the most common cancer in females in the UK, with 31% of 
newly diagnosed cancer cases in women being breast cancer (CRUK 
Statistics 2010). The lifetime risk for a woman to develop breast cancer in the 
UK is 1 in 8 (CRUK Statistics 2010). It is the third most common cause of 
cancer related deaths in UK and second most common cause of death from 
cancer in women, responsible for 15% of cancer related deaths for females 
in UK (CRUK Statistics 2010).  
 
The incidence rate of invasive breast cancer, similar to in situ disease, was 
substantially affected by  the introduction of the NHSBSP and due to the pool 
of undetected breast cancer cases, increased more rapidly  until 1992 then 
showed a slight increase until 2010 (Figure 1-3) (CRUK Statistics 2010).   
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Figure 1-3: Invasive breast carcinoma age-standardized incidence rates 
between 1975 and 2010. The rates increased between 1975 and 1992 then 
slightly dropped and remained relatively stable until 2010 when compared to 
the increase between 1980 and 1992 (Figure extracted from 
www.cancerresearchuk.org).  
 
Nearly half (48%) of diagnosed breast cancer cases occur in women aged 
50-70 years. Despite the fact that breast cancer is rare in women under or in 
their early 20s, it is the most common cancer in females under the age of 39 
accounting for 1,350 new cases per year (CRUK Statistics 2010).    
 
Interestingly, breast cancer incidence is higher in economically developed 
countries [2, 3] such as Western Europe. Risk factors for development of 
breast cancer include late first pregnancy, late menopause, high breast 
density, alcohol consumption and taking hormone replacement therapy 
(CRUK Statistics 2010). 
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There is an overall decrease in breast cancer mortality rates when compared 
to the early 1970s. This has been attributed to facts such as improvements in 
screening, surgical techniques, radiotherapy and adjuvant therapies 
including tamoxifen [4, 5].  
  
1.2 Ductal Carcinoma in situ 
 
1.2.1 Structure of Breast  
 
Breast tissue is composed of a branching ductal network which terminates in  
functional acini called terminal duct lobular units (TDLU) [6]. These structures 
are made up of an epithelial-bilayer: an inner columnar luminal epithelial cell 
(LEC) compartment and outer myoepithelial cell (MEC) compartment (Figure 
1-4) [6]. Physiologically these cell groups are responsible for milk production 
and ejection, respectively [7-9]. During lactation, LECs synthesise milk 
components, which are collected in the duct lumen as a result of MEC 
contraction, and transported to the nipple [7-9]. In resting breast these 
compartments are represented in approximately the same cell number, 
however the proliferation of the luminal group is dependent on hormonal 
activity, and fluctuates with menstrual cycle and expands with pregnancy [10, 
11]. This functional bilayer epithelium is embedded in stroma which consists 
of adipose and fibrous tissue in varying proportions [8, 12-14]. The MEC 
organisation differs between ducts and lobules; in excretory ducts, MEC are 
arranged in an almost continuous layer around LECs but form more of a 
basket like structure in lobules [8]. MECs are separated from the connective 
tissue by the underlying basement membrane (BM) [15]. BM is produced 
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mainly by MECs and consists of Collagen-IV, fibronectin, laminin, Nidogen, 
glycosaminoglycans and proteoglycans. Receptors of BM components, 
especially cell adhesion molecules such as integrins, present in MECs, are 
responsible for interaction with the BM and neighbouring cells [8, 16]. 
 
 
 
Figure 1-4: Schematic of the structure of normal breast. Human breast 
comprises a branching ductal network terminating in TDLU. These functional 
units are lined with a dual epithelial layer consisting of LECs and MECs. 
Once milk is produced by LECs it is transferred by the contractile action of 
MEC into interconnecting ducts, lactiferous sinuses and ultimately to the 
nipple. Figure taken and adapted from Allred et al 2010 and Cichon et al 
2010 [7, 17]. 
 
DCIS is the proliferation of malignant cells enclosed by the surrounding MEC 
layer and BM without stromal invasion (Figure 1-5) [18, 19]. It represents the 
earliest definable stage of breast cancer and is the non-obligate precursor to 
invasive disease. Therefore, DCIS is regarded as the ideal target for breast 
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cancer treatment [18, 19]. Although DCIS was diagnosed very rarely until 
1980, as a result of widespread mammographic screening, 20% of breast 
cancer cases detected today are classified as DCIS (CRUK Statistics 2010) 
[20]. It is difficult to study the natural history of DCIS, however, it is reported 
that 50% of untreated cases may progress to invasive disease and that the 
time to progression is variable up to 4 decades [19, 21, 22]. There is no 
single molecular marker identified hitherto that predicts in situ to invasive 
disease progression [23, 24]. To evaluate whether the tumour is likely to 
progress into invasive cancer is the main challenge in DCIS treatment [23, 
24]. 
 
 
 
Figure 1-5: Schematic of DCIS versus invasive ductal carcinoma. In 
DCIS the proliferative tumour cells fill the duct lumen, retained by the BM and 
MEC layer. During invasion MEC-BM integrity is lost and tumour cells invade 
through disrupted foci. Figure taken and adapted from Cichon et al 2010 [17].     
 
Altered MEC 
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1.2.2 DCIS Classification 
 
DCIS shows heterogeneity in both morphology and cell biology as evidenced 
by proliferation index, signalling pathway activation and cellular composition, 
and reflected in clinical behaviour [19]. Traditionally DCIS classification is 
based on nuclear morphology, growth rate, cytonuclear differentiation and 
the presence or absence of necrosis [19]. The Van Nuys classification 
system uses nuclear grade and necrosis. This approach classifies DCIS into 
three subgroups: non-high-grade without necrosis, non-high-grade with 
necrosis and high-grade with or without necrosis [19]. Another system is 
recommended by National Coordinating Group for Breast Screening 
Pathology in the UK. This system is based on cytological and architectural 
features and divides DCIS into low, intermediate or high grade DCIS [19]. 
The first group contains small regular cells and shows cribriform or 
micropapillary patterns. High grade DCIS is often called comedo DCIS and in 
contrast to low grade disease the malignant cells show marked 
pleomorphism with mitotic figures and is frequently characterised by a central 
mass of necrotic tumour cells. Intermediate DCIS exhibits nuclear 
characteristics between these groups [19, 25]  
 
With regard to the heterogeneous biology of DCIS, histological classifications 
present an over simplified approach and provide limited information about 
the complex structure and outcome of the disease. The classification based 
on nuclear morphology divides DCIS into three groups which are low-, 
intermediate-, and high grade DCIS. This system provides a degree of 
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predictive value, in that high-grade DCIS has higher risk of recurrence but 
the system has limited reproducibility due to subjective interpretation [19, 26]. 
 
Additional classification methods may assist better treatment choice. Gene 
expression profiling can also categorize in situ disease as well, intermediate 
and poorly differentiated DCIS [19].  
 
Differences observed between well and poorly differentiated DCIS includes 
genes associated to metabolism and cell communication [21]. The cases 
which carry high diversity also show high levels of p53 mutation [27, 28]. 
High expression of anti-apoptotic protein B-cell lymphoma (Bcl) -2 and 
oestrogen receptor (ER) positivity characterise low-grade (well differentiated) 
DCIS [28].  
 
Over recent years there have been considerable advances in the 
classification of invasive breast cancer and this is partly reflected in DCIS. In 
invasive ductal carcinoma (IDC) the classification, based on parameters such 
as morphology, histologic grade, expression of steroid and growth factor 
receptors, oestrogen inducible genes and mutation in the p53 gene, remains 
over simplified with respect to the repeatedly observed great variability in 
behaviour between cases [29-31].  Gene expression arrays have identified 
gene signatures that classify breast cancer into 5 main groups: Luminal A, 
Luminal B, HER-2 amplified, Basal-like and normal-like [29]. Whilst identified 
through microarray analysis, considerable progress has been made in 
generating surrogate immunohistochemical signatures [29].  
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Luminal tumours express luminal cytokeratins (CK) -8 and CK-18 and are 
characterised by ER expression. This group can be further divided into at 
least two subtypes according to ER and progesterone receptor (PR) 
expression levels with Luminal A group (ER+/PR+/ Human epithelial growth 
factor receptor- HER-2-) having higher ER and PR levels than Luminal B 
group (ER+/PR+or-/HER-2-). In comparison to the other groups Luminal 
tumours show better prognosis and response to therapies, particularly 
Luminal A [29-31]. 
  
HER-2 amplified, Basal-like and normal-like groups are characterised by 
down regulation of ER and most of the ER related genes. HER-2+ tumours 
are characterised by amplification of HER-2 and several genes related to 
HER-2 on chromosome 17 such as Growth factor receptor-bound protein 
(GRB) -7. This group also frequently shows p53 mutation and are identified 
on immunohistochemistry (IHC) as ER-, PR-, HER-2+ [29-31]. The normal-
like breast cancers show high expression of genes related to MEC and 
adipose cells and low expression of the genes related to LECs. However, 
they have been more difficult to identify as a distinct entity in further studies 
and it is unclear if this is a true subgroup [29-31].  
 
Basal-like tumours express CK-5, 14, 17 and laminin, which are 
characteristics of MECs. They generally lack ER, PR and HER-2 expression 
and so frequently are referred as Triple Negative tumours. Whilst there is 
considerable overlap between Basal-like and Triple Negative tumours, they 
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are not in fact identical [29-31]. It has been suggested that Basal-like 
tumours are best characterised on 5 markers consisting of ER, PR, HER-2, 
epidermal growth factor receptor (EGFR) and CK5/6. Basal-like tumours are 
negative for ER, PR, HER-2 and positive for EGFR and CK5/6, whilst ‘triple 
negative’ may be classified according to negativity for all 5 markers [32] . The 
Basal-like group is also associated with breast cancer gene (BRCA)-1 
mutation. This mutation is linked with high proliferation, p53 mutation and 
often lack of HER-2 expression. Basal like tumours have the highest 
frequency of distant metastasis and shortest survival and relapse free 
survival time [29-31]. This classification based on molecular signatures 
indicates that the transcriptional programme and genetic alterations have 
significant impact on disease prognosis [29-31]. 
 
Further comparative use of histological markers and gene expression 
analysis between DCIS and IDC demonstrate that DCIS also can be 
categorised as Basal-like, HER-2+ and luminal type tumours in a similar 
fashion to invasive disease [21, 28, 33, 34]. Hannemann and colleagues 
employed microarray analysis to compare gene expression profile of 40 in 
situ and 40 invasive breast cancers. By performing two-dimensional 
hierarchical clustering they showed that the basal-like, HER-2 type and 
luminal type can also be observed in DCIS [21].  
 
Cheang and colleagues used a panel of 5 markers similarly classified DCIS 
[35]. However, differences in clinical behaviour observed within the same 
groups based on these markers suggest that this panel is too limited. Clark 
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and co-workers evaluated a greater number of biomarkers, including ER, PR, 
HER-2, CK5/6, CK14, topoisomerase IIα, β4 integrin, β6 integrin, Bcl-2, 
maspin and p53, in a large cohort  of 188 DCIS cases [26]. The most 
significant variability in gene expression was seen in maspin, p53, EGFR and 
topoisomerase IIα. A strong correlation was observed between ER and PR 
whereas there was an inverse correlation with HER-2. The basal markers 
CK5/6 and CK14 were positive in approximately 10% of the cohort, indicating 
the rare existence of the basal type in DCIS. Bcl-2 expression is also 
associated with well differentiated DCIS and good prognosis. It is noteworthy 
that Bcl-2 is also identified as an independent predictive tool for good 
prognosis in IDC [26, 33, 36]. A cluster analysis developed based on these 
markers identified 4 subtypes of DCIS (Figure 1-6). 
  
 
Figure 1-6: The classification of DCIS according to molecular markers. 
This classification is indicating that the subgroups identified for IDC already 
exist in DCIS. TN subtype contains tumours with basal-like features. Figure 
adapted from Clark et al 2010 [26].  
 
DCIS
ER- PR-
Bcl-2-
Her-2+ Her-2-
ER+ PR+
Her-2-
Bcl-2- Bcl-2+
HER-2 
amplified
TN Luminal-A Luminal-A
  
30 
 
Although the molecular subgroups identified for IDC can be detected at the 
DCIS stage, the relative frequency of each subtype is different; for example 
in DCIS, the basal subtype is rarely found (10% of the cohort accounts for 
approximately 18% of invasive carcinoma) [26]. Importantly, HER-2 positivity 
shows a higher frequency in DCIS than in IDC [37, 38]. HER-2 amplification 
and over-expression was reported for 50% of DCIS cases and is considered 
as a particular characteristic of DCIS [38, 39]. In fact HER-2 over-expression 
in MCF10A cells results in the generation of DCIS-like structures, which are 
composed of proliferating cells filling the lumen encapsulated by an intact 
Collagen-IV layer with no invasion into BM, in 3D culture systems [40], and 
based on these findings the authors suggest that HER-2 amplification is 
considered an early event in breast cancer development [21]. However only 
~20% of invasive breast cancers show HER-2 amplification, so this cannot 
be essential for breast cancer development.  
  
The different frequencies of HER-2 positivity in DCIS and IDC lead to two 
hypotheses; HER-2 amplification might be lost during the DCIS-IDC switch, 
or HER-2 positive DCIS cases may not develop into invasive disease. To 
investigate these possibilities Park and colleagues compared HER-2 levels 
between pure DCIS cases and DCIS associated with IDC, furthermore they 
compared the intraductal and invasive components of the same IDC case. 
They showed that HER-2 amplification is significantly more frequently 
detected in DCIS and, interestingly the intraductal and invasive component of 
the same case is similar in terms of HER-2 amplification which shows that 
progression to invasive disease is not a function of a change (loss) of HER-2 
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amplification. Taking this result into consideration it can be concluded that a 
clonal expansion model which supports the differential progression of DCIS 
and IDC in early stages of breast cancer would be a better explanation of the 
discrepancy observed in HER-2 status [37]. 
 
1.2.3 Pathways of Progression of DCIS 
 
The first progression model of breast cancer suggested that breast tumours 
would originate either from ducts or lobules and therefore were named after 
the location from which they arose; ductal carcinoma or lobular carcinoma, 
respectively. However Wellings and colleagues showed that breast cancer is 
mostly generated from the TDLU [41]. The demonstration of a single 
anatomical site of origin for breast carcinoma was followed by the proposition 
of  a linear evolutionary pathway for breast cancer progression through which 
TDLUs transform into flat epithelial atypia (FEA) that give rise to atypical 
ductal hyperplasia (ADH) that develop into low grade DCIS (Figure 1-7). It 
was suggested that low grade DCIS can progress into high grade DCIS by 
accumulation of genetic and epigenetic alterations and therefore gain the 
ability to invade [41].  
 
Lobular breast neoplasia differs from ductal types based on cell morphology. 
Lobular cancer consists of small, non-polarised, discohesive low-cuboidal 
luminal cells whereas the ductal type is composed of larger mostly polarised 
cells showing characteristics of low columnar cells of the duct [41, 42]. 
Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) are 
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non-obligate (risk indicators) of ILC, the equivalent ductal lesions  FEA, ADH 
and DCIS being non-obligate precursors for IDC [41].  
 
Figure 1-7: The linear model proposed for breast cancer evolution 
based on histomorphological characteristic. This model is now regarded 
as an oversimplified approach. Figure adapted from Simpson, 2005 and 
Sgroi, 2010 [41, 43] 
 
It is now recognised that the linear model of breast cancer progression 
oversimplifies the extensive genotypic and phenotypic differences in breast 
cancer. An accumulating body of evidence shows that ER+ and ER- breast 
cancers are distinct diseases which follow two genetically distinct molecular 
routes; those leading to the development of low grade (well differentiated) 
and high grade (poorly differentiated) group of carcinomas, respectively [29, 
30]. This underlines the critical role of expression of ER and activation of the 
ER pathway [29, 30].  In the ER+ group the variety and number of genetic 
abnormalities in cancer cells are associated with the histological grade (the 
degree of differentiation). The ER- group is a much more heterogenous 
group of lesions including the Basal and HER-2 amplified tumours.  
 
One of the main findings supporting this proposal of two distinct disease 
pathways is the demonstration of the recurrent (> 80% of cases) loss of long 
arm of chromosome 16 (16q) in low grade DCIS and low grade invasive 
cancers whereas in high grade cancers, despite having a more complex 
genome, 16q loss is infrequent (<30%). Therefore, it was hypothesised that 
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the vast majority of high grade disease does not originate from low grade 
lesions since the regaining of a lost region of genomic material is an unlikely 
event. In fact, Balleine and colleagues [44] employed microarray based gene 
expression profiling and array based genomic hybridization techniques to 
establish the gene expression profile of DCIS associated with low grade and 
high grade invasive breast carcinoma and the DCIS classification generated  
relates to the coexisting invasive cancer grade. This classification clusters 
DCIS into low molecular grade and high molecular grade (rather than stage), 
again suggesting these are distinct molecular entities [45, 46].  
 
Buerger and colleagues took a comparative genomic hybridization (CGH) 
approach in order to investigate specific genomic alterations in DCIS (pure or 
associated with invasion). 38 cases were classified morphologically as well, 
intermediate or poorly differentiated then microdissected and CGH was 
performed. A number of aberrations were observed in almost all 
chromosomes. They found that 16q loss is seen commonly in well and 
intermediate grade DCIS. Intermediate grade DCIS frequently displayed 1q 
gain and 11q loss. The average number of genetic imbalances (overall gains 
and losses) increased from well to poorly differentiated DCIS. The poorly 
differentiated DCIS showed frequent 1q gain and amplification of 11q, and 
17q where BRCA1 gene is located. Although it has greater number of 
genetic imbalances when compared to well differentiated DCIS; 16q loss was 
very rarely detected. Interestingly, 11q amplification was restricted to DCIS 
associated with invasion when compared to pure DCIS.  Furthermore, DCIS 
and the invasive compartment adjacent to DCIS are almost identical in terms 
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of genetic pattern. The multitude of aberrations observed in all cases 
identifies DCIS as a genetically advanced stage of breast cancer progression 
and a direct precursor of IDC [46-48].   
 
Although ADH and low grade DCIS are immunophenotypically and 
genomically similar diseases, the risk of low grade DCIS to progress into 
invasive cancer is greater than the risk of ADH [41, 43].   
 
Since the molecular subtypes determined for invasive breast cancer are 
shown to be already definable at the DCIS stage; the existence of distinct 
evolutionary paths for each subtype from early stages of breast cancer 
development can be argued. The potential ability to invade is determined 
already at the DCIS stage mostly through specific genetic alterations, and is 
preserved through breast cancer evolution [28, 49-51]  
 
In contrast, Allred and co-workers reported that different DCIS subtypes can 
coexist in the same case and that the degree of diversity within cases is 
correlated with p53 mutation which leads to genetic instability [28]. They 
speculate that this implies that high grade DCIS can develop from low grade 
DCIS.  
 
Taking into consideration that low grade breast cancers are strongly 
associated with ER positivity and ER expression is one of the features that is 
demonstrated to be highly preserved through breast cancer progression [52]; 
Natrajan et al hypothesised that if  low grade tumours can develop into 
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higher grade than this progression should result in ER+ high grade tumours 
encompassing 16q loss [53]. Therefore they compared changes in 16q by 
microarray based CGH (aCGH) in fresh-frozen high versus low grade 
tumours and grouped cases according to degree of 16 q loss: 16q whole lost 
(16qWL), 16q partial loss (16qPL) and no loss in 16q (16qNL). Interestingly, 
this revealed a pattern associated with molecular breast cancer subgroups. 
Tumours harbouring 16qWL strongly associated with ER+ luminal 
phenotype, tumours with16qPL associated with Basal-like phenotype and 
16qNL associated with HER-2 amplified phenotype. They found that nearly 
30% of ER+ high grade tumours have 16qWL, which indicates that 
upgrading from low to high grade occurs uncommonly and that it occurs 
preferentially in tumours with the luminal phenotype. Furthermore overall 
genetic instability was higher in ER+ high grade tumours with 16qWL, when 
compared to low grade tumours with 16qWL. The authors suggested that 
tolerance to genetic instability, such as displaying homologous recombination 
DNA replication defects, which is rarely reported in low grade tumours, can 
drive progression from low to high grade [53]. The finding of relatively more 
common 16q loss in high grade luminal type tumours in comparison to low 
grade tumours may indicate that low grade precursors can develop into high 
grade luminal subtype cancer [53]. 
 
To conclude pre-invasive stages of breast cancer are non-obligate 
precursors of invasive breast carcinoma and they progress into grade 
matched invasive disease. The latter observation is translated into an 
alternative progression model for breast cancer in which low and high grade 
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cancers follow two distinct evolutionary routes, though there is some 
evidence to indicate that in some circumstances low grade may progress to 
high grade (Figure 1-8).  
 
 
Figure 1-8: Postulated lines of progression of breast cancer. ER+ low 
grade breast neoplasia family: ER+ PR+ HER-2-, lack basal markers, carry 
diploid or near diploid karyotypes, and show 16q deletion and 1q and 16p 
gains. High grade breast neoplasia family: ER+/- PR+/-, HER-2 amplification, 
expression of basal markers and carry a complex karyotype, 11q and 17q 
gain. Figure adapted from Simpson, 2005 and Sgroi, 2010 [41, 43] 
 
1.2.4 Molecular Factors Determining The Transition of DCIS to 
Invasive Disease 
 
Phenotypic, gene expression and genomic studies have shown that; when 
matched by histological grade and ER expression, high grade DCIS and high 
grade invasive breast cancer show similar profiles [49, 54, 55]. Interestingly, 
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when focused on breast tumour cells, stage specific signatures that could be 
used as a marker for invasive disease progression could not be identified 
[49, 54, 55]. Ma and colleagues integrated laser capture micro dissection 
with genome wide DNA microarray analysis to identify genes differentially 
expressed at different stages of breast cancer progression [49]. They 
revealed that the pre-invasive and invasive breast cancer cells are almost 
identical at transcriptome level. Moreover the gene expression signatures 
from different stages in the same sample are more similar than the matched 
stage from other samples. When gene expression was examined by a 
function of tumour stage (ADH, DCIS or IDC) and cluster analysis was done, 
intriguingly, a cluster pattern corresponding to tumour grade rather than 
stage was revealed; low grade and high grade tumours show reciprocal gene 
expression signatures and intermediate grade tumours exhibit hybrid 
patterns of high and low grade clusters. This overlap of gene expression 
patterns in intermediate grade might again indicate a link of progression from 
low to high grade. To analyse whether there is a difference in gene 
expression that contributes to the transition of DCIS to IDC; expression 
levels of a test gene set was analysed in DCIS versus IDC. They identified a 
set of consistently up-regulated genes in a set of high grade IDC compared 
to its DCIS conponent. These were genes involved in cell cycle, centrosomal 
function and DNA repair, and implicate these as playing a role in the 
progression of high grade disease [49].  
 
Similarly Schuetz and colleagues [56] investigated the gene expression 
profile of case matched DCIS and IDC samples using laser capture 
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microdissection and affymetrix oligonucleotide microarray analysis.  In 
keeping with previous studies they found that matched DCIS and IDC from 
the same patient cluster more closely than grade matched lesions from 
different patients. They also revealed a group of differently expressed genes 
between consecutive stages. The majority of these genes are involved in 
cell-cell and cell-microenvironment interaction, for example matrix 
metalloproteinase (MMP) -11 was found to be up-regulated and BP180 
(Bullous pemphigoid antigen -BPAG -1), a component of hemidesmosomes, 
was shown to be down-regulated in IDC.    
 
Recently it was shown that p16+, cyclo-oxygenase (COX) -2+ and Ki67+ 
(triple positive) DCIS cases have a higher risk of development of subsequent 
invasive cancer than p16-, COX-2- and Ki67- cases [57]. 
 
To conclude, whilst in a subset of high grade disease, there appears to be 
changes in cell cycle related genes, in the majority of cases, most of the 
genetic aberrations of invasive breast cancer are already present in DCIS 
[41, 45].  
 
1.2.5 Role of Microenvironment  
 
The great similarity shared between DCIS and invasive tumour cells, and the 
association of cancer invasion with loss of an intact MEC layer and BM, 
prompted the hypothesis that the stromal environment could be a major 
component that triggers invasion, perhaps in combination with a gain of 
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function in malignant cells [56, 58-60]. In fact the heterogeneous nature of 
malignant cells is accompanied by dramatic changes in stroma such as 
activation and proliferation of fibroblasts, infiltration of immune cells, and 
angiogenesis [12, 17, 61, 62]. The accumulation of these changes leads to a 
tumour-favourable microenvironment termed the tumour associated stroma. 
In breast cancer there is a growing body of evidence that this stroma co-
evolves with the tumour epithelium, even before tumour invasion occurs [17, 
18, 51] and cell-cell and cell-matrix interactions between epithelia and stroma 
via paracrine mechanisms play a significant role in progression [51, 63]. This 
cross-talk includes exchange of soluble factors such as chemokines, growth 
factors, and MMPs between tumour and stromal cells at the host tumour 
interface as well as direct cell-matrix interactions [64, 65].  
 
Normal adult tissue stroma compromises both an extracellular matrix (ECM) 
-structural compartment and a cellular compartment, and provides regulatory 
information to maintain normal tissue architecture and homeostasis. In 
contrast, with malignant transformation of epithelial cells this regulatory 
interaction is disturbed [62]. Fibroblasts are a major component of the 
stroma, therefore much of the evidence for tumour related changes in stroma 
is based on work on cancer associated fibroblasts (CAFs) [62]. 
   
A major insight into the role of CAFs came from the classic tissue 
recombination studies described by Olumi et al [66]. They isolated normal 
fibroblasts from prostate and CAFs from prostate tissue containing 
carcinoma. They combined either CAFs or normal fibroblasts with 
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immortalised prostate epithelial cells in Collagen-I and implanted these co-
cultures in male mice. Those recombinants containing CAFs showed greater 
epithelial cell proliferation than those with normal fibroblasts and histological 
analysis revealed features of a poorly differentiated adenocarcinoma, with 
80% epithelium and 20% stroma, in contrast to those recombinants 
containing normal fibroblasts which showed no evidence of tumour 
formation. 
 
This indicates that CAFs significantly differ from their normal counterparts in 
terms of contributing towards cancer progression. Aberrant signalling derived 
from CAFs can interfere with the normal physiological epithelial cell-
microenvironment communication [66].  
 
Another study used a model of chemical carcinogenesis to address whether 
the target of the carcinogen was the epithelial or stromal compartment. 
Mammary epithelium was isolated from rat, cultured in vitro for several 
passages to reduce the risk of fibroblast contamination and exposed to N-
nitrosomethylurea (NMU) (a model carcinogen with a short half life) or 
vehicle control and transplanted into the cleared fat pad of rats (hosts) which 
were treated with NMU or vehicle control. Tumour formation was observed 
only in NMU treated animals regardless of whether the injected epithelial 
cells were treated with NMU or control. Immunohistochemical analysis 
showed that all the neoplastic cells were CK positive and vimentin negative 
which demonstrated that tumours were of epithelial origin. This suggests that 
the host must be exposed to the carcinogen, with exposure of epithelial cells 
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alone being insufficient to generate transformation. A number of studies have 
started to define the characteristics of CAFs that contribute to their tumour 
promoting function. They show altered expression of several growth factors 
such as platelet derived growth factor (PDGF), insulin like growth factors 
(IGF) -I and II, transforming growth factor (TGF-β) -I, hepatocyte growth 
factor (HGF), EGF and keratinocyte growth factor (KGF) compared to normal 
counterparts [67].  
   
One established paracrine interaction between CAFs and tumour cells is via 
secretion of CXC ligand (CXCL) -12 chemokine. This chemokine is 
expressed in CAFs and acts through binding to its receptor CXC receptor 
(CXCR) -4 which is on tumour cells and induces tumour cell proliferation [68]. 
It is also shown that this chemokine can promote angiogenesis by acting on 
endothelial cells and enhance endothelial precursor cell infiltration to tumour 
side. In addition CXCR4 expression is shown to be a predictor for poorer 
overall and disease free survival [69].  
 
Another similar interaction is the activation of COX-2 in MCFDCIS cells in the 
presence of CAFs which leads to promotion from in situ to invasive cancer in 
mice (Miller et al., 2000). When CAFs and MCFDCIS cells are co-injected 
with a COX inhibitor, transition to invasive stage disease is completely 
ablated [70, 71]. 
 
One striking change in CAFs is the up-regulation of alternative spliced 
variants of ECM proteins such as tenascin and fibronectin [72, 73]. The 
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oncofetal form of fibronectin (FN-EDA) is up-regulated in the breast cancer 
microenvironment [72, 73] and is involved in activation of the pro-form of 
TGF-β which is regarded as a major pathway leading to generation of 
myofibroblasts from normal fibroblasts [74]. 
 
There are different explanations about the origin of CAFs [61, 64, 75]. The 
source of CAFs can be sustained paracrine interactions such as chronic 
inflammation which may lead residual fibroblasts to develop into 
myofibroblasts [67, 76]. Alternatively CAFs can be generated from bone 
marrow derived cells that differentiate into CAFs in tumour related stroma 
[77]. Indeed it was shown in prostate cancer that bone marrow derived 
progenitor cells can differentiate into stromal cells that have altered 
epigenetic mechanisms [78].  
 
Microenvironment related gene expression alterations have been repeatedly 
reported in breast cancer [12, 51, 79, 80]. Several proteins are up-regulated 
in DCIS associated stroma; most notably ECM components, MMPs and cell 
cycle related genes. Another interesting observation is the down-regulation 
of cytoplasmic ribosomal proteins whereas mitochondrial ribosomal proteins 
are up-regulated. This decrease in cytoplasmic ribosomal proteins may 
cause a subtle alteration in ribosomal structure that ultimately allows the 
translation of proteins involved in tumour growth [51].  
 
In keeping with gene expression changes, there are controversial data on 
genetic abnormalities in tumour associated stroma. Allinen and colleagues 
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reported that genetic changes are exclusive to tumour cells using  aCGH and 
single nucleotide polymorphism (SNP) array approaches on isolated cell 
populations [8, 12-14]. Conversely; a body of evidence reports loss of 
heterozygosity (LOH), microsatellite instability (MSI) and point mutations 
related to tumour suppressor genes such as tumour protein 53 (TP53) and 
phosphatase and tensin homolog (PTEN) and oncogenes in tumour 
associated stroma. It is of note that these studies were performed on 
formalin fixed paraffin embedded (FFPE) tissue [81]. The techniques used in 
these studies, such as mutlisatellite PCR, are prone to produce artefactual 
results with poor quality DNA input from a limiting number of cells (or 
template) is employed [27, 82-84]. The reports showing somatic TP53 
mutation in stroma propose that the existence or absence of this mutation in 
stromal cells could be used as a prognostic marker to predict nodal 
metastasis [85]. Despite the evidence from several other reports for TP53 
mutations in CAFs [27, 85-88] no mutations have been detected in fresh 
frozen samples [89] and immunohistochemical analysis and SNP array 
showed that p53  mutation was found in only 4% of isolated primary breast 
cancer CAF samples [90]. In keeping with this there are also conceptual 
problems in understanding somatic mutation occurrence in the 
microenvironment. From an evolutionary point of view the function of a 
somatic mutation is the establishment of a selective advantage against 
environmental pressure, however the alterations seen in the 
microenvironment is for the benefit of cancer cells. In other words, if the 
somatic mutation model is correct therefore these changes should result in a 
sarcoma [75]. However CAFs do not exert in vivo tumourigenicity and 
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undergo senescence after several passages [91] but, intriguingly, senescent 
CAFs were shown to still be able to contribute to tumourigenesis of ovarian 
surface epithelial cells [92].   
 
Stable phenotypical abnormalities in cancer related stroma may, in part, be 
explained by epigenetic regulation mechanisms [61, 75]. Several studies 
have identified distinct patterns of methylation in the stromal compartment, 
MEC population and epithelial cell populations, suggesting this may 
contribute to the generation of an altered microenvironment, though the 
functional significance of these changes has not been established [79, 93, 
94].  
 
All cell types and ECM components of a tissue contribute distinct mechanical 
properties such as elasticity and stiffness. Altogether these characteristics 
determine the tissue response to forces. Intracellular or extracellular forces, 
mechanoresponsive elements and interactions with intracellular signalling 
pathways ultimately modulate cellular response to ECM such as adhesion 
and spread [95].    
 
Microenvironment dependent physical forces in breast cancer, (ECM 
strength and stiffness) strongly affect the topography and hence the 
presentation of ligands to their cell-ECM receptors (integrins) [96-98]. This 
disruption of normal cell-ECM interaction can result in induction of cell 
proliferation and gaining of cancer related properties such as proliferation 
and a migratory phenotype [97, 98].  
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Particularly in DCIS the continuous growth of tumour cells in a confined 
volume (the duct) could increase cell and tissue tension [95, 99, 100]. In 
addition compression of an expanding tumour mass by the surrounding 
tissue interferes with the normal tissue architecture and may ultimately affect 
cell-cell junctions and hence, cellular polarisation [95]. In high grade DCIS 
the intratumour pressure could be further increased due to hypoxia and a 
central necrotic mass [101]. This increase is associated with the release and 
activation of several growth factors including angiogenic factors anchored in 
the ECM [95]. In addition the shrinkage of interstitial volume results in 
enhanced concentration of the growth factors [102]. In a model system it has 
been shown that neovascularisation enhances the interstitial flow within 
tumour associated stroma, which can trigger transformation of tumour stroma 
residential fibroblasts into myofibroblasts via TGF-β signalling [103]. Thus, 
the mechanical changes in the environment can contribute directly to altered 
function of stromal cells [102, 103]. Myofibroblasts can establish stronger 
adhesions and show enhanced cellular contractility which, through a positive 
feedback mechanism, further increases ECM tension and TGF-β activation 
[103]. Enhanced Collagen cross linking is one of the major factors 
contributing to ECM stiffness [95]. Lysyl oxidase (LOX) which has the ability 
to crosslink Collagen-I and ultimately stiffens the breast tissue, has been 
implicated in progression of breast cancer [104, 105]. Collagen crosslinking 
was shown to induce integrin clustering, focal adhesion maturation and 
consequently upregulate migration-related signalling pathways 
(mechanosignalling) such as phosphoinositide 3-kinase (PI3K), which results 
in acquisition of an invasive phenotype in breast cancer cells [105, 106]. The 
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mechanical properties of a tumour evolve according to the disease stage; 
DCIS and invasive breast cancer could differ significantly in terms of 
mechanical characteristics but this remains to be further studied [95, 107].  
  
1.3  Myoepithelial Cells 
 
1.3.1 Myoepithelial Cells in Normal Breast 
 
A unique component of the microenvironment of DCIS is the MEC 
population. MECs are regarded as a hybrid cell type which exhibit both 
smooth muscle cell and epithelial cell characteristics. They express smooth 
muscle actin (SMA), smooth muscle myosin heavy chain (SMMHC) and 
calponin [108-110]. They also express desmosomal proteins which compose 
adhesive intercellular structures and attach MECs to each other and to 
LECs. The desmosomes that exist between a MEC and a LEC are 
composed of desmoglein-2 (Dsg-2) and desmocollin-2 (Dcs-2) whereas the 
desmosomes exist between two MECs are composed of Dsg-3 and Dcs-3. 
These structures have a central role in correct LEC-MEC positioning [108-
110]. MEC of the normal breast are responsible for the maintenance of 
apico-basal polarity and hence the integrity and assembly of the LEC layer. 
In normal breast they are the major source of laminin-I-I-I ,which is a 
component of ECM, and its robust effect on correct polarisation of LECs has 
been demonstrated [13, 111, 112]. Moreover MECs show expression of 
basal cytokeratins CK5, CK14 and CK17 [113].  
 
  
47 
 
MECs are natural tumour suppressor cells, which are directly involved in the 
interaction between LECs and ECM [114, 115]. They surround LECs, 
produce BM [79] and secrete several tumour suppressor proteins which 
underline the importance of paracrine regulations in tumour suppressor 
function [114, 115]. They show high expression of ECM proteins, proteinase 
inhibitors and anti-angiogenic factors [114, 115]. Therefore not only do MECs 
form a physical barrier but also they are ideally positioned to direct the 
communication between BM and LECs; to act as a checkpoint for factors 
such as nutrients or growth factors secreted from or targeted to LECs and to 
supply signals for maintenance of normal breast tissue polarization [8, 13, 
116].  
 
 MEC form the interface with the BM and in keeping with this they express 
high levels of BM receptors, most importantly integrins [16, 117]. MECs form 
unique hemidesmosomal structures in which α6β4 integrin is involved. This 
complex acts as a laminin-3-3-2 receptor, and therefore has a key role in 
attachment of MECs to BM [8, 13, 14]. The loss of HD complexes in 
tumourigenesis underscores the mechanism involved in the detachment of 
MECs from their micro-ecology.  
 
The origin of MECs is still unclear since the phylogeny in human breast 
tissue is not fully understood [8, 14, 116, 118]. A stem cell which gives rise to 
a common progenitor of LECs and MECs was identified to exhibit cluster of 
designation (CD) 49fhi (integrin α6 subunit), Epithelial cell adhesion molecule 
(EpCAM) -/low, CD24-, CD133-, ER-, PR-, HER-2- phenotype (Figure 1-9). A 
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luminal progenitor can develop into a LEC or during pregnancy into an 
alveolar cell. There may be a distinct myoepithelial progenitor differentiated 
from a common progenitor or they may arise from luminal or alveolar 
ancestors which result in differences in cell morphology (mirroring the 
amount of myofilaments that exist in the cell) [13]. MECs have been shown 
to exhibit a CD49fhi, EpCAM-/low basal phenotype, which shares several cell 
markers with mammary stem cells [14].  
 
 
Figure 1-9: Model of phylogeny proposed within mammary epithelium. 
MEC layer may arise from a myoepithelial progenitor, or a luminal progenitor 
might develop into alveolar progenitor which can give rise to MEC [14].   
 
In vitro and in vivo studies show that MECs have a central role during 
mammary gland morphogenesis during embryological development [13, 
119]. Proteases and growth factors produced mainly by MECs are involved 
in ECM remodelling and can affect LEC proliferation and branching 
morphogenesis [120-125].  
MUCI
- 
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MEC rarely form tumours and those that do develop are usually benign 
neoplasms which show no degradation of BM [125, 126]. Sternlicht and co-
workers [125] have developed MEC lines and xenografts that are derived 
from benign breast (and salivary gland) myoepitheliomas. MEC lines were 
characterized by immunoreactivity for maspin and other protease inhibitors 
such as plasminogen activator inhibitor (PAI) -1, similar to normal breast 
tissue MECs. In transwell invasion assays these cell lines inhibited 
melanoma and breast cancer cell invasion, partly by a maspin dependent 
mechanism. Furthermore, the matrix generated from the xenografts 
(Humatrix), composed of both BM and non-BM components, down-regulated 
cancer cell invasion compared to Matrigel. Similarly, conditioned media from 
MEC lines was sufficient to show an invasion suppressor effect in transwell 
assay. Moreover Humatrix abolished (melanoma) tumour invasion and 
metastasis in vivo [125].   
 
Jones and colleagues [117] investigate the interaction of MECs with breast 
cancer cells and fibroblasts in transwell invasion assays. Normal MECs and 
fibroblasts were isolated from reduction mammoplasty tissue. MECs were 
characterised by expression of myoepithelial markers such as β4 integrin, 
CK-14, Common acute lymphoblastic leukemia antigen (CALLA) and Dsg-3, 
and lack of expression for luminal associated proteins such as CK-18 or 
EMA, whereas fibroblast populations were negative for these markers by IHC 
or at mRNA level. When MECs were co-cultured with a panel of ER positive 
or ER negative breast cancer cells in transwell invasion assays the breast 
cancer cell invasion was negatively regulated compared to baseline levels, in 
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contrast when fibroblasts were co-cultured with breast cancer cells the 
invasion was increased. Interestingly when three cell populations were 
cultured the invasion was down-regulated indicating a dominant suppressor 
role for MECs. In addition when conditioned media collected from MECs 
were substituted for the MEC population it was sufficient to reproduce similar 
results. This supports the importance of secreted factors in the tumour 
suppressor role of MEC. Moreover when fibroblasts or breast cancer cells 
were co-cultured with MECs; this resulted in a consistent decrease of MMP 
expression and activity. This might in part explain the invasion suppressor 
role of MECs to modulate fibroblast or cancer cell function [117].   
 
Another tumour suppressor protein expressed by MECs is maspin which is a 
serine protease shown to inhibit tumour growth, invasion and metastasis [8, 
127, 128]. MECs also express p63 and p73 which play central roles in the 
control of cell growth and survival [113]. Other examples of suppressor 
proteins include tissue inhibitor of metalloproteinase-1 (TIMP-1) which 
decreases invasion and CD44 which blocks adhesion and migration of 
human malignant cells in vitro  [114, 115]. MECs can control steroid hormone 
metabolism within breast tissue by their ability to express steroid sulphatase 
(STS) and process inactive precursors which are therefore available for 
LECs as active steroid hormones [8, 129].   
 
MECs can also modulate cell proliferation. Their ability to induce growth 
arrest (G2/M status) in breast cancer cells has been demonstrated [128]. In 
addition, Hu and co-workers used MCF10ADCIS.com cells to resemble 
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human breast cancer to investigate the importance of MECs in disease 
progression. In vivo these cells give rise to comedo DCIS-like structures; 
surrounded by a cell layer which shows positivity for MEC markers (such as 
CALLA and p63) and BM rich in laminin-3-3-2, which can spontaneously 
develop into invasive tumours. When MCF10ADCIS.com cells are co-
injected into mice with normal primary MECs or MECs isolated from a normal 
cell line, they develop smaller tumours (compared to MCF10ADCIS.com 
cells alone) than when injected together with fibroblasts derived from 
invasive breast carcinoma or rheumatoid arthritis. When all three cell groups 
were injected together smaller tumours developed, once again showing the 
dominant suppressor effect of MECs over both tumour cells and fibroblasts. 
Histology of the tumours also differed between different co-injection groups; 
MCF10ADCIS.com alone or together with normal MECs formed DCIS-like 
lesions while all the fibroblast co-injections (including fibroblast derived from 
normal breast tissue) resulted in invasive tumours. Intriguingly the 
differences observed in tumour growth or histology were not a result of  
permanent genetical alterations in the tumour cells since when 
MCF10ADCIS.com cells of invasive tumours were isolated and injected 
alone in mice again they generated DCIS structures [130].  
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1.3.2 Myoepithelial Cells in DCIS 
 
During the development and progression of DCIS, MECs undergo several 
dramatic alterations which potentially could result in compromised 
suppressor function [79]. Gene expression and epigenetic profiles 
demonstrate that DCIS associated MECs exhibit a phenotype distinct from 
normal MECs [79]. In DCIS, MECs appear to show reduced differentiation 
[12, 79, 93, 131]. In addition epigenetic analysis has revealed distinct 
methylation profile alterations [93].   
 
DCIS associated MECs up-regulate genes involved in promoting 
proliferation, migration, invasion and angiogenesis, whereas they show 
reduced expression of genes coding for certain tumour suppressor proteins 
also genes involved in the normal function of the cell such as 
thrombospondin and oxytocin receptor [79].  
 
One of the most notably over-expressed proteins in DCIS associated MECs 
is the chemokine CXCL14 which can bind to leukocytes as well as LECs, 
and has previously been shown to influence cell proliferation, differentiation, 
migration and invasion [12]. Furthermore MECs in DCIS have been shown to 
increase MMP expression especially MMP-14, and cathepsin secretion 
which may aid ECM degradation [79].  
 
Consistent with the gene profiling studies, DCIS associated MECs exhibit 
alteration in many markers; reduced immunohistochemical staining has been 
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shown for SMA, Calponin, CALLA, CK 5/6, p63 and a dramatic loss in 
SMMHC in DCIS associated MECs in comparison with the normal MECs of 
the same breast [131]. These differences again indicate that MECs are 
losing normal cell function.  
 
One consistent change in DCIS-associated MECs noted in our lab is the up-
regulation of αvβ6. This has been shown to activate TFG-β and leads to up-
regulation of MMP-9 in MECs, which promotes tumour cell invasion [132, 
133].  
 
In DCIS, focal disruption of the intact MEC layer leads to rearrangement of 
normal tissue boundaries and is accompanied by BM breakdown [59, 60]. 
The focal loss of the intact MEC layer and consequent aberrant exposure of 
DCIS tumour cells to ECM was extensively studied by Man et al. They 
showed that the cancer cells in juxtaposition to the MEC layer disruption 
become invasive and show dramatic reduction in ER expression and LOH at 
different chromosomal loci including the Wilm’s tumour suppressor (WT) -1 
gene [59, 60]. They also up-regulate invasion and metastasis related gene 
expression. In addition an increased level of leukocyte infiltration was 
observed around disrupted MECs [59, 134]. The implication is that the loss of 
the MEC results in acquisition of the tumourigenic phenotype in adjacent 
cells. 
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1.4 Matrix Metalloproteinases  
 
1.4.1 Classification and Roles in Cancer 
 
The protease clan compromises 5 classes: Metalloproteinases, serine, 
cysteine, threonine and aspartic proteases [135]. MMPs are a large family of 
endopeptidases which have the ability to remodel ECM and are up-regulated 
in many cancers, such that the MMP family is conventionally regarded a key 
factor contributing to the process of cancer cell invasion and metastasis [22, 
136-141]. In addition to remodelling ECM they can process many non-
structural substrates such as cytokines and growth factors and influence cell 
proliferation, differentiation, angiogenesis and apoptosis [142-144], thus they 
impact  on a diverse range of biological processes [22, 139, 145].  
 
MMPs belong to the metzincins super-family which also includes ‘a 
disintegrin and metalloproteinases’ (ADAMs) and ‘a disintegrin and 
metalloproteinase with thrombospondin motifs’ (ADAMTSs) members. In 
humans there are 24 MMP genes, including duplicated MMP-23 genes. The 
total set of proteases expressed in human tissues and cells is called the 
human degradome and contains 569 enzymes. This information comprises 
1.7% of the human genome [146, 147].  
 
MMPs share common structural features [140]. From the N to C terminus 
(Figure 1-10 A); MMPs have a signal peptide involved in secretion, a 
prodomain which contains a cysteine residue, a catalytic domain which 
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contains a zinc (Zn) ion, a linker hinge region and a haemopexin domain that 
confers substrate specificity [140, 145, 148, 149]. MMPs become activated in 
a process called the cysteine switch. The interaction between the cysteine 
residue and the zinc ion allows the enzyme to stay in the latent phase by 
stopping a water molecule necessary for catalysis from binding to the zinc 
atom. This link needs to be interrupted for activation either by complete 
removal of the prodomain or chemical alteration of the cysteine residue to 
release active enzyme [13, 139, 140, 150, 151]. MMPs can be activated 
extracellularly by other MMPs, serine proteases such as plasmin or reactive 
oxygen species (ROS). An alternative intracellular activation can also occur 
by furin, but the intracellular roles of MMPs remain elusive [145].  
 
MMPs are traditionally classified according to their substrate specificity and 
structure into 5 main categories (Figure 1-10 B) [140, 145]:  
 
1. Collagenases: This family contains MMP-1, MMP-8 and MMP-13. They 
can process interstitial fibrillar collagens; Collagen-I, II and III into ¾ N 
terminus and ¼ C terminus fragments which denaturate to gelatine 
spontaneously, and also can cleave other ECM proteins (such as 
gelatine) and non structural substrates such as interleukin (IL) -10 [145, 
152, 153]. The haemopexin domain has been shown to facilitate collagen 
cleavage by controlling binding and mediating the unwinding of the triple 
helix structure [154, 155]. Collagenases are involved in embryonic 
development, tissue regeneration and wound repair. There are many 
links between collagenases and cancer. MMP-1 is the first identified MMP 
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[156] and its over-expression has been shown to be related to increased 
metastasis to bone in breast cancer and poor prognosis in breast cancer 
as well as colorectal cancer and malignant melanoma [157, 158]. MMP-
13 expression is restricted to a few physiological conditions involving 
extensive collagenous ECM remodelling such as fetal bone development 
[159]. Over-expression of MMP-13 is seen mainly in squamous cell 
carcinoma of head and neck and correlates with invasion and metastasis 
[152]. 
 
2. Gelatinases: This family contains MMP-2 and MMP-9. They carry three 
fibronectin type II repeats which mediate binding to their substrate gelatin 
[160]. They can also process Collagen-IV and to a lesser Collagen V and 
XI, laminin and aggrecan. MMP-9 can convert cryptic vascular endothelial 
growth factor (VEGF) into its bioavailable form for its receptor (VEGFR) 
[140, 145]. The gelatinases have frequently been implicated in cancer 
[161-169] 
  
3. Stromelysins: The members of this family are MMP-3, MMP-10 and 
MMP-11.  They are structurally similar to collagenases but they do not 
have the ability to cleave interstitial collagens. MMP-3 and MMP-10 are 
involved in proMMP activation (including MMP-8), and MMP-11 cleaves 
serpins, and also can be activated intracellularly via a furin recognition 
sequence, but the intracellular function of this enzyme is unknown [140, 
152]. 
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4. Matrilysins (Minimal domain arrangement): This family consists of MMP-7 
and MMP-26. MMP-7 is involved in apoptosis by processing Fas ligand 
and pro tumour necrosis factor (TNF) -α, and interacts with E-cadherin 
[139]. Unlike most of the members of the MMP family MMP-26 can be 
stored mainly intracellularly and secreted upon exposure to appropriate 
stimuli [140, 152].  
 
5. Membrane Type MMPs (MT-MMPs): This family contains four 
transmembrane enzymes MT1-MMP, MT2-MMP, MT3-MMP, MT5-MMP 
(MMP-14, 15, 16 and 24) and two glycosylphosphatidylinositol (GP)-
anchored enzymes MT4-MMP MT6-MMP (MMP-17 and 25). They all 
have a furin recognition motif therefore can be activated intracellularly. 
Their main function is to activate other MMPs, localising proteolytic 
activity to the cell membrane [140, 152]. MT-MMPs can also regulate 
cytokine function [140, 152]. 
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Figure 1-10: Structural characteristics and classification of MMPs. A 
Structural features of MMPs. All MMPs have a signal peptide, a propeptide 
and a catalytic domain. All regions that vary between different subgroups are 
shown. B The classification of MMPs, which is based on structure. Other 
than MMP-7,MMP26 and MMP-23A/B all MMPs have a haemopexin region, 
MT-MMPs contain a transmembrane domain and a cytoplasmic tail or a GP 
anchor. Gelatinases have fibronectin type II repeats and MMP-23 possess 
an Ig-like domain.  Figure extracted from Lafleur et al., 2003 [140].  
 
A 
B 
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MMP function can be regulated in four main ways: transcriptional and 
translational regulation [170], compartmentalisation, proenzyme activation 
and through endogenous inhibitors –TIMPs [139]. Transcriptional control is 
the major physiological mechanism since most of the MMP family share 
common cis-acting elements which in part explain their co-activation and co-
repression upon various signals [149, 171]. 
 
In humans there are 4 TIMPs [172]. TIMP-1, TIMP-2, and TIMP-4 are soluble 
proteins whereas TIMP-3 is anchored to ECM [140, 145]. They contain 184-
194 amino acids and have a rather simple structure with an N-terminus 
domain which is responsible for inhibitory function and a highly variable C-
terminus domain [140, 145]. TIMPs have a “wedge like” shape and form a 
non covalent complex with their binding partners in a 1:1 stoichiometry via 
the N terminus [145]. This contact interferes with the catalytic site of MMP 
and inhibits its function. The roles of TIMPs are more complicated than a 
simple inhibitory function, also their interaction with substrates other than 
proteases is not precisely known [140, 145]. TIMPs are also shown to be up-
regulated in many cancer conditions. This apparent contradiction reflects the 
limitations in knowledge of TIMP function and raises the question whether 
increased activity of MMPs is due to up-regulation of MMP or deregulation of 
inhibitors [22]. 
 
Given the central roles of MMPs in BM penetration, this family is a promising 
target for anti-cancer therapy. The main support for the association of MMPs 
with cancer progression comes from in vivo studies [165]. As an example 
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MMP-1 has been shown to control the metastatic activity of breast cancer 
cells. When MMP-1 expression is knocked down in MDA MB 231 cells and 
then implanted in mice by tail vein injection, this results in reduced lung 
metastatic capacity [173]. Tester and co-workers generated proMMP-2 over-
expression in MDA MB 231 cells which endogenously express the proMMP-2 
activator MT1-MMP. When these cells were injected into the mammary fat 
pad of nude mice, orthotopic tumour growth was enhanced compared to 
vector control. Also metastasis to brain, liver, bone and kidney was 
enhanced after intracardiac inoculation [161]. 
 
It has recently been recognised that MMPs can exert tumour suppressor 
functions [135, 147, 174-176]. Broad range MMP inhibitors (MMPIs) can 
counterbalance the host protective effects of MMPs. Therefore anti-target 
MMPs should be identified and trials need to be tailored carefully to avoid 
targeting these MMPs. Furthermore the same MMP can act both as a target 
and an anti-target at different stages of a disease as shown by in vivo studies 
[135, 147, 174-176].  
 
There is a growing body of evidence to show that MMPs can be involved in 
early stages of breast cancer progression [177]. For example; in the mouse 
mammary tumour virus (MMTV) driven breast carcinoma model, MMP-11 
knockout mice generated fewer spontaneous tumours compared to wild type 
(WT) counterparts [178]. Similarly MMP-7 over-expression in the MMTV 
system leads to development of mammary hyperplasias, and increased the 
rate of tumour formation [179]. 
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MMP expression has also been associated with the progression of breast 
cancer. Gene expression levels of MMP-1 and MMP-9 make up part of the 
70 gene signature that predicts distant metastasis in lymph node negative 
breast cancer [162]. High levels of MMP-1 in fibroblasts detected by IHC 
staining correlates with a high rate of distant metastases [180]. Interestingly 
MMP-1 expression in patients with ADH can be used as a predictive marker 
for developing breast cancer [181]. High MMP-9 expression in the stromal 
compartment and in mammary tumour cells also is associated with poor 
prognosis [163]. Similarly a general increased expression of MMPs in stroma 
(fibroblasts and macrophages) including MMP-1,7,9,13 and MT1-MMP 
correlates with higher risk of distant metastasis [180]. An enhanced ratio of 
MMP-2/TIMP-2 or MMP-9/TIMP-1 also has been associated with lymph node 
metastasis and poor prognosis [164]. 
 
Other evidence suggests a more complex role for MMPs in tumour 
progression. MMP-9 plays a dual role in angiogenesis. MMP-9 is a key 
element in the angiogenic switch in pancreatic carcinoma [167]. MMP-9 null 
mice show reduced tumour growth and neovasculature [167]. Conversely 
plasminogen degradation by MMP-3, 7, 9 and 12 can produce angiostatin 
which is an anti-angiogenic factor [168]. In addition MMP-7 and MMP-9 over-
expression, in an integrin α1 knock out system, can reduce angiogenesis and 
tumour growth in vivo [169].   
 
  
62 
 
Furthermore, depending on tumour stage, MMP-9 can exhibit both anti and 
pro-tumourigenic function [165]. In a human papilloma virus (HPV) -16 
multistage skin carcinogenesis model, mice lacking MMP-9 (HPV16/MMP-9-/-
) generated fewer tumours and exhibited an extended latency period when 
compared to HPV16/MMP-9 proficient mice. However when these tumours 
were assessed for differentiation, using CK as a phenotypic marker, it was 
revealed that in MMP-9 null tumours keratinocytes were less differentiated, 
which is an indication of more aggressive behaviour. Interestingly in MMP-9 
proficient tumours, MMP-9 expression is restricted to infiltrating immune cells 
such as neutrophils, macrophages, and mast cells whereas the tumour cells 
were negative [166].  
 
MMP-12 plays an anti-angiogenic role via cleavage of plasminogen 
generating angiostatin [182]. In fact MMP-12 over expression in melanoma 
cells reduced tumour growth and vascularisation [182]  and in colorectal 
carcinomas is correlated with increased survival [183]. However, there is 
evidence of tissue specificity since in other carcinomas such as non small 
cell lung cancer it associates with worse prognosis [184]. It is of note that the 
source of MMP-12 is also important; when it is expressed by stromal cells it 
is favourable but when tumour cell derived MMP-12 appears to confer a poor 
prognosis [185, 186]. Further, MMP-12 was also shown to be involved in 
urokinase-type plasminogen activator receptor (uPAR) processing [187]. 
 
TIMP-1 levels can be a marker of good or poor prognosis and better 
understanding of its dual role is needed [188]. Plasma levels TIMP-1 in 
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patients with metastatic breast cancer were evaluated by ELISA and higher 
levels of TIMP-1 correlated to reduced survival [189]. Interestingly high 
TIMP-3 mRNA levels in breast tumours indicate good prognosis and longer 
disease free survival [188]. Conversely TIMP-3 levels have been shown to 
be elevated in dense breast tissue which carries higher risk for breast cancer 
development compared to non-dense breast [190]. It is also of note that 
TIMP-3 expression is absent in the normal breast epithelial compartment and 
tumour cells of DCIS but highly up-regulated in myofibroblasts and MECs 
surrounding the DCIS [12].   
 
Several MMP inhibitors have reached phase III clinical trials, but 
nevertheless have failed to show any significant effect on patient survival 
[147]. The failure of broad spectrum MMP inhibitors (MMPI) in anticancer 
trials suggests an incomplete understanding of the complex function of this 
family; of precisely when and how they act in cancer [22, 138-140]. This may 
also be affected by the tumour suppressor function of some MMPs [146]. 
The majority of MMPI act via chelating the Zn ion which is a consensus 
structure for proteases [147]. Therefore these inhibitors can target ADAMTSs 
as well, which considering their anti-cancer function, should be avoided [191-
197]. Moreover, targeting one MMP can influence other MMPs being 
activated or inhibited by the target, or a feedback loop to compensate the 
target MMP can be triggered [146, 147]. In addition the administration of 
MMPIs to patients with advanced cancer might not have a significant effect 
on prognosis considering the role of MMPs in early cancer stages [174, 177].  
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Taken together it is clear that MMPs can have stage- and source-specific 
functions. This spatiotemporal change in MMP activity may be in part 
explained by the availability of specific substrates at a particular site of MMP 
expression [175]. Therefore identification of the substrate repertoire for each 
MMP will contribute to a better understanding of the protease web, and 
potentially lead to more informed development of MMPI [175].    
 
1.4.2 Matrix Metalloproteinase-8  
 
MMP-8 (also known as neutrophil collagenase or collagenase-2) is the 
second member of the collagenase family of MMPs. Although MMP-8 was 
originally reported to be expressed exclusively by neutrophils, where it 
locates to specific granules and is secreted upon neutrophil activation [198, 
199], it has become evident that it can be produced by many other cell types 
including endothelial cells, odontoblasts, and benign and malignant 
keratinocytes [175, 200, 201]. The gene is located to the telomeric site of 
chromosome 11 with the other members of the collagenase family [152].  
 
MMP-8 preferentially targets Collagen-I; to a lesser extent it can cleave 
Collagen-III and Collagen-II [202]. Collagens are the main component of the 
ECM with Collagen-I being the major collagen. These molecules have three 
α-chains and form a triple helix. Collagen-I is cleaved at Gly775- Ile776 
residues of the α1 chain and Gly775- Leu776 residues of α2 chain. This 
cleavage yields to ¾ N-terminal and ¼ C-terminal fragments [202]. These 
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fragments spontaneously denature to gelatine at body temperature as 
previously described [152].  
  
MMP-8 shows an archetypal structure, like other collagenases it consists of a 
signal peptide, a propeptide, a catalytic domain, a hinge region and a 
haemopexin like domain [140]. It is secreted as an 85kDA inactive form [152] 
and can be activated extracellularly by other MMPs such as MMP-3 and 
MMP-10 [203, 204]. The activated MMP-8 form varies in molecular weight 
depending on its cellular source [205, 206] which may reflect the degree of 
glycosylation levels [201]. MMP-8 has 6 different glycosylation sites and 
enhanced glycosylation may block its secretion and be associated with its 
storage in the intracellular granules [201]. In addition, an alternative 870bp 
splice variant of MMP-8 has been identified which has an extra exon of 91bp 
between residues 174 and 175 and lacks the signal peptide. The function of 
this form is not known [207]. 
 
There is accumulating evidence that MMP-8 acts as a tumour suppressor 
since the demonstration that MMP-8-/- male mice exhibit increased incidence 
of skin tumours in a chemically induced carcinogenesis model system [208]. 
The progression rate of these benign lesions to malignancy did not differ 
between MMP-8 null or WT mice, which implies that MMP-8 is particularly 
involved in suppression of early stages of tumourigenesis [208]. Similarly in 
MMP-8-/- mice subjected to Methylcholanthrene (MCA), as a different model 
of chemically induced carcinogenesis, the rate of development and the 
number of fibrosarcomas were significantly enhanced compared to WT 
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littermates [208]. Since there was no difference in MMP-8-/- female mice and 
WT mice; in order to understand the action of sex hormones the ovaries of 
female mice were removed, or alternatively, the mice were treated with 
tamoxifen. In these cases MMP-8-/- female mice showed significantly higher 
susceptibility to develop skin tumours when exposed to 7,12-
dimethylbenz[a]anthracene (DMBA) and 12-O-tetradecanoyl-phorbol-13-
acetate (TPA). Thus ovarian-derived oestrogen might have a protective role 
on tumour development in this system [208]. Moreover bone marrow 
transplantation from WTmice to MMP-8-/- mice was sufficient to rescue the 
expression of MMP-8 in (bone marrow derived) neutrophils and the 
susceptibility of MMP-8-/- mice to tumourigenesis after exposure to MCA 
[208].  
 
Histopathological analysis of skin tumours or wounds in MMP-8 null mice 
revealed that the lack of MMP-8 down regulates early neutrophil infiltration to 
the wounded skin site (determined by Ly-6G neutrophil marker 
immunostaining) and delayed wound closure, but once the immune response 
is established it is abnormally sustained in wounds and skin tumours [208, 
209]. The delay in early response may in part be due to the reduced ability of 
leukocytes to migrate towards the tumour or inflammatory site without MMP-
8 dependent activity against Collagen-I [208-210].  
 
Importantly, a non-matrix substrate of MMP-8 has been identified [208].  A 
chemoattractant - lipopolysaccharide induced CXC chemokine (LIX) (IL-8 
and CXCL5 murine homolog), which is involved in the chemotaxis of 
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polymorphonuclear cells (PMNs), was shown to be cleaved at Ser4-Val5 and 
Lys79-Arg80, and subsequently activated by MMP-8 [208, 211, 212]. The 
resultant processed form exerts enhanced chemotactic activity on 
neutrophils. Therefore the absence of MMP-8 dependent activation of LIX, 
may result in reduced PMN cell influx. The sustainment of the late immune 
response was, however, explained by a defective apoptosis mechanism in 
neutrophils [213]. It was hypothesised by the authors (Balbin et al., 2003) 
that the persistent accumulation of infiltrating leukocytes may result in 
chronic inflammation through generation of ROS, which in turn may interact 
with DNA in proliferating epithelium resulting in permanent genomic 
alteration and instability which predisposes to tumour development. This 
hypothesis might in part explain the link between MMP-8 loss and cancer 
development via chronic inflammation [139, 214].  
 
Furthermore, evidence for a tumour suppressor role for MMP-8 was provided 
by Gutierrez-Fernandez and co-workers who over-expressed MMP-8 in 
B16F10 melanoma cells and inoculated these cells in MMP-8-/- back crossed 
C57BL/6 mice (with an intact immune system) via the lateral tail vein to study 
metastasis formation [215]. MMP-8 over-expression significantly down-
regulated lung metastasis formation (size and number) compared to Empty 
vector transfected B16F10 cells. Interestingly, over-expression of an inactive 
form of MMP-8 in B16F10 cells was unable to suppress metastasis, 
indicating the involvement of enzymatic activity in the metastasis protective 
function of MMP-8 [215]. Furthermore, MMP-8 expression did not alter 
B16F10 cell proliferation in vitro, or tumour weight in vivo when B16F10 cells 
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were injected sub-cutaneously. In addition MMP-8 over-expressing B16F10 
melanoma cells showed reduced invasion in vitro in Matrigel-coated Boyden 
chamber assays, and decreased transmigration through human unbilical vein 
endothelial cell (HUVEC) monolayers compared to the control tranfection 
group. In addition when neutrophils from MMP-8-/- mice were isolated and a 
transwell invasion assay was set up, these neutrophils showed reduced 
invasion when compared to the invasion of neutrophils isolated from WT 
mice. Interestingly MMP-8 transfected B16F10 cells adhered more strongly 
to Collagen-I and spread more on laminin-I-I-I than Empty vector transfected 
cells, suggesting that MMP-8 modulates adhesion and spreading on ECM 
[215].  
 
In order to explore the role of host derived MMP-8 rather than tumour derived 
MMP-8; B16F10 (parental) cells were injected tail veins of MMP-8-/- or WT 
mice to investigate experimental metastasis. There was a significant 
increase in the number of lung metastasis in MMP-8-/- mice when compared 
to WT mice. In order to assess spontaneous metastasis formation, Lewis 
lung carcinoma (LLC) cells were injected sub-cutaneously to MMP-8-/- or WT 
mice. There was no difference on primary tumour growth but MMP-8 
deficient mice developed significantly increased number of lung metastasis 
which shows that host derived MMP-8 can also contribute to metastasis 
protective function [215]. 
 
MMP-8 expression has also been shown to correlate with improved survival 
in patients with squamous cell carcinoma (SCC) of the tongue [198, 216, 
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217]. To evaluate the suppressor role of MMP-8 Korpi and colleagues used a 
chemical induced model of tongue SCC by exposing MMP-8-/- or WT mice to 
4-Nitroquinoline 1-oxide (4NQO). Female MMP-8 null mice were significantly 
more susceptible to SCC than WT mice [216]. This is in contrast with the 
hypothesis of Balbin and colleagues that ER might play a protective role in 
tumour formation in MMP-8 deficient system [175] but may indicate site-
specific differences. Korpi et al also showed that MMP-8 can cleave ER-α in 
a dose dependent manner [216]. The MMP-8 promoter does not contain an 
ER response element, however it includes CCAAT/enhancer-binding protein-
β site (C/EBP) element which has been shown to associate with ER-α. This 
complex can act as a transcription factor [152, 216, 218]. Therefore, in the 
future detailed studies scoping the interaction of MMP-8 with the ER pathway 
would be warranted. 
  
In contrast to tumour suppressor function; in head and neck squamous cell 
carcinoma and ovarian carcinoma, MMP-8 expression was associated with 
the presence of metastasis [200, 219]. Polymorphism in the MMP-8 gene 
(MMP-8 78K/E) is associated with increased bladder cancer risk [220], and in 
pancreatic cancer MMP-8 has been shown to be up-regulated [221] and 
demonstrated to cleave the C terminus of Eph receptor ligand, Ephrin B1, 
which makes pancreatic cancer cells more invasive [222, 223]. Thus MMP-8 
appears to have different functions in different settings.  
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Macrophage inflammatory protein-1α (MIP-1α) has also been identified as a 
non-matrix substrate of MMP-8 [209, 224], and MMP-8-/- mice also showed 
down regulation of active TGF-βI and reduced activation of IL-10 [153].  
 
Mutational analysis in malignant melanoma identified a number of frequent 
mutations in MMP-8 which were accompanied with LOH and reduced 
Collagenolytic activity [217]. Based on the nonsynonymous to synonymous 
mutation ratio, these mutations are identified as driver mutations. The 
mutated forms or WT MMP-8 was stably over-expressed in Mel-STR human 
melanocytes. The WT but not the mutated forms significantly blocked 
anchorage independent colony growth in soft agar colony formation assays 
in vitro. In vivo, Mel-STR cells over-expressing WT MMP-8 when injected 
subcutaneously into Non obese diabetic/severe combined immunodeficiency 
(NOD/SCID) mice did not form ulceration (an indicator of aggressiveness of 
melanoma) or lung metastasis whereas cells expressing mutated MMP-8 
developed numerous lung metastases though no difference in primary 
tumour growth rate, once again demonstrating the suppressor role of MMP-8 
on metastatic potential [217]. In keeping with the reduced enzymatic activity 
in the mutated forms this study once again implicates the role of enzymatic 
action in its biological role. According to recent findings whether the loss of 
tumour suppression depends on the absence of WT MMP-8 or presence of 
mutant MMP-8 is not clear [225]. To date, no such mutations have been 
reported in breast cancer or its microenvironment.  
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Gutierrez-Fernandez and colleagues demonstrated the formation of specific 
MMP-8/MMP-9 complexes in isolated bone marrow cells of WT mice (this 
complex did no longer exist in bone marrow cells of MMP-8 knockout or 
MMP-9 knockout mice). The biological significance of these complexes is 
under investigation but binding of MMP-8 might change activity of MMP-9 
and vice versa [209]. 
 
Recently it was reported that over-expression of catalytically active MMP-8 
enhanced expression of IL-6 and IL-8 in a number of breast cancer cell lines 
including MDA MB 231 and MCF-7 but not in the non-cancerous mammary 
epithelial cell line HMT-3522 S1 [212]. This effect may involve nuclear factor-
κβ (NF-κβ) signalling since a pharmacological inhibitor of NF-κβ significantly 
down-regulated the IL-6 and IL-8 secretion. In contrast, MMP-8 WT over-
expressing MDA MB 231 cells reduced colony formation in vitro compared to 
Empty vector or inactive MMP-8 over-expressing cells. Furthermore 
treatment of parental MDA MB 231 cells with recombinant IL-6 significantly 
induced MMP-8 expression, which indicates an immunomodulatory circuit 
generated in this system [212].    
 
Previous work from our own lab has shown that the expression of MMP-8 in 
normal breast is almost exclusively restricted to the MECs (Figure 1-11) 
[215]. The expression of MMP-8 by MECs shows a gradual loss through 
cancer progression which correlates with their loss of suppressive activity 
[215]. When total mRNA was isolated from invasive breast cancers and an 
RT-PCR approach was taken, invasive breast cancers showing expression 
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of MMP-8 were associated with lower lymph node metastasis and good 
prognosis [215]. In addition four SNPs have been identified for MMP-8 in 
breast cancer patients and the T allele (minor allele) is once again 
associated with reduced risk of lymph node metastasis [226]. 
 
 
 
 
 
 
Figure 1-11: MMP-8 localisation in normal breast versus DCIS. A: 
Localisation of MMP-8 staining to MEC-BM interface in normal breast, B: 
Diffuse cytoplasmic staining of neoplastic cells and loss of MEC-BM staining 
in DCIS (arrow heads) [215]. 
 
To conclude, the mechanism by which MMP-8 acts as a tumour suppressor 
in normal breast is not fully understood, and the biologic significance of its 
loss in MECs during DCIS progression remains to be elusive.  
 
This project is focused on the interaction of the microenvironment with the 
cancer cell, particularly on the paracrine interaction between MECs, LECs 
and stroma via MMP-8 and loss of this mechanism in DCIS. 
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1.5 Integrins 
 
1.5.1 Classification  
 
Integrins are a superfamily of transmembrane cell adhesion molecules which 
can directly bind components of ECM and act as a transmitter between the 
external environment and cytoskeleton to supply traction for cell migration 
and invasion [227]. Integrins consist of heterodimers of distinct α and β 
subunits in various combinations. In humans, at least 18α and 8β subunits 
form 24 heterodimers which have distinct but partially overlapping ligand 
repertoire (Figure 1-12) [227, 228]. The extracellular part of each subunit 
generates a specific surface for ligand binding. Most integrins have a short 
cytoplasmic domain comprising less than 75 amino acids; the β4 integrin 
subunit is unique in having a cytoplasmic domain of 1000 amino acids. The β 
integrin cytoplasmic tail has a tyrosine residue, the phosphorylation of this 
residue can result in various responses in integrin function (Figure 1-13) 
[227, 228]. Upon ligation to ligand, integrins cluster in the cell membrane, α 
and β units show conformational change and recruit adaptor molecules such 
as talin which binds and therefore provides connection to the actin 
cytoskeleton, and signalling molecules such as focal adhesion kinase (FAK) 
which acts as a phosphorylation-regulated bridge for Src family kinases 
(SRKs) and facilitates assembly of focal adhesion structures. Recruitment of 
FAK activates signalling through several pathways such as PI3K, Rac, NFκβ 
and ERK/MAPK [229]. Focal adhesions are dynamic structures that 
transduce the outside information such as differences in extracellular forces 
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or ligands into the cell in a mechanism known as outside-in signalling. 
Divalent cations exist in the matrix microenvironment and are involved in 
initial cell-ECM engagement. Both extracellular integrin subunits have cation 
binding sites; cations such as calcium (Ca++), magnesium (Mg++), and 
manganese (Mg++) are required for formation of the tertiary structure of 
integrin-ligand complexes, and an abundance of divalent cations can 
influence integrin binding affinity [227, 230].   
 
Integrin affinity can be also regulated by inside-out signaling that controls 
integrin activity. The binding of talin to β integrin cytoplasmic tail triggers the 
disassociation of α and β cytoplasmic units and straightens the folded 
extracellular integrin structure. These conformational changes in extracellular 
regions result in increased ligand affinity [227, 230].  
 
The repertoire of integrins on the cell surface dictates ECM sensing and 
response, as well as modulating signalling pathways involved in cell 
behaviour such as proliferation, survival, adhesion, and motility on different 
substratum [227, 230].  
 
Some integrins, such as β1, are ubiquitously expressed whilst others are 
restricted to defined cell types, for example, α6β4 is expressed in basal cells 
at the cell-BM interface, including keratinocytes and MECs. 
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Figure 1-12: The classification of integrins according to ligand. The 
black lines indicate heterodimer formation. Figure adapted from Hynes., 
2002, Takada et al., 2007 and Thomas, Nystorm, Marshall, 2006 [227, 231, 
232]  
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Figure 1-13: Integrin structure (α and β subunits) and signalling 
pathways downstream of integrin activation. Phosphorylation of the β 
subunit activates various pathways including ERK/MAPK, Rac and PI3K 
which modulate cell proliferation, cell survival and migration. Figure adapted 
from Guo et al., 2004 [229].  
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1.5.2 Integrins in Cancer 
 
Altered integrin expression profiles in cancer cells compared to normal tissue 
have been repeatedly reported [227-229]. Given the central functions of 
integrins in ECM sensing and regulation of cell behaviour; cancer cells may 
be expected to down-regulate integrins that mediate stable adhesion to ECM 
and maintain cell quiescence (resting state) and differentiation, and up-
regulate integrins that provide growth advantage and motility [233]. The 
context of aberrant integrin expression in cancer is complex and varies 
according to cell type [227-229]. The impact of a particular integrin therefore 
will depend on the overall integrin repertoire of the cell and the environment 
to which it is exposed [233].  It is also well established that integrins are 
associated with receptor tyrosine kinases (RTKs) and growth factor receptors 
[227-229].     
 
Immunohistochemical profiling of integrins in normal, DCIS and invasive 
breast cancer tissue reveals that in normal breast MECs are the dominant 
source of α1, α2, α3, α6, αv, α9, and β1 and β4 subunits, with β4 being 
almost exclusive to MECs (Table 1-1) [234-237]. These subunits are 
polarised at MEC-BM interface. In DCIS this phenotype is largely maintained 
(Table 1-1) but in invasive breast cancer an overall decrease in integrin 
expression is reported [234-237]. However, expression of certain integrins 
are correlated with clinical outcome. Expression of the β4 subunit is strongly 
correlated with increased tumour size and higher nuclear grade [238]. 
Similarly expression of the α6 subunit is correlated with metastasis formation 
and reduced survival [239].  More recently, it also has been demonstrated 
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that α6 and β4 sub units are over-expressed in aggressive Basal-type breast 
tumours [240].  
 
Integrin Normal Breast DCIS 
MEC LEC MEC Cancer 
α1 ++ +/- +++ - 
α2 ++ + ++ - 
α3 +++ + +++ + 
α6 +++ +/- ++ +/- 
αv + +/- +/- + 
β1 ++ +/- ++ + 
β4 ++ +/- ++ - 
 
Table 1-1: Comparison of the integrin repertoire of normal LEC and 
MEC and the same cell components in DCIS.– not expressed, +/- unclear 
expression, + low expression, ++ intermediate expression, +++ high 
expression.  Table adapted from Koukoulis et al., 1991, Shaw, 1999 and 
Lambert et al., 2012 [235-237] 
 
1.5.3 α6β4 Integrin and Hemidesmosomes 
 
Stable attachment of basal cells to BM is achieved by anchor like structures 
called hemidesmosomes (HDs) which link the keratin cytoskeleton to the BM 
[109, 241-243]. These structures (Type I HD) are composed of α6β4 integrin, 
CD151 tetraspanin protein, Bullous pemphigoid (BP) 180 transmembrane 
protein, BP240 and plectin (HD-1) [244, 245]. The β subunit of α6β4 contains 
two pairs of fibronectin type III repeats and a connecting domain. α6β4 can 
attach to plectin at two regions; one spans the second fibronectin repeat and 
connecting segment, and the other spans the third fibronectin repeat 
carboxyl terminal [246, 247]. The extracellular domain of α6β4 acts as a 
receptor for laminin 3-3-2. [248]. CD151 interacts with α6β4 and mediates 
outside-in signalling [249, 250].    
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The basal layer of the skin is made up of basal keratinocytes. MECs and 
keratinocytes share a number of characteristics including integrin repertoire 
[251]. The function of α6β4 has been extensively studied in keratinocytes. An 
α6β4 knock out system revealed the role of α6β4 in skin integrity, since α6β4 
null mice show severe skin blistering [252]. The epidermis of α6β4-/- mice 
detached immediately after birth and the offspring die shortly after. Further 
investigation of the skin in α6β4-/- mice by immunostaining for HD molecules 
and electron microscopy showed that neither integrin α6 subunit nor plectin 
was nucleated at the basal surface of basal keratinocytes indicating lack of 
HD formation. Furthermore, it was shown that keratin filaments of 
keratinocytes were unable to anchor to basal plasma membrane [252]. 
Residual keratinocyte attachment may be due to the activity of α3β1 [252].   
 
The HD structure is dynamic and can disassociate upon a migratory signal 
(Figure 1-14), mainly from growth factors such as EGF [244, 248, 253, 254] 
which mediates α6β4 tyrosine or serine phosphorylation [255, 256]. α6β4 
can be phosphorylated at specific serine residues by PKC-α which also has 
been shown to have play a role in HD dynamics [247, 248, 257]. This post 
transcriptional alteration disrupts α6β4-HD linkage, and α6β4 dislocates from 
HD and shuttles to actin rich filopodia where it promotes cell migration 
(Figure 1-14). α6β4 lacks an actin binding site therefore a linker protein is 
employed to achieve α6β4-actin association. Plectin contains an actin 
binding site (as well as a keratin binding site), and this site can also bind to 
α6β4 [258]. Therefore actin and α6β4 compete for plectin binding; in other 
words if plectin is bound to α6β4 its binding to actin is inhibited. In keeping 
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with this BP230 is proposed to be the actin-α6β4 linker in filopodia [244, 248, 
253, 254]. This might explain the contradictory effects of α6β4; that it can be 
both involved in stationary cell adhesion and migration dependant on its 
localisation in the cells [245]. Therefore, inhibition of kinase activity is a key 
process to maintain intact hemidesmosomal structures. This is in contrast 
with the formation of focal contacts where phosphorylation of integrin β 
subunit is needed [233].  
 
Phosphorylation of the intracellular β4 subunit can also amplify several signal 
transduction pathways (Figure 1-15). There is some dispute about the 
interaction between α6β4 and FAK. The early reports showed that α6β4 
does not bind FAK mainly due to absence of intracellular FAK binding 
domain in both α and β intracellular subunits [259]. Nevertheless recent 
articles reported co-immunoprecipitation of α6β4, FAK and adaptor molecule 
Src in endothelial cells [260, 261].  It is also shown that α6β4 intracellular 
domains lack binding a sequence for PI3K [259]. However α6β4 can still 
activate PI3K-Akt and affect downstream of Rac which mediates invasion of  
MDA MB 435 in transwell invasion assays [262]. Mammalian target of 
rapamycin (mTOR) which is a downstream element of Akt was shown to be 
activated by α6β4 and signal via eIF-4E and induce expression of VEGF 
[263] in MDA MB 231 breast carcinoma cells. As well as enhancing tumour 
angiogenesis; VEGF expression by this α6β4 dependent mechanism triggers 
PI3K signalling which creates an autocrine circuit and contributes to breast 
cancer cell survival [263]. This shows that α6β4 can regulate growth factor 
expression.   
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Laminin-3-3-2 ligation by α6β4 can also be involved in anchorage 
independent cell survival via a mechanism dependent on Rac, involving NF-
κβ activation and shuttling to the nucleus where it can induce transcription of 
anti-apoptotic factors [264, 265]. This mechanism is independent of PI3K. 
Weaver and colleagues generated a 3D reconstituted BM (Matrigel) system 
in which they grow the normal mammary LECs model (isolated from 
reduction mammoplasty) and by sustained passaging and growth factor 
withdrawal they have generated cells that spontaneously acquired 
tumourigenic properties. They showed that normal but not their tumourigenic 
counterparts polarised correctly in the 3D system, judged by α6β4 and 
laminin-3-3-2 staining on the cell-BM interface, and generate acini which are 
resistant to apoptosis in part due to the activation of endogenous NF-κβ. 
Moreover they showed that HD assembly is important in maintaining correct 
polarity, active NF-κβ and resistance to apoptosis [265].  It should be noted 
that in this study the glandular structures are composed only of LEC, 
whereas in human breast tissue LECs are surrounded with MECs which are 
the predominant source of α6β4. 
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HD disassembly is a well established mechanism of keratinocyte migration in 
wound healing and re-epithelisation [245, 266]. Ozawa and colleagues 
compared the dynamics of focal adhesion and HD like structure formation in 
HaCat keratinocyte cells. Although cultured cells maintain the expression of 
HD proteins they failed to construct bona fide HD assembly whereas the 
cells form HD rich protein clusters [245, 266]. In contrast, keratinocytes form 
focal adhesions under tissue culture conditions while the importance of these 
adhesions in vivo intact skin is debatable [245, 266]. Ozawa and co-workers 
employed scratch wound assay and showed that focal adhesions assemble 
where filopodial structures are formed and HD structures are located 
immediately behind focal adhesions. α6β4 was needed to establish directed 
migration since treatment with an α6 integrin function blocking antibody 
(repeated with β4 antibody) disrupted HD structures. Cell movement was 
random, not directed [267, 268]. Moreover under this condition in which α6β4 
activity is blocked, cell polarity was lost and HaCat cells showed rounded 
morphology implying a role for α6β4 in cellular spread. In contrast when α3 
integrin-function blocking antibody was used to interrupt focal adhesions the 
cell migration was inhibited and HD structures were stabilised in the plane of 
the cell membrane. When plectin was knocked down keratinocyte migration 
was induced. Therefore assembly and disassembly of focal adhesions and 
HD structure are intricately linked in order to regulate cell migration (during 
wound closure).  
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Figure 1-15: Summary of the signalling pathways associated with α6β4. 
α6β4 can be phosphorylated either with PKC-α or Fyn under the control of 
binding EGF to its receptor and activates several downstream pathways 
including Rho, Rac, Ras, PI3K which result into cell proliferation, survival and 
migration.  Figure adapted Mariotti et al., 2001, Dans et al 2001., Mainiero et 
al., 1996, Santoro et al., 2003, Cantley et al., 1994, Shaw et al 1997, Chung 
et al., 2002, Zahir et al., 2003, Weaver et al., 2002 [253, 255-257, 259, 262-
265].  
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involved in signalling in cell migration [269-271]. MMP-2, 3, 12, 13, 20 and 
MT1-MMP can process laminin γ2 chain at an identical N terminus sequence 
(Ala586-Leu587), whereas α3 and β3 chains remain intact, which triggers 
mammary epithelial cell migration over laminin-3-3-2 in transwell migration 
assays, in which MCF-7 or MCF10A cells were plated on laminin-3-3-2 
coated transwells and incubated in presence of the various MMPs listed 
[269-271]. Moreover MCF10A cells seeded on processed laminin-3-3-2 
showed microscopic features of a migratory phenotype filopodial and 
lamellipodial structures [269]. It is further shown that processed laminin γ2 
chain is found in tissue extracts from mouse skin carcinoma or breast of 
pregnant rat but not in quiescent rat breast [269]. Interestingly MMP-8 was 
also shown to cleave laminin γ2 chain at a distinct sequence (Leu587-Thr588) 
from other MMPs, but this does not result in significant induction of cell 
migration [270].  Intriguingly, in contrast with the γ2 chain cleavage, laminin-
3-3-2 can be also proteolysed at α3 chain by plasmin which promotes HD 
assembly formation and hampers cell motility [272].  
 
MMP-2 is expressed by stromal cells around the tumour and laminin-3-3-2 is 
expressed by and nucleated at the invasive front of colon and breast cancer 
cells [269]. Therefore cancer cell-microenvironment crosstalk can be 
fundamental for cancer cell invasion.   
 
MMP-2 activation occurs via a unique mechanism in which the MT1-MMP 
and TIMP-2 are involved [273]. Further detailed information by Koshikawa 
and colleagues revealed the dependence of MT1-MMP activity in MMP-2 
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derived the γ2 chain processing [271]. Dual-immunofluorescent staining of 
human breast tissue for either laminin-3-3-2 and MT1-MMP or laminin-3-3-2 
and MMP-2 showed that laminin-3-3-2 is predominantly expressed at the 
outer (invasive) edge and it is well co-localised with MT1-MMP or MMP-2 
[271]. MT1-MMP is anchored to the cell membrane; therefore it can spatially 
cluster MMP-2 activation and laminin-3-3-2 cleavage to invasive interior and 
forms migration promoter cues along BM. This is of importance especially in 
early stages of invasion such as during the in situ stage where the local 
invasion depends on the context of external factors (BM).  
 
1.5.4 Integrin αvβ6  
 
αvβ6 integrin is an epithelial cell specific integrin that is largely undetectable 
in normal tissue but is up-regulated in many cancers and in wound healing 
[227, 231, 232, 274]. Over-expression of αvβ6 has been described in several 
cancer types including breast cancer [275], oral cancer [227, 231, 232, 276], 
colon cancer [277-280], basal cell carcinoma [281] and squamous cell 
carcinoma [282]. αvβ6 is a receptor for the RGD motif (arginyl-glycyl-aspartic 
acid), therefore it binds to  fibronectin, vitronectin and tenascin as well as the 
latency associated peptide (LAP) of TGF-β [227, 231, 232, 283]. Binding of 
αvβ6 to LAP activates TGF-β [227, 231, 232]. There is accumulating 
evidence showing that αvβ6 is involved in cancer progression by promoting 
tumour cell invasion, blocking apoptosis, up-regulating MMP expression, and 
activating TGF-β and therefore modulating TGF-β signalling [227, 231, 232, 
275, 278]. The role of αvβ6 integrin in inducing normal oral keratinocyte 
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migration was shown to be dependent on up-regulation of MMP-9 [274]. 
Moreover, a switch from αvβ5 to αvβ6 occurs in keratinocytes during 
transformation to malignancy and this contributes to anchorage independent 
growth of malignant keratinocytes [282]. 
 
1.6 Transforming Growth Factor-β 
 
TGF-β is a growth factor widely implicated in cancer metastasis [284-286]. 
There are three TGF-β isoforms and receptors. TGF-βI preferentially signals 
through TGF-β receptor (TGF-βR) II.  TGF-βRII and ligand complex has high 
affinity for TGF-βRI. Therefore TGF-βRII and TGF-βRI form a heteromeric 
signalling complex. This complex triggers phosphorylation of downstream 
elements SMAD-2 and SMAD-3 which than form a complex with mediator 
SMAD-4 [285]. These complexes then shuttle to the nucleus where they 
regulate transcription of various TGF-β responsive genes [285]. In addition 
TGF-β can act in a SMAD-independent manner [285, 286]. 
 
The genes under control of TGF-β induced transcription include integrins, 
integrin ligands and integrin-related proteins such as adaptor proteins [286]. 
TGF-β is secreted as a latent form non-covalently conjugated with LAP and 
latent TGF-β binding protein (LTBP). During the activation of TGF-β it is 
disassociated from the inactive complex. TGF-βI and TGF-β3 contain RGD 
motifs in LAP-1 and LAP-3 respectively which is a recognition sequence for 
integrins particularly αv integrins [286]. Binding of αvβ6 to the LAP N 
terminus results in a conformational change and therefore activates TGF-β 
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[283, 286]. The activation of TGF-β by integrins is found to be physiologically 
relevant since mice devoid of αvβ6 and αvβ8 show similar defects to those 
seen in TGF-βI and TGF-β3 knockout mice, such as severe autoimmunity 
syndrome, cleft palate and lack of Langerhans cells [287]. Interestingly active 
TGF-β has been reported to be restricted to the epithelial cell surface in the 
normal mammary gland suggesting that activation of latent TGF-β takes 
place locally on a cell by cell basis [288].  
 
TGF-β plays a dual role during cancer progression; in early stages it acts as 
a tumour suppressor for epithelial cells, mainly by inhibiting cell proliferation, 
but in later stage disease, TGF-β is associated with tumour progression, via 
mechanisms including cancer cell and host-tumour interactions [284-286]. 
This dual role is mainly due to the involvement of TGF-β in complex 
mechanisms influencing cell survival, proliferation and differentiation. In 
keeping with this the over-expression of TGF-β is correlated with many 
cancer types including breast, prostate and colorectal cancer [284-286, 289]. 
The serum level of TGF-β was found to be elevated in breast cancer patients 
[290], and Yang et al hypothesised that there may be a critical level of TGF-β 
in tissues and when this is exceeded the undesirable effects of TGF-β might 
be triggered [291]. Yang and colleagues generated a transgenic mouse 
model expressing soluble TGF-βRII antagonist under the regulation of 
MMTV. When isogenic melanoma cells were injected via the tail vein, these 
mice were resistant to development of liver metastases, moreover when 
crossed with MMTV-neu to generate a metastatic breast cancer model, 
interestingly primary tumourigenesis was not accelerated, but there was a 
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significant reduction in formation of lung metastasis. This mouse model did 
not show other pathological features of lack of TGF-β-/- mice, such as 
immune system dysfunction and it was hypothesised by the authors that the 
soluble antagonist might only block the metastasis-associated action of TGF-
β whereas the regulatory action of TGF-β in normal tissue remains functional 
[291].  
 
In human breast cancer secreted TGF-βI was shown by 
immunohistochemistry to be localised at the invading front of the primary 
tumours following collagen tracks and metastases of lymph nodes [289].  
 
Yin and colleagues used MDA MB 231 cells to over-express a dominant 
negative mutant of TGF-βRII lacking most of the cytoplasmic domain, in 
order to block TGF-β responsiveness [292]. When treated with TGF-β in 
vitro, proliferation of mutant TGF-βRII transfected cells was not altered but 
that of control MDA MB 231 cells was down-regulated [292]. Conversely, in 
an experimental in vivo bone metastasis model when injected in the left 
cardiac ventricle of female nude mice, mutant TGF-βRII transfected MDA MB 
231 cells reduced bone metastasis formation when compared to non-
transfected MDA MB 231 counterparts while there was no difference 
between mutant TGF-βRII bearing or control cells in terms of primary tumour 
formation after cells were administered intramuscularly into the right thigh of 
female nude mice [292]. This study again underscores the role of TGF-β to 
act as metastasis promoter rather than influencing primary tumour growth. 
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In this study, Transwell invasion assays and 3D organotypic assays were 
used. In the first assay, cancer cells were plated onto a cell permeable 
membrane coated with Matrigel, which represents BM, and MECs were 
seeded in the outer chamber as described in 2.8. During the assay cancer 
cells cross the Matrigel barrier, this requires degradation of Matrigel and 
migration. The assembly of this assay allows study of the paracrine 
interactions between two cell types. The advantages of the Transwell 
invasion assay incudes short incubation period (24 or 48 hours according to 
cancer cell type) and requirement for low cell numbers [320]. However this 
set up lacks the fibroblast compartment of the microenvironment and the 3D 
assembly of breast tissue, therefore 3D invasion assays which recapitulate 
the breast tissue architecture is needed for a better understanding of breast 
cancer cell invasion [309, 319, 320]. As a 3D model, organotypic gels were 
prepared using a Matrigel-Collagen mixture. Fibroblasts were embedded in 
the organotypic gels to create physiological-like microenvironmental effects. 
MECs and breast cancer cells were seeded onto gels to mimic the double 
layered breast duct. In comparison to Transwell invasion assays, organotypic 
cultures require longer incubation time (10 days) and greater cell numbers. In 
the current study, normal breast fibroblasts were used, since they are 
available in our laboratory. Although normal fibroblasts have been shown to 
be sufficient to induce formation of invasive breast tumours, probably via 
tumour cells inducing a myofibroblast phenotype [74, 117, 130], recently it 
was shown that CAFs behave significantly different to normal fibroblasts in 
organotypic assays [330]. When fibroblasts were collected from different 
stages (pre-invasive and invasive) of the MMTV-PyMT mouse model and 
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embedded in organotypic gels, CAFs promoted significantly more cancer cell 
invasion and contracted the gel significantly more than normal fibroblasts, 
indicating a greater ability of CAFs to remodel the ECM [330]. Thus, to 
understand the effect of cancer related stroma, there is an argument that 
CAFs should be used in organotypic cultures in place of normal fibroblast 
populations. 
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2 Materials and Methods 
 
2.1 Cell Lines and Cell Culture 
 
All breast cancer cell lines were obtained from American Type Culture 
Collection (ATCC) and verified with STR profiling (LGC Standards, 
Teddington, UK, tracking number 710081047). MDA MB 231 and MCF-7 
cells were cultured in Dulbecco's modiﬁed Eagle's medium (DMEM, PAA, 
E15-843) containing 10% (volume/volume, v/v) Fetal Bovine Serum (FBS, 
PAA, A15-14), hereafter termed complete medium. SUM159 cells were 
grown in complete HAM F12 (PAA, E15-817) with hydrocortisone (Sigma, 
HO 888, 1µg/ml) and insulin (Sigma, I9278, 1µg/ml).   
 
Cell line Media Supplement  Concentration 
MDA MB 231  DMEM                    Fetal Bovine Serum  10% 
MFC-7 DMEM FBS 10% 
SUM159  HAM F12 FBS 10% 
  Hydrocortisone 
(Sigma, HO 888) 
1µg/ml 
 Insulin 
(Sigma, I9278) 
1µg/ml 
Table 2-1: List of breast cancer cell lines used and the details of media 
and supplement.  
 
2.2 Generation of MEC Lines 
 
The human telomerase reverse transcriptase (h-TERT) immortalised MEC 
1089 cell line was a kind gift from Prof M. O’ Hare, and Prof P. Jat, Institute 
of Neurology, UCL, London. These cells were isolated from reduction 
mammoplasty tissue as described by Gomm et al., 1995 [293], immortalised 
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as described by O’Hare et al., 2001 [294] and termed as Myo 1089 cell line. 
This cell line originally was a mixed population composed of MECs express 
differing levels of α6β4. These cells were sorted by their α6β4 expression 
using β4 antibody (Millipore, MAB 1964) coated magnetic beads (Dynal 
Invitrogen, 110.31). The cell line generated by this selection was called β4-
1089 and fully characterised to demonstrate MEC features including 
expression of vimentin, SMA, p63 (Dr. M.D. Allen personal communication). 
In order to generate an αvβ6 integrin over-expressing cell line, AM12 
packaging cell line was transfected with either empty pBABE-puro vector, or 
vector containing β6 integrin insert (Addgene plasmid:1734). β4-1089 cells 
were cultured with the media collected from control or β6 carrying AM12 cells 
and selected for puromycin (Sigma, P8833, 1µg/ml) resistance. Control and 
αvβ6 over-expressing cell lines were called 1089-N (Myo-puro) and 1089-β6 
(Myo-β6) respectively. These cell lines were shown to switch their phenotype 
over time in culture; most notably they show gradual α6β4 integrin down 
regulation. In order to maintain α6β4 expression, cells are enriched by 
positive selection on β4 antibody-coated anti-mouse magnetic beads every 
10-13 weeks. Along with this enrichment 1089-β6 cells are re-sorted by 
positive selection on αvβ6 coated beads, whereas 1089-N cells are 
negatively selected.   
 
These cells were cultured in the presence of hydrocortisone (1µg/ml), 
Epidermal Growth Factor (EGF, Sigma, 9644, 10ng/ml), insulin (1µg/ml) and 
puromycin. 
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2.3 Isolation of Primary LEC and MEC Populations from Normal 
Breast and DCIS 
 
The cell isolation protocol was adapted from Gomm et al 1995 [293]. 
Reduction mammoplasty tissue was collected and used to prepare breast 
organoids. The tissue was chopped and digested overnight at 37˚C with 
collagenase (1 mg/ml, Sigma, C2674) and hyaluronidase (Sigma, H3506) on 
a roller-mixer. The following day the fat layer was separated by decanting 
and organoids and single cells were washed three times with RPMI (PAA, 
E15-840) and followed by 3 sedimentation steps at room temperature (RT) to 
isolate the fibroblast-containing stromal compartment. After each 30 minutes 
sedimentation step the supernatant was removed and kept. In order to get a 
single cell suspension, the sedimented organoids were digested with 1X 
trypsin/EDTA (PAA, L11-004) –Dnase (Roche Diagnostics, 10104159001) 
for 30 minutes after washing with phosphate buffered saline (PBS). The 
digest was stopped with RPMI containing 10% FBS and the cell suspension 
was filtered through gauze (pore size: 56μm2, Henry Simon, Stockport). Cells 
were counted and incubated in a 1:1 ratio sequentially with  magnetic beads 
coated with CALLA antibody (AbD serotech, MCA1556)  to isolate MECs, 
followed by magnetic beads coated with EpCAM (Ber-EP4) antibody 
(Invitrogen, 161.02) to isolate LECs, at 4˚C for 15 minutes on a roller-mixer. 
This bead/antibody complex-cell suspension was diluted with RPMI and 
bound cells were isolated using a magnet (Dynal, MPC-1, 120-01). Further 
incubations with magnetic beads were employed until depletion of each cell 
type was achieved. The bead/cell pellet was washed and grown in tissue 
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culture according to conditions described in Gomm et al 1995 [293].  For 
DCIS associated MEC and LECs, cells were isolated from DCIS tissue; 
organoid digests were incubated with β4-integrin antibody coated magnetic 
beads as explained above to select MECs and followed by an incubation 
step with anti-EpCam beads for LECs.   
 
 
Figure 2-1: Diagram showing isolation of normal primary cells from 
reduction mammoplasty tissue. For DCIS associated cells, DCIS tissue 
was used and anti-β4 antibody was used to isolate MECs. Adapted from 
Gomm et al., 1995 [293].  
 
2.4 MMP-8 Gene Over-expression 
 
The MMP-8 WT and inactive MMP-8 EA (E198A) plasmids were kind gifts 
from Dr Dylan Edwards, Dr Julie Decock and Sally Thirkettle, University of 
East Anglia, Norwich [212]. Empty pcDNA4/TO (Invitrogen, K103002) was 
used for generation of control group.  
 
 
Breast tissue 
Organoids 
Stromal cells 
Collagenase Hyaluronidase 
Sediment Adhesion 
Single cells 
Epithelial cells 
Myoepithelial 
cells 
EpCam beads 
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Figure 2-2: Map of pcDNA.4/V5-His A vector contains MMP-8 insert. 
Adapted from pcDNA.4/V5-His A, B, and C User manual, Version D 
11/09/11, Invitrogen.  
 
500ng of plasmid was digested with a digest mixture (Table 2-2) for 2 hours 
at 37˚C. The digest products were ran in 1% (weight/volume, w/v) agarose 
(Invitrogen,16500-500) in Tris acetate-EDTA (TAE), for 45 min at 100v.  
 
Component Amount (µl) 
EcoR1 (NEB, RO1O1T) 1 
Xho1 (NEB, R0146S) 1 
Bovine serum albumin (BSA) (NEB, B9001S) 0.25 
EcoR1 buffer (NEB, B0101) 2.5 
Table 2-2: Mixture prepared for plasmid digest. Total volume was 
adjusted to 25µl with nuclease free water.  
 
The sequence was confirmed with sequencing using T7 primers. For detailed 
information see appendix. 
 
Myo-β6 cells were plated 24 hours prior to transfection at a density 7x104 
cells per well onto a 6-well plate in complete HAM F12. On the day of 
CMV promoter: bases 209-863 
T7 promoter/priming site: bases 863-882 
Multiple cloning site: bases 895-1008 
V5 epitope: bases 1009-1050 
Polyhistidine tag: bases 1060-1077 
BGH reverse priming site: bases 1100-1117 
BGH polyadenylation signal: bases 1009-1313 
f1 origin: bases 1366-1789 
SV40 promoter and origin: bases 1854-2178 
EM7 promoter: bases 2186-2241 
Zeocin™ resistance gene: bases 2261-2635 
SV40 polyadenylation signal: bases 2764-2894 
pUC origin: bases 3278-3951 
Ampicillin resistance gene: bases 4095-4956 
(complementary) 
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transfection, media was replaced with 2ml of fresh complete media. For one 
well of a 6 well plate 6μl Gene juice reagent (Novagen, 70967) was added to 
100µl Opti-MEM (Gibco, 51985, 026). This transfection cocktail was mixed 
quickly by vortex and incubated for 5 minutes at RT. 1μg of DNA (plasmid 
contains MMP-8 WT or MMP-8 EA insert, Empty vector) was added to 
media/gene juice complex and mixed gently by pipetting, then incubated at 
RT for 20 minutes. After incubation DNA/gene juice complex was added to 
cultured cells (100µl per well) drop wise and the flask was swirled to ensure 
equal transfection coverage, then incubated for 5 hours at 37˚C. After that 
the media containing transfection complexes was changed to 2ml complete 
media and incubated for 24 hours. All functional assays were done 24 hours 
after transfection. For conditioned media (CM) generation, complete media 
was changed to 2ml serum free media (SFM) after two washes with 1ml SFM 
per well and harvested after 24 hours incubation. CM were collected, spun at 
1200 rpm for 3 minutes to remove dead cells and kept at -80˚C. Cells were 
harvested for RNA or protein extraction. 
 
2.5 MMP-8 Gene Knock-down 
 
Myo-Puro cells were seeded onto 6-well plates at a density 7x104 cells per 
well and incubated for 24 hours at 37˚C in 2ml complete HAM F12. After 24 
hours the media was replenished and Myo-Puro cells were transfected with 
pooled MMP-8 small interfering RNA (siRNA) (Thermo Scientific, MU-
005969-00-0020), MMP-9 siRNA (Thermo Scientific) or Luciferase GL3 
Duplex control siRNA (Thermo Scientific, D-001400-01-20) [295] by using 
  
99 
 
Interferin transfection reagent (Polyplus tranfection, Peqlab, 409-01). All 
siRNAs are kept at 20µM stock and used at 4nM final concentration (For 
MMP-9 1nM final concentration was used). Therefore 24µl interferin 
transfection reagent was added to 13.2µl siRNA in 1200 µl SFM and mixed 
with vortexing for 10 seconds. Then the siRNA mixture was incubated for 10 
minutes at RT. After that the mixture was added to the 6 well plate (200µl per 
well) drop wise and the plate was immediately swirled to give a homogenous 
distribution of the siRNA mixture. All functional assays were carried out 96 
hours after transfection. CM was generated as described in 2.4.  
 
2.6 Reverse Transcription and Real Time Polymerase Chain 
Reaction 
 
RNA was extracted with QuickRNA miniprep kit (Zymo Research, R1054) 
and reverse transcribed by Super Script II (Invitrogen, 11064-014) according 
to manufacturer’s instructions. 100ng cDNA were used per reaction. Primer 
sequences (Invitrogen) and polymerase chain reaction (PCR) cocktail are as 
shown in Tables 2-3, 2-4, 2-5 and 2-6. All primers were kept at 100mM stock 
concentration and used at 0.4mM final concentration. 18s was used as 
housekeeping gene.  
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MMP-8 
Primers 
Sequence 5’-3’ Exon 
Forward  GGTAGAGTTTGAAGAGAAGATCATGTTC 1 
Forward  GCCGAAGAAACATGGACCAAC 4 
Forward  ACTCCTCTGACCCTGGTGCC 5 
Reverse TCCATT GGGTCCATCAAATGG 4 
Reverse  TGAGGATGCCTTCTCCAGAAG 8 
Reverse GGATACAGCCACATTTGATTTTGC 10 
Table 2-3: Primer sequences designed for MMP-8 and used in reverse 
transcription PCR. 
 
18s Primers Sequence 5’-3’ 
Forward CACGGGAAACCTCACCCGGC 
Reverse AACGGCCATGCACCACCACC 
Table 2-4: Primer sequences designed for 18s and used in reverse 
transcription PCR. 
  
β6 Primers Sequence 5’-3’ 
Forward GAAGGAATGATCACGTACAAG 
Reverse AGCAGGGAGTCTTCACAGGT 
Table 2-5: Primer sequences designed for β6 integrin and used in 
reverse transcription PCR.  
 
Component Amount (µl) 
Immomix Red (Bioline,Bio 25-022 )  11 
Forward Primer  1 
Reverse Primer  1 
Nuclease free water  10 
Table 2-6: PCR cocktail prepared for reverse transcription PCR. 
 
For nested PCR targeting MMP-8 mRNA; in the first run of PCR the 4F 
forward and 8R reverse primers were used and run for 35 cycles. 2μl product 
was used for a second run in which nested 5F forward and 8R reverse 
primers were used and run for 25 cycles to end the reaction in the linear 
phase. PCR cycle conditions were as summarised in Table 2-7 and for αvβ6 
in Table 2-8). 18s was used as internal standard. The products from first and 
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second run of PCR were run on a 1% agarose/TAE gel for 45 min at 100v 
and visualised under ultraviolet (UV) light (AutoChemi System).  
 
Step Temperature (C) Duration 
Hot Start 95 8 min 
Denaturation 94 30 sec 
Annealing 56 30 sec 
Extension 72 43 sec 
Extension 74 10 min 
Cooling  16  
Table 2-7: Cycle details for MMP-8 PCR 
 
Step Temperature (C) Duration 
Initial 
Denaturation 
95 1 min 
Denaturation 95 30 sec 
Annealing 50 30 sec 
Extension 72 1 min  
Extension 72 5 min 
Cooling  16  
Table 2-8: Cycle details for αvβ6 PCR 
 
Real Time PCR was done by using SYBR green chemistry (Applied 
Biosystems, 4367659) according to manufacturer’s instructions. 100ng cDNA 
input was used per reaction. Primers were used at 0.3mM final 
concentration. A PCR mix was prepared for each reaction as shown in Table 
2-9 for 10μl total volume. Reactions were run using a step one plus 
instrument (Applied Biosystems). 
Component Amount (µl) 
SYBR Green   5 
Forward Primer  1 
Reverse Primer  1 
Nuclease free water  2 
Table 2-9: PCR cocktail prepared for real time PCR. 
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2.7 Western Blotting 
 
The CM collected from Myo-Puro or Myo-β6 cells was concentrated 20 times 
with centrifugal units (Millipore, 4FC 800324) with 3K molecular weight cut off 
(MWCO) at 4000g for 45 minutes at 4˚C. The same volume of sample was 
prepared from each condition and boiled in reducing (β-Mercaptoethanol 
containing) or non reducing Laemmli buffer for 5 minutes at 95˚C. The cell 
lysates were prepared with radio immunoprecipitation assay (RIPA) buffer 
containing proteinase inhibitors (Calbiochem, 539131). The protein 
concentration was quantified by Biorad DC protein assay (Biorad, reagent A: 
500-0113, reagent B: 500-0114, reagent S: 500-0115) according to 
manufacturer’s instructions.   
 
10% Acrylamide -sodium dodecyl sulphate (SDS) separating gel (Table 2-10) 
and 5% stacking gel (Table 2-11) were cast. Samples were carefully loaded 
onto the gel. Recombinant human MMP-8 western blot (WB) standard (R&D 
Systems, WBC017) was loaded as a positive control and the gels run at 
125v for 90 minutes at RT. After protein separation, the gel was removed 
from the cassette and placed in a transfer assembly where it faces towards a 
nitrocellulose membrane (Hybond C extra, RPN203E) and was run at 30v for 
90 minutes at RT. After transfer the membrane was blocked with 5% (w/v) 
non-fat milk (Marvel) and 0.1% (v/v) Tween 20 (Applichem A 1389,0500) in 
phosphate buffered saline (PBS-T) for 1 hour at RT then probed with primary 
antibody prepared in blocking solution or 5% (w/v) bovine serum albumin 
(BSA, PAA, K45-001) containing PBS-T according to antibody 
manufacturer’s instructions, and incubated at 4˚C overnight. Primary 
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antibodies used are listed in Table 2-12. For MMP-8 over-expressing cell 
samples the membrane was probed with anti V5 antibody (Invitrogen, R960-
25) to detect the V5 tag. The membrane was washed with PBS-T 3 times for 
5 minutes. Depending on the species in which the primary antibody is raised, 
horseradish peroxidase (HRP) conjugated mouse secondary (Dako, P0447), 
rabbit secondary (Dako, P0448) or goat secondary (Dako, P0160) antibody 
was prepared in 5%milk PBS-T at 1/2000 dilution and added after 3 washing 
steps for 5 minutes with PBS-T, then incubated for 1 hour at RT. Finally the 
membrane was washed as described and developed with enhanced 
chemiluminescence (ECL- GE healthcare, RPN 2106). For antibodies 
against phosphorylated forms of SMAD-2 and SMAD-3 ECL prime was used 
(Amersham, RPN2135). 
 
Component Amount  Company  Cat no 
Sterile distilled water  4.6ml N/A N/A 
30% Acrylamide 
 
2.7ml National Diagnostics EC-890 
1.5M Tris (pH 8.8) 2.5ml Sigma T1503 
10% (w/v) SDS 100µl National Diagnostics EC-874 
Tetramethylethylenediamine 
 (TEMED)  
6µl Flowgen Bioscience H17459 
10% Ammonium persulfate  
(APS) 
100µl AGTC Bioproducts EC-504 
Table 2-10: Recipe of the separating gel prepared for WB. This recipe is 
for 1 gel.  
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Table 2-11: Recipe of the stacking gel prepared for WB. This recipe is for 
1 gel.  
 
Antibody name Host Dilution  Company  Cat no 
MMP-8 Mouse 1/500 R&D Systems mAb 908 
MMP-8 Rabbit 1/1000 Millipore  81016 
SMAD-2 Rabbit 1/1000 Cell signalling 3122 
pSMAD-2 Rabbit 1/1000 Cell signalling 3101 
SMAD-3 Rabbit 1/1000 Cell signalling 9523 
pSMAD-3 Rabbit 1/1000 Cell signalling 9520 
HSC70 Mouse 1/10000 Santa Cruz sc-7298 
Actin Goat 1/1000 Santa Cruz sc-1615 
αvβ6 Goat 1/500 Santa Cruz sc-6632 
V5 Mouse 1/5000 Invitrogen R960-25 
Table 2-12: Primary antibody list used for WB. 
  
2.8 Invasion Assay 
 
2x104 modified Myo-β6 or Myo-Puro cells were seeded into one well of a 24 
well plate in 500µl complete HAM F12 and incubated for 24 hours. After 
incubation 500µl complete media was replaced with 500µl SFM after 2 
washes with SFM to remove residual serum.    
 
One volume of Matrigel (9mg/ml, BD Biosciences, 354234) was mixed with 2 
volumes of ice-cold SFM according to the breast cancer cell line used, to 
give 3mg/ml concentration; for MCF-7, MDA MB 231 DMEM was used and 
Component Amount  
Sterile distilled water  3.4ml 
30% Acrylamide 830µl 
1M Tris (pH 6.8) 630µl 
10% (w/v) SDS 50µl 
TEMED 5µl 
10%APS 50µl 
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for SUM159 HAM F12 was used. Boyden chamber transwells (pore size: 
8µm2, Corning, 3422) were coated with 70µl diluted Matrigel and allowed to 
set for 1 hour at 37˚C. After 1 hour transwells were placed in wells of a 24 
well plate containing the appropriate transfected cell type. Then, 3x104 MDA 
MB 231, SUM159 or MCF-7 cells were seeded onto Matrigel and incubated 
for 24 hours for MDA MB 231 or SUM159 cells and for 48 hours for MCF-7 
cells at 37˚C. Following this, the cells that had invaded through Matrigel and 
attached to the underside of the transwell were harvested with 10x trpsin/ 
Ethylenediaminetetraacetic acid (EDTA- PAA, L11-003) for 1 hour at 37˚C. 
Cells were removed by washing the well and underside of the transwells 3 
times with 500µl trypsin then diluted 1/10 in isoton solution (BD, 342003) and 
counted with a CASY counter (Schärfe System). 
 
For Collagen-I invasion assay; transwells were coated with 50µl 200µg/ml 
Rat Tail Collagen-I (BD Biosciences, 354236) [296]. Collagen-I was set 
according to manufacturer’s instructions and as shown in Table 2-13.  
 
Component Calculation (μl) 
Total volume                
10x PBS               ⁄  
Stock Collagen-I                                 
                   1
 
1M NaOH                                
Distilled water                                    
        
Table 2-13: Calculation of Rat tail Collagen-I preparation for Collagen-I 
invasion assay (same calculation method was used for Collagen-I 
zymography). 
 
                                                          
1
This concentration is different for every lot.  
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Collagen-I was mixed with 10x PBS and distilled water then neutralised with 
1M NaOH (Sigma, S8045). All reagents were kept on ice until needed. 
Collagen-I solution was mixed gently by inverting. 
 
50µl diluted and neutralised Collagen solution was aliquoted into each 
transwell and set at RT overnight [107]. The invasion assay was constructed 
as described above by co-culturing with modified Myo-β6 or Myo-Puro cells. 
The number of invaded cells was counted as described previously.   
 
Figure 2-3: Diagram showing the invasion assay set up. A. Breast cancer 
cells seeded on top of Matrigel. B. Cancer cells invaded through Matrigel 
after incubation.  
 
2.9 Proliferation Assay 
 
To analyse MEC proliferation; 3x104 Myo-β6 or Myo-Puro cells were seeded 
per well onto a 24 well plate and incubated for 24 hours at 37˚C. After 
incubation, the media was replaced with 400µl fresh media, and 80µl 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) reagent (Promega cell titer 96 Aqueous, G5421) was 
added (5:1 media:MTS v/v ratio) then incubated for 1 hour at 37˚C. Following 
this the MTS containing media was mixed by pipetting and transferred to a 
MDA MB 231 
SUM159
MCF-7
Matrigel
Transwell
Modified MEC
Incubation
A B
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96 well plate as 120µl aliquots. The plate was read at A˚495 (Tecan, infinite 
F50).  
 
To analyse breast cancer cell proliferation 3x104 MDA MB 231, SUM159 or 
MCF-7 cells were treated with CM collected from modified Myo-β6 or Myo-
Puro cells. Incubation was 24 hours for MDA MB 231 and SUM159 cells and 
48 hours for MCF-7 cells, corresponding to the duration of the invasion 
assay. Proliferation was quantified by using MTS reagent as described 
above. 
 
 
Figure 2-4: Diagram showing MTS assay set up and regimen. This set up 
is for analysing the paracrine activity of MMP-8.  
 
2.10 Gelatine Zymography 
 
A gelatine solution (porcine skin type A gelatine, Sigma, G2500) of 2.8mg/ml 
was prepared by dissolving 28mg of stock gelatine in 10ml sterile distilled 
water in a microwave for 20 seconds (900w) and kept at -20˚C. The resolving 
gel was prepared with 4.6ml sterile distilled water, 2.7ml 30% acrylamide, 
2.5ml 1.5M Tris (pH 8.8), 100µl 10%SDS, 285µl 8% gelatine, 6µl TEMED 
and 100µl 10%APS to reach 8% acrylamide concentration. Stacking gel was 
Modified
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SFM
Harvest mediaStarvation for 24 hours Treat breast cancer cell
Breast cancer 
cells
Media from 
Modified 
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prepared with 3.4ml sterile distilled water, 830µl 30% acrylamide, 630µl 1M 
Tris (pH 6.8), 50µl 10%SDS, 50µl 10% APS and 5µl TEMED.   
 
The CM collected from modified MECs and concentrated as described in 
section 2.4 was added to non-reducing Laemmli buffer. Recombinant human 
MMP-2 (Calbiochem, PF037) and recombinant human MMP-9 (Calbiochem, 
PF038) were prepared as stock solutions of 10µg/ml and diluted  with sterile 
water to reach a final concentration of 10ng/ml and 20ng/ml respectively, 
then added to non-reducing Laemmli buffer.  
 
Samples and standards were loaded onto the gelatine gel and run for 50 
minutes at 200V using running buffer as explained in section 2-7. After that 
separation the gel was carefully removed from the cassette and placed in an 
air tight container and washed with 2.5% (v/v) Triton X-100, in sterile distilled 
water 4 times for 15 minutes. The gel was developed with developing buffer 
(10ml 1M Tris (pH 7.5), 8ml 5M NaCl (Fisher Scientific, BP358), 1ml 1M 
CaCl2 (Sigma, C7902), 1.6ml 2.5%Triton X-100 and 179.4 ml sterile distilled 
water). 20ml developing buffer was added and incubated overnight at 37˚C. 
Coomasie blue staining solution was prepared with 0.5g Coomasie blue R-
250 (Thermo Scientific, 20278), 250ml methanol (Fisher Scientific, M/4000, 
17), 100ml acetic acid (Sigma, A6283) and 150ml sterile distilled water. After 
incubation the gel was carefully transferred to a 150mm petri dish and 
stained with Coomasie blue for 1 hour, following which the staining solution 
was decanted and the gel was rinsed with destaining solution containing 1.5L 
methanol, 50ml Formic acid (Sigma, F0507) and 3.5L sterile distilled water. 
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Destaining solution was replenished and the gel was placed on a shaker until 
lytic gelatine bands appear.  
 
2.11 Collagen-I Zymography 
 
For Collagen-I zymography 2ml Collagen-I solution per gel was prepared as 
described in Section 2.8. Separating gel and stacking gel components were 
mixed in the order listed in the Tables 2-14 and 2-15 and allowed to 
polymerise.  
Component Amount  
1.5M Tris (pH 8.8) 1.3ml 
Collagen-I solution 1.9ml 
30% Acrylamide 1.7ml 
10% (w/v) SDS 50µl 
TEMED 2µl 
10%APS 0µl 
Table 2-14: Recipe for the separating gel prepared for Collagen-I 
zymography. This recipe is for 1 gel.  
 
Component Amount  
Distilled water 3.05mL 
1M Tris (pH 6.8) 1.25mL 
30% Acrylamide 650ul 
10% SDS 50ul 
TEMED 5ul 
10% APS 25ul 
Table 2-15: Recipe for the stacking gel prepared for Collagen-I 
zymography. This recipe is for 1 gel.  
 
After the gels set, samples were prepared, run and developed as described 
for gelatine zymography in Section 2.10.  
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2.12 Adhesion Assay  
 
Non-tissue culture treated 96 well plates were coated with 100µl of Plasma 
fibronectin, Rat tail Collagen-I, tenascin-C, laminin-I-I-I, Collagen–IV and LAP 
in triplicate (at concentrations listed in Table 2-16), 3 wells of each plate were 
coated with 0.1%BSA in PBS as a control. Coated plates were incubated for 
1 hour at 37°C after which the wells were washed 2 times with 100 µl PBS 
per well. 
 
Table 2-16: List of ECM used in adhesion assay and concentration 
details. The same ECM are used at the same concentrations in migration 
the assay. 
 
Modified MECs were serum starved for 24 hours in serum free HAM F12 
prior to the experiment. 3x103 cells were seeded in 100 µl of SFM per well 
and allowed to adhere for 1 hour at 37°C, then 0.25µl of Calcein AM 
(Invitrogen, C1430) cell tracker was added and incubated for 15 minutes at 
37°C. After this the plate was washed twice with 100µl PBS per well and 
100μl SFM was added. The plate was read at A˚490/520 on a fluorescent plate 
reader (BMG Labtech, FL40star Optima) and the adhesion was calculated 
from the fluorescence of adherent cells.   
 
 
ECM Conc. (μg/ml) Company Cat no 
Laminin-I-I-I 10 Sigma L2020 
Collagen-I  0.5 BD Biosciences 354236 
Collagen-IV 10 Sigma C6745 
Fibronectin 1 Sigma F1141 
Tenascin-C 3 Millipore CC065 
LAP 0.5 Sigma L3408 
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Figure 2-5: Diagram showing adhesion assay set up.  
 
2.13 Immunoprecipitation for Conditioned Media 
 
Protein A sepharose beads (GE Healthcare, CL-4B) were prepared in PBS 
according to manufacturer’s instructions (10% v/v). 200μl bead/PBS solution 
was spun at 6000 rpm for 2 minutes at 4°C. Supernatant was removed and 
the remaining 20µl of bead pellet was washed 3 times with 100μl serum free 
HAM F12 at 6000 rpm for 2 minutes at 4°C. To minimise non-specific binding 
of the CM to beads 200µl, 20X concentrated CM samples were cleared with 
20μl Protein A sepharose beads for 1 h at 4˚C on rotation. After that, 
samples were spun at 6000 rpm for 2 minutes at 4˚C and the supernatants 
were collected. Pre-cleared CM were divided into 100µl aliquots and 
incubated with 5mg MMP-8 antibody (R&D Systems, mAb 908) or mouse 
IgG (Sigma, I5381) overnight at 4°C on rotation. For MMP-8 antibody at 500 
μg/ml stock solution; 10μl antibody was used. For non-immuno mouse IgG at 
1 mg/ml stock solution; 5μl antibody was used. 
 
Antibody treated CM were then added to 20µl fresh beads and incubated for 
4 hours at 4°C with rotation. Samples were centrifuged as previously 
described. Supernatant was carefully collected and kept as the unbound 
fraction. The remaining pellet was washed with SFM as explained. In order to 
remove the precipitates from the beads; 40μl non-reducing Laemmli buffer 
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was added to 20μl cleared bead pellet and incubated for 10 minutes at RT 
then spun once again at 6000 rpm for 1 minute at 4˚C. Supernatant was 
collected with a fine ended loading tip and kept as the bound fraction. 
Laemmli buffer was added to unbound fraction and incubated for 10 minutes 
at RT. 20µl of prepared sample of bound or unbound fractions were loaded 
and separated on an SDS Acrylamide gel and transferred to nitrocellulose 
membrane as described in Section 2.7. Membrane was probed with anti 
MMP-8 or anti V5 antibody as the pcDNA4 vector into which MMP-8 is 
cloned carries a V5 epitope (Figure 2-2). 
 
2.14 Invadopodia Assay (In vitro zymography) 
 
To prepare the gelatine solution; 178.12mg NaCl, 94.57mg NaBH4 (Aldrich, 
21,346-2) and 100mg gelatine was dissolved in 50ml PBS for 1hour at 37˚C 
(pH=9.3). After this 1.8mg rhodamine (Sigma) was added to the solution and 
mixed for 2 hours in the dark to fluorescently label the gelatine. This gelatine 
solution was dialysed against PBS for 48 hours in the dark using Slide-A-
Lyzer Dialysis Cassettes (MWCO: 10K, Volume: 30ml, Pierce, 66830). PBS 
was replenished every 24 hours. After dialysis, gelatine was collected and 
centrifuged at 1200 rpm for 10 minutes to remove un-dissolved particles, and 
then 1g sucrose (Fisher Scientific, 8060153) was added and dissolved.  
 
Rhodamine-conjugated gelatine was spun at 1200prm for 10 minutes then 
heated up to 37°C. 40μl drops were aliquoted onto a 10cm tissue culture 
plate. 13mm coverslips were placed on each drop and incubated for 20 
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minutes. All incubation steps were done in the dark since rhodamine is 
sensitive to light. In another dish 1% (v/v) glutaraldehyde solution (Sigma, 
G5882) in PBS was aliquoted as 40µl drops. After 20 minutes; gelatine 
covered coverslips were placed on the glutaraldehyde solution to create a 
dual layer and incubated for 15 minutes. Then the coverslips were placed in 
a 24 well plate (dual layered side facing up) and washed 3 times with 500μl 
PBS. After this washing step 500µl 5mg/ml NaBH4 was added and incubated 
for 20 minutes then washed as previously described. For sterilisation, the 
coverslips were incubated with 500µl 70% ethanol for 5 minutes, followed by 
a washing step with PBS then equilibrated with 500μl complete HAM F12 for 
20 minutes at 37˚C. Finally 4x104 modified Myo-β6 or Myo-Puro cells were 
layered onto the coverslips and incubated for 24 hours (Figure 2-6).    
 
After incubation the cells were washed 3 times with 500µl PBS and fixed in 
4% paraformaldehyde (PFA, Sigma, P6148) (w/v) in PBS for 15 minutes at 
RT then washed once again as described. Cells were blocked in 0.1%BSA 
and 0.1% (w/v) NaN3 (Fisher Scientific, S227I) in DMEM for 15 minutes in the 
dark at 4°C. Cells were stained with Fluorescein isothiocyanate (FITC) 
labelled phalloidin (Invitrogen, A22283) for 20 minutes in the dark at RT then 
mounted in ProLong Gold Antifade aqueous mounting reagent (Invitrogen, P-
36931)  with 4',6-diamidino-2-phenylindole (DAPI). Images were taken on a 
confocal microscope (Section 2.24). Images from ten random fields on each 
coverslip were taken and the total area degraded was analysed using 
ImageJ software (National Institute of Health, version: 1.39u) (Figure 2-7). In 
the case of MMP-9 inhibition, cells were incubated with 25, 50 and 100nM 
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MMP-9 inhibitor (Calbiochem, 4444278). Control cells were generated by 
treating with Dimethy Sulphoxide (DMSO) vehicle only.    
 
 
Figure 2-6: Diagram showing invadopodia assay set up.  
 
 
Figure 2-7: Illustration of the steps of image taking and analysis. 
Degraded gelatine appears as black dots on a red background. Images were 
taken using confocal microscopy and analysed using ImageJ by converting 
the image into binary and inverting the image in order to analyse black area 
on white background.   
 
2.15 Migration Assay 
 
The underside of Boyden chamber transwells were coated with 100µl of 
ECM or 0.1% BSA in PBS as a control and incubated for 1 hour at RT. ECM 
components and concentrations were the same as used for the adhesion 
assay (Section 2.12). After this incubation step, transwells were washed 
carefully with 100µl PBS avoiding disruption of the transwell membrane with 
the pipette tip, and placed into 500µl of SFM in the well of a 24 well plate.      
Rhodamine-gelatin Modified MEC
Coverslip
Rhodamine tagged
(red) gelatine
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appears as black area
Convertion of the image
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and quantification
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3x104 modified Myo-β6 or Myo-Puro cells were added into the inner chamber 
in 200µl SFM and incubated for 8 hours at 37˚C. After that the media in the 
inner and outer chambers were replaced with 200µl and 500µl 10x 
trpysin/EDTA, respectively and incubated for 1 hour at 37˚C. The trypsin 
solution with cells was harvested and collected as described for the invasion 
assay (Section 2.8). The number of migrated cells as well as the number of 
cells in the inner chamber which have not migrated was counted using a 
CASY counter. The total cell number was calculated by adding the counts of 
matching tubes from the inner and the outer chambers. The percentage of 
migrated cells was calculated by using the counts of the outer chamber 
versus total cell number. 
 
Figure 2-8: Diagram showing the migration assay set up.  
 
2.16 Organotypic Culture 
 
Organotypic gels were constructed using Rat tail Collagen-I and Matrigel. 
The Collagen telopeptide is intact. For 10 gels; 4.9 ml Rat tail Collagen-I was 
mixed with 2.1 ml Matrigel (7:3 v/v ratio), 1ml 10x DMEM (Sigma, D2429) 
and 1 ml FBS on ice. The pH of the solution was neutralised by adding 1M 
NaOH drop wise until the mixture turn an orange-pink colour. 5x106 MRC5 
fibroblasts or primary normal breast fibroblasts were suspended in 1ml 
complete DMEM and added to the neutralised gel mixture. 1ml gel mixture 
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was poured into 1 well of a 24 well plate and set for 1 hour at 37˚C. After that 
complete DMEM was added drop wise on top of the gels and the gels were 
equilibrated at 37˚C overnight. The following day, media was aspirated from 
the top of the gels, 2.5x105 (per gel) modified Myo-β6 or Myo-Puro cells were 
suspended in 500µl complete HAM F12 and added on top of the gels, then 
incubated for 4 hours at 37˚C. After this 2.5x105 (per gel) MDA MB 231 or 
SUM159 cells in 500 µl complete DMEM were added and incubated 
overnight at 37˚C.  
 
In order to provide a stand for the organotypic gels, sterile 1 inch2 nylon 
membranes (pore size:100µm2, Tetko Inc) were coated with Rat tail 
Collagen-I as follows; 7 volumes of Rat tail Collagen-I was mixed with 1 
volume of 10x DMEM, 1 volume of FBS and 1 volume of complete DMEM. 
This mixture was adjusted to neutral pH with 1M NaOH as explained. 250µl 
coating mixture was aliquoted onto each membrane and incubated for 20 
minutes at 37˚C. In order to induce crosslinking of Rat tail Collagen-I; the 
membranes were then covered with 1%glutaraldehyde solution in PBS, and 
incubated for 1 hour at 4˚C. The glutaraldehyde solution was then removed 
and membranes were washed 3 times with PBS, followed by 2 more washing 
steps with complete DMEM. Finally fresh complete DMEM was added and 
incubated overnight at 4˚C. After that the coated nylon membranes were put 
on top of steel grids (coated side facing up) in a well of a 6 well plate. Then 
the gels were carefully removed from the 24 well plate with a sterile spatula 
and placed on top of the nylon membranes. The well was filled with complete 
DMEM until the liquid reached the grid-membrane interface level. Media was 
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replenished every 2 days, and gels were harvested 11 days after rising for 
the over-expression system and 5 days for the siRNA system. The gels were 
then fixed in 10% neutral buffered formalin (Cell Path, BAF-0010-037) 
overnight, then transferred to 70% ethanol for 24 hours. Gels were mounted 
in paraffin and sectioned (4 mμ thickness) (BCI pathology core facility). 
Figure 2-9: Diagram illustrating organotypic culture set up. On Day -1 
the gel was cast and covered with complete DMEM, on Day 0 modified 
MECs and breast cancer cells were added, on Day 1 organotypic cultures 
were raised to an air liquid interface. Col-I., Collagen-I. Adapted from 
Froeling et al., 2008, Froeling et al., 2011, Holliday et al., 2009 and Chioni et 
al., 2012 [297-300].    
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The organotypic sections were stained with Hematoxylin and Eosin (H&E) 
(BCI pathology core facility). Bright field images were taken using a 10x 
objective on a light microscope (Section 2.24) , and processed and analysed 
with ImageJ [301]. The images were converted into binary and the depth of 
invaded cells was measured (3 measurements from each photograph). To 
quantify the area of invaded cells the holes in the binary image were filled. 
The non-invaded cell layer on the top of the gel was removed and the total 
number of particles and total area was measured (Figure 2-10).   
 
The invasion index was calculated as the multiplication of the average of the 
depth of invading cells, the number of invading particles and the total area of 
invading particles. 
 
 
Figure 2-10: Diagram summarising the steps of organotypic gel 
quantification. The image was converted into 8 bit type, and brightness and 
contrast were adjusted. Then the processed image was converted into 
binary. The holes were filled and the top later of the gel was cleared. Then 
the particle number and area was quantified.  
 
In order to analyse proliferation, gels were stained with Ki67 proliferation 
marker (Section 2.19). The Ki67 index is calculated as the percentage of 
8 bit image Binary image
Holes filled Non invaded layer removed
Quantification 
Microscope image
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Ki67 positive cells in total cell number (calculate with DAPI staining). This 
analysis was done for the cells invaded into the gel.  
 
2.17 Immunohistochemistry on Frozen Sections and Paraffin 
Blocks 
 
FFPE sections were dewaxed at 60˚C for 10 minutes and rehydrated by 
xylene (Fisher Scientific, X5-1) followed by alcohol dilutions. Several antigen 
retrieval methods were used: 2.1% (w/v) Citric acid (pH 6) (Fischer Scientific, 
Cat no: 5949-29-1), 0.1M Tri-sodium Citrate (pH 6), Tris–EDTA (Fischer 
Scientific, 6381-92-6) (pH 9). Antigen retrieval solution was boiled for 6 
minutes in microwave. Then slides were added for another 11 mins. For citric 
acid, the slides are boiled for 5 minutes twice (antigen retrieval solution level 
was checked and topped up with distilled water) and incubated on the bench 
for 20 minutes.  
 
Sections were incubated in horse serum for 20 minutes then MMP-8 
antibody diluted in 0.1%BSA/PBS was added and incubated for 1 hour. A 
number of different MMP-8 antibodies were evaluated, and these are 
detailed in Table 3-1. After a washing step with PBS the secondary horse 
anti-mouse antibody (Vector labs, PK 610-2) diluted 1/200 (in PBS) was 
added and incubated for 40 minutes. The avidin-biotin complex (ABC) layer 
(Vector labs, PK 610-2) was added after the second washing step and 
incubated for 30 minutes. Sections were developed in diaminobenzidine 
(DAB) (Vector lab, SK-4100) following the third washing step. Mayer’s 
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hematoxylin (Sigma, MHS32) was used for counter staining. Sections were 
then dehydrated through graded alcohol to xylene and mounted in Distyrene-
tricresyl phosphate-xylene (DPX) (VWR, BDH Prolabo, 360294H)  
 
A double staining procedure was also carried out. The protocol for double 
staining was as described above for the first antibody then as follows. A 
second incubation with horse serum was carried out. Mouse anti- human 
Calponin antibody (Abcam, ab700-500) diluted 1/100 in 0.1%BSA/PBS, was 
added and incubated for 1 hour. After a washing step, secondary mouse 
antibody was added and incubated as described above. Following a further 
washing step, alkaline phosphatase (Vector labs, SA5100) was then added 
and incubated for 40 minutes. The sections were then developed with the 
Vector blue kit (Vecto labs, SK 5300) after the third washing step and 
counterstained in Mayer’s hematoxylin. Glycergel (Dako, C0563) was used 
to mount the sections since vector blue kit is xylene sensitive. 
 
2.18 Immunofluorescence Staining for Cells 
 
For immunofluorescence staining (IF) 13mm2 glass coverslips were coated 
with 200μl of 1μg/ml fibronectin solution and incubated for 1 hour at 37˚C. 
After that the coating solution was removed and coverslips were washed 
twice with 500μl PBS. 2x104 modified Myo-β6 or Myo-Puro cells were seeded 
per coverslip in complete HAM F12 and incubated for 24 hours at 37˚C. 
Following incubation, cells were washed once with 500μl PBS then fixed with 
4%PFA in PBS for 10 minutes at RT. PFA was removed and cells were 
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washed 3 times with 500μl PBS. The cells were then blocked and 
permeabilised with 2% BSA and 0.1% Triton 100X in PBS for 15 minutes and 
incubated with primary antibody prepared in blocking solution at 1/100 
dilution for 1 hour at RT. Primary antibodies are listed in Table 2-17. Then 
cells were washed as described above and incubated with secondary 
antibody conjugated with FITC or cyanine (Cy) -3 diluted in 2% BSA in PBS, 
for 45 minutes in dark at RT. Details of secondary antibodies used are given 
in Table 2-18. The cells were washed again, followed by an extra washing 
step with distilled water and mounted in ProLong Gold Antifade aqueous 
mounting reagent with DAPI.  
 
Antibody name Host Company  Cat no 
α6β4 Mouse Millipore 1964 
Plectin Rabbit Epitomics 1399 
Table 2-17: List of primary antibodies used in IF staining.  
 
Antibody name Dye Host Company  Cat no 
Anti Mouse FITC Goat Invitrogen A11029 
Anti Mouse Cy3 Goat Invitrogen A11030 
Anti Rabbit FITC Goat Invitrogen A11008 
Anti Rabbit Cy3 Goat Invitrogen A11035 
Table 2-18: List of secondary antibodies used in IF staining. 
 
 
2.19 Immunofluorescence Staining for Organotypic Culture Paraffin 
Sections 
 
Sections were dewaxed and rehydrated as described in Section 2.17. 
Antigen retrieval was achieved by boiling the sections in 10mM Tri-sodium 
Citrate (pH 6) for twice 10 minutes in the microwave (900w) (antigen retrieval 
solution level was checked and topped up with distilled water), followed by 
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incubation for 15 minutes at RT. The sections were then washed with PBS 
for 3 times 1 minute and blocked with 5% BSA/PBS for 1 hour at RT and 
incubated with primary antibodies diluted in blocking solution for 1 hour at 
RT.  After that the sections were washed with PBS 3 times 5 minutes and 
incubated with secondary antibodies (diluted in blocking solution) conjugated 
with FITC or Cy3 dye (Table 2-18) and incubated 45 minutes at RT. The 
sections were then washed as described followed by an extra washing step 
with distilled water. Finally the sections were mounted in ProLong Gold 
Antifade reagent with DAPI and stored at 4°C. Details of primary antibodies 
used are given in Table 2-19. 
Antibody name Host Dilution  Company  Cat no 
p63 Mouse 50 Dako  M7247 
Neso Rabbit 300 N/A N/A 
Ki67 Mouse 100 Novocastra NCL-L-Ki67-MM1 
Table 2-19: List of primary antibodies used in IF staining of paraffin 
organotypic culture blocks.  
 
2.20 TGF-β Stimulation Assay 
Modified Myo-β6 or Myo-Puro cells were serum starved for 24 hours, 
following which the cells were stimulated with 5ng/ml recombinant human 
active TGF-β (R&D Systems, 240-B-002) for 5, 10 and 15 minutes. The TGF-
β-containing media was then removed and the cells were washed with PBS 
and kept on ice to stop stimulation. Cells were scraped in RIPA buffer 
(containing protease inhibitors) (50μl buffer/well) then lysates were prepared 
and subjected to WB as described in Section 2.7.   
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2.21 MMP-8 Stimulation Assay 
 
Parental Myo-β6 cells were seeded on 1μg/ml fibronectin and grown 
overnight. The following day complete media was removed and Myo-β6 cells 
were washed twice with SFM. Recombinant human MMP-8 (rhMMP-8, R&D 
Systems, 908-MP-010) was reconstituted with assay buffer containing 
50 mM Tris, 10 mM CaCl2, 150 mM NaCl and 0.05% (w/v) Brij-35 (Sigma, 
16005) (pH 7.5) according to the manufacturer’s instructions and diluted to 
50ng/ml in SFM. Myo-β6 cells were treated with rhMMP-8, and the control 
group was incubated with assay buffer (vehicle only).  
 
2.22 Luciferase Reporter Assay 
 
MDA MB 231 cells transfected with firefly and renilla luciferase reporter gene 
fused with the PAI-promoter (MDA MB 231-Luc) were a gift from Dr Caroline 
Hill, London Research Institute. These were cultured in DMEM in the 
presence of 50μg/ml blasticidine (Sigma, 15205). MDA MB 231- Luc cells 
were seeded into a 96-well plate at a density of 4x104 cells per well and 
incubated overnight at 37˚C then serum starved for 4 hours. After that 5x104 
modified Myo-β6 or Myo-Puro cells were seeded on top of MDA MB 231- Luc 
cells in SFM and co-cultured overnight. The following day media was 
removed and cells were washed with 100μl PBS. Cell lysis and luciferase 
activity quantification was done using Dual-Luciferase reporter assay system 
(Promega, E-1910) according to the manufacturer’s instructions.  
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2.23 MMP-8 Purification 
 
MMP-8 was purified from MMP-8 WT transfected Myo-β6 cells under native 
conditions using Pro-Bond Purification system (Invitrogen, 45-0055) for 
polyhistidine-containing recombinant proteins (MMP-8WT is tagged with 
hexahistidine and V5- section 2.4).  
 
1x106 cells were seeded in a T175 flask. After 24 hours Myo-β6 cells were 
transfected with MMP-8 WT construct as described in Section 2.4 and 
incubated for 24 hours at 37˚C. After that complete media was aspirated and 
cells were serum starved for 24 hours. The CM was then collected and spun 
for 3 minutes at 1200 rpm. Supernatant was kept and dead cells were 
removed as a pellet. Harvested media were kept at - 80˚C until needed.  
 
Media were dialysed against native purification buffer. To prepare 5x 
purification buffer; 35g NaH2PO4 (Sigma, S5011) and 146g NaCl were 
dissolved in 1L distilled water then adjusted to pH 8 with 10M NaOH. This 
stock concentration (250mM NaH2PO4 and 2.5M NaCl) was diluted 5 times 
with distilled water before use. 50ml of CM was placed in a dialysis cassette 
(Slide-A-Lyzer Dialysis Cassettes, MWCO: 10K, Volume: 70ml, Pierce, 
87733). Air was removed from the cassette with a 30ml syringe (BD 
Plastipak, 301229) to maximise the media-membrane interface area. The 
dialysis cassette was put in a beaker containing 5L 1x native purification 
buffer and left on slow speed stirring overnight at 4˚C.    
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The media was removed from the dialysis cassette and put in a 50 ml tube 
containing Nickel-nitrilotriacetic acid (Ni-NTA) agarose resin (washed and 
prepared according to manufacturer’s instructions). The tube was placed on 
a roller and incubated overnight at 4˚C to allow binding of MMP-8 WT to the 
resin. Then media was centrifuged for 1 minute at 800G at 4˚C and the 
supernatant kept as the unbound fraction. The remaining agarose resin was 
washed, and MMP-8 was eluted according to manufacturer’s instructions.    
 
2.24 Microscopy 
 
Confocal images were taken using a confocal laser scanning microscope 
LSM510 (Carl Zeiss). FITC dye was excited with the argon laser at 488 nm, 
Cy3 dye was excited by a HeNe laser at 543 nm. Images were captured at 
1084x1084 resolution. Images of the coverslips were acquired using 63x oil 
immersion objective and images of organotypic sections were taken with 40x 
objective. Co-localisation analysis was done on at least 4 different fields per 
experimental condition by Carl Zeiss confocal Meta software. Total field was 
analysed and co-localisation was displayed as the green (FITC- Plectin) 
pixels overlapping with red (Cy3- α6β4) pixels.     
 
Bright images of organotypic sections were taken with light microscope 
(Axiophot, Zeiss) using 10x objective.  
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2.25 Statistical Analysis 
 
Statistical significance was determined by two tailed Student’s t-test using 
Prism (Graphpad Software) or Microsoft Excel. Results were considered as 
significant with p value less than 0.05.  
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3 Effect of MMP-8 on MEC Functions 
 
3.1 Introduction and Aims 
 
MMP-8 has previously been shown to exert a tumour suppressor effect. 
Balbin et al., demonstrated that MMP-8 knockout male mice show higher 
susceptibility to skin cancer than WT mice after exposure to chemical 
carcinogens [208]. Moreover Gutierrez-Fernandez and colleagues showed 
that MMP-8 over-expression in B16F10 melanoma cells reduces formation of 
lung metastasis after injected into tail vein of MMP-8 knockout mice (back 
crossed with C57BL/6 mice) when compared to control vector over-
expression [215]. Importantly, they showed that MMP-8 expression in 
melanoma cells enhances the spread and adhesion to ECM and reduced 
migratory phenotype in vitro [215]. Furthermore Palavalli and co-workers 
revealed that there frequently is LOH at the MMP-8 locus in melanoma, 
which is a hallmark of tumour suppressor genes [217]. In fact when mutated 
forms were over-expressed in Mel-STR melanoma cells and injected 
subcutaneously in NOD/SCID mice, these cells formed lung metastases 
whereas the Mel-STR cells over-expressing the WT form did not generate 
any lung metastases [217].  
 
MECs in normal breast exhibit a tumour suppressor phenotype [117], but 
there is evidence that function becomes altered in at least some cases of 
DCIS, and this may contribute to progression of DCIS to invasive disease 
[275]. Previously in our lab we have shown that a consistent change in DCIS-
associated MECs is up-regulation of αvβ6. We have shown that this leads to 
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a switch in MEC function, and these cells promote tumour cell invasion in a 
TGF-β dependent and MMP-9 dependent manner [275]. Furthermore, in a 
series of DCIS cases with long term follow-up, the expression of αvβ6 on 
DCIS MECs can predict recurrence and progression [275]. We also have 
shown that in normal breast, MECs are the major source of tumour 
suppressor MMP-8 but this expression is lost in DCIS associated MECs 
[215]. The functional significance of this loss in DCIS MECs is not known.   
 
The aims of this chapter are:  
 
 To confirm the localisation of MMP-8 in MECs in normal breast and its 
loss in DCIS associated MECs 
 To evaluate MMP-8 expression in an αvβ6 over-expressing MECs 
recapitulating DCIS and in a normal MEC model, lacking αvβ6 
 To use MEC lines to evaluate the effect of loss or gain of MMP-8 on MEC 
function.  
 Specifically;  
o To over-express MMP-8 in αvβ6 positive DCIS MEC model to 
study gain-of-function effect, using 
 WT MMP-8  
 Mutant inactive MMP-8 to investigate the dependence of 
biological function on enzymatic activity  
 An appropriate control DCIS model which carries Empty 
vector 
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o To knock-down MMP-8 expression in normal αvβ6 negative MEC 
model to study loss-of-function effect using 
 MMP-8 siRNA treated normal MEC model 
 Comparable control for normal MEC model treated with 
control (non-targeting) siRNA 
 To dissect whether MMP-8 influences MEC adhesion and migration on 
different ECM.  
 
 
3.2 Results  
 
3.2.1 Localisation of MMP-8 in Tissue Sections  
 
In order to analyse the localisation of MMP-8 in breast tissue; IHC was 
performed on normal breast, DCIS and invasive breast cancer sections as 
described in Section 2.17. A number of antibodies were tested for IHC 
staining (Table 3-1). FFPE materials as well as frozen samples were stained. 
Antigen retrieval was done by pressure cooking or microwaving FFPE 
sections in antigen retrieval buffer, for frozen samples no antigen retrieval 
was done. Normal breast tissue was used as a positive control. High level of 
background staining was present for all the antibodies used and no specific 
staining was observed (data not shown). Based on the previous findings 
[215] staining of endothelial cells and of MECs in breast tissue was used as 
an endogenous positive control but no specific staining in these cell types 
was detected with any of the antibodies or staining conditions applied 
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indicating that the MMP-8 antibodies available were not adequate for IHC 
staining. 
 
Company  Host Cat no Outcome 
Abcam  Rabbit 11609 High background  
Abcam Rabbit 81286 High background 
Millipore Mouse 3316 High background 
Millipore Rabbit 81016 High background 
R&D Systems Mouse 9081 High background 
R&D Systems Mouse 908 High background 
Santa Cruz Goat sc-8848 No staining 
Sigma Rabbit 021221 High background 
Table 3-1: List of antibodies used in IHC staining for MMP-8 on FFPE 
and frozen sections.  
 
3.2.2 MMP-8 Expression Levels in Breast Cell Populations 
 
In order to confirm MEC dependent expression of MMP-8 in normal breast 
and loss of this expression in DCIS, primary normal MECs and LECs (and 
fibroblasts), and their DCIS-associated counterparts were isolated from 
normal breast (reduction mammoplasty) and DCIS tissue respectively [293]. 
Total RNA was isolated and reverse transcribed. A nested PCR targeting 
MMP-8 mRNA was carried out; eukaryotic ribosomal 18s was amplified as a 
house keeper control. A poorly metastatic melanoma cell line, G361, was 
used as a positive control [302, 303]. Figure 3-1 shows that normal breast 
MECs express MMP-8 whereas no band was observed in DCIS associated 
MEC. MMP-8 expression was not detected in LEC or fibroblast populations 
derived from either normal or DCIS tissue.  
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Figure 3-1: Analysis of MMP-8 expression profile in normal versus DCIS 
tissue. Primary normal MECs LECs and fibroblasts were isolated from 
normal breast; DCIS associated MECs and LECs were isolated from DCIS 
tissue as described in Section 2.3. Nested RT-PCR confirmed the expression 
of MMP-8 in the normal breast MECs and lack of this expression in DCIS 
MECs, with no expression in normal or DCIS associated LECs, or fibroblasts. 
FB., Fibroblast, bp., base pair, representative for 2 independent experiments.  
 
 
3.2.3 Comparison of MMP-8 Expression Levels in Normal Versus DCIS 
Cell Line Models 
 
To establish a model for DCIS-associated MECs an αvβ6 integrin over-
expressing cell line termed Myo-β6 was generated from a normal MEC line, 
termed Myo-puro as described in Section 2.2. To confirm that the MEC lines 
recapitulate the in vivo phenotype of MEC populations thus showing down-
regulation of MMP-8 upon gaining αvβ6 integrin expression, a nested RT-
PCR and a quantitative RT-PCR (QRT-PCR) for MMP-8 was undertaken in 
both Myo-β6 and Myo-Puro cell lines. The G361 metastatic melanoma cell 
line [302, 303] was used as a positive control. As shown in Figure 3-2 A and 
B, MMP-8 expression was decreased at mRNA level in Myo-β6 cells 
compared to Myo-Puro cells. This observation was confirmed at the protein 
level (Figure 3-2 C); CM was collected from both cell lines, concentrated 20x 
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and separated by acrylamide gel under reducing conditions as described in 
Section 2.7. A reduction in MMP-8 expression at protein levels was also 
observed in CM from Myo-β6 cells reflecting mRNA expression. 
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Figure 3-2: MMP-8 expression in Myo puro versus Myo-β6 cell lines.  
A; Nested RT-PCR and B; QRT-PCR showed that MMP-8 expression was 
down-regulated upon β6 over-expression at the mRNA level. β6 subunit was 
analysed. In addition amplification was also detected in the G361 positive 
control. C; 20x concentrated conditioned media collected from Myo Puro and 
Myo-β6 cells were separated by WB and probed for MMP-8, for αvβ6; cell 
lysates were prepared separated by WB and probed for αvβ6. Protein levels 
of MMP-8 reflected mRNA levels and an inverse correlation was observed 
between MMP-8 and αvβ6. kDa., kilodalton, Figures are representative of 3 
independent experiments.  
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3.2.4 Over-expression of Wild Type or Inactive MMP-8 in Myo-β6 Cells  
 
To analyse the gain-of-function effect of MMP-8 in the DCIS associated 
system, MMP-8 was over-expressed in Myo-β6 cells by plasmid transfection 
(MMP-8 WT) as described in Section 2.4. To further dissect the involvement 
of proteolytic activity of MMP-8 in its biological role; an enzymatically inactive 
form of MMP-8 (MMP-8 EA), was also over-expressed in Myo-β6 cells. This 
form carries a point mutation in the catalytic domain thus retaining the 
enzyme in the latent form [212]. Figure 3-3 A illustrates the mutation within 
the catalytic site. To compare MMP-8 expression at mRNA level, RNA was 
collected 24 hours after transfection and reverse transcribed. PCR targeting 
MMP-8 mRNA was carried out. Figure 3-3 B shows a similar level of 
expression of MMP-8 mRNA with WT and EA constructs in Myo-β6 cells. In 
order to compare protein expression levels; CM were collected from MMP-8 
WT and MMP-8 EA or Myo-β6 cells transfected with Empty pcDNA4 after 24 
hours serum starvation and concentrated 20x, then immunoprecipitated for 
MMP-8 using  protein A beads coated with MMP-8 antibody (R&D, mab908) 
as described in Section 2.13. Unbound and immunoprecipitated (bound) 
fractions were subjected to western blotting under non-reducing conditions. 
Membrane was probed with V5 antibody. Figure 3-3 C upper panel confirms 
similar protein expression levels of the two constructs in CM. 
 
To examine the proteinase activity of MMP-8 WT and MMP-8 EA mutant, CM  
were collected from modified Myo-β6 cells as explained above and were 
subjected to Collagen-I zymography, since MMP-8 is the major MMP 
processing Collagen-I [201]. As shown in Figure 3-3 C lower panel 
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degradation of Collagen-I was solely observed in CM collected from MMP-8 
WT whereas MMP-8 EA or Empty vector control failed to show any 
degradation.  
 
 
Figure 3-3: Investigation of MMP-8 over-expression in Myo-β6 cells.  
A; Schematic illustration of MMP-8 WT and MMP-8 EA indicating the site of 
mutation.  
B; PCR targeting MMP-8 revealed similar expression levels for MMP-8 WT 
and MMP-8 EA at mRNA level.  
C; MMP-8 WT and inactive form (EA) was over-expressed in Myo-β6 cells, 
CM were collected after 24 hours of starvation and concentrated 20x. MMP-8 
was immunoprecipitated with MMP-8 antibody conjugated protein A 
sepharose beads. Upper panel; WB confirms the presence of MMP-8 protein 
in MMP-8 WT coding plasmid or MMP-8 EA coding plasmid transfected cells. 
WB was blotted for V5. Lower panel; Collagen degradative activity of 
different forms of MMP-8 was analysed with Collagen-I zymography. 
Substrate degradation was solely observed in MMP-8 WT bound fraction 
whereas no activity was seen in MMP-8 EA bound or unbound fractions. bp., 
base pair, kDa., kilodalton, B., bound fraction, UB., unbound fraction,  
representative for 3 independent experiments. 
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3.2.5 The Effect of MMP-8 Over-expression on Myo-β6 Proliferation 
 
In order to analyse whether MMP-8 WT or EA over-expression in Myo-β6 
cells influence cell proliferation, modified Myo-β6 cells were cultured (on 
plastic) for 24 hours, and MTS assay was done and normalised to the 
proliferation of the Myo-β6 cells transfected with Empty vector control as 
described in Section 2.9. There was no significant difference in proliferation 
rate between different transfection groups (p>0.05, n=3) (Figure 3-4).  
EMPTY MMP-8 WT MMP-8 EA
0.0
0.5
1.0
1.5
n.s.
R
e
la
ti
v
e
 p
ro
li
fe
ra
ti
o
n
 (
A
.U
.)
 
Figure 3-4: Effect of MMP-8 loss on Myo-β6 proliferation. Myo-β6 cells 
were grown and MTS proliferation assay was done as described in Section 
2.9. Proliferation rates showed no significant difference between MMP-8 WT, 
MMP-8 EA or Empty vector transfected Myo-β6 cells. A.U., arbitrary unit, 
n.s., not significant, representative for 3 experiments. 
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3.2.6 Effect of MMP-8 Over-expression on Myoepithelial Phenotype 
 
To evaluate the effect of MMP-8 on myoepithelial phenotype, MMP-8 WT or 
Empty vector transfected control Myo-β6 cells were seeded onto fibronectin 
(1μg/ml) coated coverslips in SFM and grown for 24 hours. On this matrix, 
MMP-8 WT cells showed more spreading with a significant increase in 
occupied area (in pixels) (Figure 3-5 A and B) compared to Empty vector 
control (p=0.02, n=1). In order to eliminate the possibility that increased area 
occupation was a result of increased proliferation in MMP-8 WT cells, 
proliferative activity of modified Myo-β6 cells after 24 hours incubation on 
fibronectin was quantified using the MTS assay as described in materials 
and methods. In contrast to data related to cell spreading, MTS assay 
showed that MMP-8 over-expression did not alter the proliferation of Myo-β6 
cells throughout the same incubation period (Figure 3-5 C) (p=0.91, n=1).  
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Figure 3-5: Effect of MMP-8 on spreading on ECM. A; MMP-8 WT or 
Empty vector transfected cells were seeded on fibronectin coated coverslips 
and pictures were taken after 24 hours. B; Quantification of occupied area by 
ImageJ, a significant increase in spreading was seen in MMP-8 WT over-
expressed cells.  C; MTS assay run for 24 hours on fibronectin and showed 
no significant difference in proliferation rate. *, P ≤ 0.05 (Student’s t test). 
Error bars show means +/- SEM. A.U., arbitrary unit, O.D., optical density, 
n.s., not significant. 
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3.2.7 Effect of MMP-8 Over-expression on Myoepithelial Adhesion 
 
To dissect the effect of MMP-8 on MEC adhesion to ECM, MMP-8 WT, 
MMP-8 EA or control cells were seeded onto different ECM coated wells of a 
96 well plate, allowed to adhere for 1 hour and tracked fluorescently by 
Calcein AM cell tracker (Figure 3-5 A). Fluorescence obtained from adherent 
cells in MMP-8 WT and MMP-8 EA was normalised to Empty vector. All 
experiments were performed at least 3 times. Figure 3-6 B shows that over-
expression of MMP-8 WT significantly enhanced adhesion to fibronectin, 
Collagen-I, laminin-I-I-I and tenascin-C whereas there was a significant 
decrease in adhesion to the N terminus latency associated peptide of TGF-β, 
LAP, when compared to Empty vector (fibronectin p=2.02E-07, Collagen-I 
p=3.35E-05, laminin-I-I-I p=0.0006 , tenascin-C p=0.01, LAP p=0.03)  and 
EA form transfected Myo-β6 cells (fibronectin p=4.85212E-06, Collagen 
Type-I p=0.001, laminin-I-I-I p=0.002, tenascin-C p=0.01, LAP p=0.04). 
MMP-8 WT did not significantly alter the adhesion to Collagen-IV compared 
to Empty vector (p=0.29) or MMP-8 EA (p=0.63). 
 
MMP-8 EA did not show a significant effect on MEC adhesion in comparison 
to Empty vector (Fibronectin p=0.12, Collagen-I p=0.44, Collagen-IV p=0.69, 
laminin-I-I-I p=0.69, tenascin-C p=0.225 LAP p=0.37). 
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Figure 3-6: Effect of MMP-8 on adhesion to ECM.  A;MMP-8 WT, MMP-8 
EA or Empty vector transfected Myo-β6 cells were seeded on different ECM 
molecules in a 96 well plate and stained with Calcein AM cell tracker. B; 
Adhesion was quantified as the amount of fluorescence measured after 
washing step to remove non-adherent cells and normalised to the Empty 
vector. In MMP-8 WT transfected cells a significant increase was observed in 
adhesion to fibronectin, Collagen-I, laminin-I-I-I and tenascin-C, however 
adhesive activity to LAP was significantly reduced compared to Empty vector 
transfected control Myo-β6 cells. In contrast inactive mutant did not show any 
significant effect. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 (Student’s t test). 
Error bars show means +/- SEM. A.U., arbitrary unit, Fib., fibronectin, Col-I., 
Collagen-I, Col-IV., Collagen-IV, Lam-I., laminin-I-I-I, Ten-C., tenascin-C, 
representative for 3 independent experiments. 
 
 
 
Fib Col-I Col-IV Lam-I-I-I Ten-C LAP
0.0
0.5
1.0
1.5
2.0
2.5
EMPTY
MMP-8 WT
MMP-8 EA
*** ***
*** **
*
R
e
la
ti
v
e
 a
d
h
e
s
io
n
 (
A
.U
.)
Modified 
MEC
SFM
ECM
A 
B 
  
142 
 
3.2.8 Effect of MMP-8 Over-expression on Myoepithelial Migration 
 
In order to explore the effect of MMP-8 over-expression on MEC migration, 
transwell migration assays were performed by coating the underside of the 
transwell with different ECM molecules as shown in Figure 3-7 A. In this 
system Myo-β6 cells were seeded on top of the transwell, and therefore are 
separated from the ECM by the cell permeable membrane. According to the 
potential of ECM to establish a gradient to trigger a movement response, 
cells migrate towards particular ECM and attach to the underside of the 
transwell. All experiments were performed a minimum of 3 times. Migration 
towards fibronectin, Collagen-I, laminin-I-I-I, tenascin-C and LAP was 
significantly abrogated in MMP-8 WT MEC (fibronectin p=0.012003, 
Collagen-I p=0.006206, laminin-I-I-I p=0.002, tenascin-C p=0.006731, LAP 
p=0.013) but not in MMP-8 EA MEC (fibronectin p=0.12783, Collagen-I 
p=0.68, Lam-I-I-I 0.068046, tenascin-C p=0.205279, LAP p=0.734778) 
compared to Empty vector controls. Migration towards Collagen-IV was not 
affected by MMP-8 WT or MMP-8 EA over-expression (Figure 3-7 B).   
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Figure 3-7: Effect of MMP-8 on migration towards ECM. A; Migration of 
modified Myo-β6 cells was analysed using Boyden chamber migration 
assays with different ECM molecules. B; After 8 hours incubation the total 
cell number and migrated cell number were counted and percentage 
migration was calculated. The graph shows a significant decrease in 
percentage cell migration towards fibronectin, Collagen type-I, laminin-I-I-I, 
tenascin-C and LAP in MMP-8 WT with no change in migration for MMP-8 
EA transfected MEC. Counts were normalised to migration rate of Empty 
vector control transfected MEC. *, P ≤ 0.05; **, P ≤ 0.01 (Student’s t test). 
Error bars show means +/- SEM. A.U., arbitrary unit, Fib., fibronectin, Col-I., 
Collagen-I, Col-IV., Collagen-IV, Lam-I., laminin-I-I-I, Ten-C., tenascin-C. 
Data is mean of 3 independent experiments. 
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3.2.9 Effect of MMP-8 Over-expression on Myoepithelial 
Hemidesmosome Formation in Myo-β6 Cells 
 
To further assess the mechanism by which MMP-8 exerts its migration 
suppressor role on MEC, the distribution of the major myoepithelial integrin, -
α6β4- was examined by IF. α6β4 integrin is a major component of 
hemidesmosome structures which are involved in the attachment of the 
basal cell surface of normal MECs to the BM.  
 
In order to investigate the localisation of α6β4 integrin to HD, modified Myo-
β6 cells were grown for 24 hours on fibronectin, fixed and subjected to dual 
IF for α6β4 and an established hemidesmosomal marker plectin (HD-1) [254] 
(Figure 3-8). Co-localisation analysis was carried out and normalised to the 
co-localisation quantified in control Myo-β6 cells. As shown in Figure 3-8, 
plectin staining revealed characteristic HD “Swiss cheese” like structures and 
co-localisation analysis on merge images showed that more α6β4 localised 
to plectin in MMP-8 WT compared to MMP-8 EA (p=0.04, n=3) and control 
cells (p=0.003, n=3) (Figure 3-9). In addition, α6β4 staining also revealed 
that this integrin can be found at cell membrane protrusions. In order to 
identify whether these structures represent filopodial protrusions, modified 
Myo-β6 cells were dual stained immunofluorescently for α6β4 and phalloidin 
as shown in Figure 3-10. However without dynamic information it cannot be 
distinguished whether these structures are filopodias or retraction fibres. 
Therefore hereafter a hybrid label ‘filopodia/retraction fibres’ will be used for 
these structures.  
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The higher magnification shows actin protrusions with co-localised α6β4. The 
quantification of length (Figure 3-11 A) and number (Figure 3-11 B) of each 
of these structures based on α6β4 staining in MMP-8 WT, MMP-8 EA or 
Empty vector transfected control cells on at least 4 different fields per 
condition containing at least 5 cells, revealed that the filopodia/retraction 
fibres are significantly shorter and fewer in number in MMP-8 WT compared 
to either EA (length p=0.0001, number p= 0.05, n=3) or Empty vector 
transfected MEC (length p=0.0001, number p=0.01, n=3). To investigate the 
spreading of modified Myo-β6 cells, phalloidin staining was further quantified 
by ImageJ to analyse the area occupied by the cells on fibronectin matrix 
(Figure 3-11 C). There was a significant increase in cell size in MMP-8 WT 
over-expressing cells in comparison to MMP-8 EA over-expressing 
(p=0.0002, n=3) or control vector transfected Myo-β6 cells (p=0.0003, n=3). 
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Figure 3-8: Effect of MMP-8 on myoepithelial α6β4 integrin distribution. 
Confocal sections of modified Myo-β6 cells grown on fibronectin for 24 hours, 
fixed with 4% PFA and co-stained for plectin (green) and α6β4 (red). Bar, 
20μm. 
 
 
 
 
 
 
 
 
 
Figure 3-9: Analysis of α6β4 and plectin co-localisation.  Co-localisation 
was analysed. There was a significant increase in α6β4 and plectin co-
localisation in MMP-8 WT compared to EA form or Empty vector transfection. 
Error bars show means +/- SEM. n.s., not significant, A.U., arbitrary unit, 
data from 3 independent experiments. 
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Figure 3-11: Effect of MMP-8 on myoepithelial filopodia/retraction fibre 
length, number and cell size. A; Length of each filopodia/retraction fibre of 
at least 5 different cells in a minimum of 4 different fields was measured 
using ImageJ. A significant decrease in overall filopodia/retraction fibre 
length was observed in MMP-8 WT compared to EA or Empty vector 
transfected Myo-β6 cells. B; The number of filopodia/retraction fibre per cell 
was calculated for each field by dividing the filopodia/retraction fibre number 
by cell number in each field and showed a significant reduction in MMP-8 WT 
compared to EA or control vector transfected Myo-β6 cells. C; Cell spreading 
on fibronectin was quantified by ImageJ as area occupied by cells based on 
phalloidin staining and normalised to the occupied area of the Empty vector 
transfected Myo-β6 cells. There was a significant increase in area occupied 
by MMP-8 WT transfected cells compared to EA or Empty vector transfected 
cells.  *, P ≤ 0.05, **, P ≤ 0.01; ***, P ≤ 0.001 (Student’s t test). Error bars 
show means +/- SEM. A.U., arbitrary unit, representative for 3 independent 
experiments. 
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3.2.10 Effect of MMP-8 Over-expression on MMP-9 Expression and 
Function in Myo-β6 Cells 
 
Previous work in our lab has shown that over-expression of αvβ6 – which 
appears to be associated with down-regulation of MMP-8 – leads to 
increased MMP-9 expression. Therefore, in order to analyse the alterations 
in MMP-9 expression in Myo-β6 cells upon MMP-8 WT , EA or Empty vector 
transfection, total mRNA were harvested from modified Myo-β6 cells 24 
hours after transfection and subjected to QRT-PCR. Experiments were 
performed a minimum of 3 times. There was no significant change in MMP-9 
expression at mRNA level in Myo-β6 cells after transfected with MMP-8 WT 
or MMP-8 EA compared to Empty vector transfection (MMP-8 WT p=0.552, 
MMP-8 EA p=0.807) (Figure 3-12).  
 
To evaluate the effect of MMP-8 over-expression on proteolytic activity of 
MMP-9, modified Myo-β6 cells were seeded on rhodamine-conjugated 
gelatine coated coverslips as described in Section 2.14 and incubated for 24 
hours. After incubation the cells were fixed and stained with FITC-conjugated 
phalloidin (Figure 3-13). The area of degraded gelatine was quantified by 
ImageJ and demonstrates a significant reduction in gelatine degradation in 
MMP-8 WT compared to EA form (p=0.03, n=3) or Empty vector (p=0.002, 
n=3) transfected cells (Figure 3-14 A). There was no difference in cell 
number per field between different transfection groups (n=3) (Figure 3-14 B).  
To confirm the effect of MMP-8 over-expression on MMP-9 function, modified 
MECs were starved for 24 hours and CM were prepared, and then subjected 
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to gelatine zymography as described in Section 2.10 (Figure 3-15 A). 
Densitometric analysis of lytic bands was done using ImageJ and normalised 
to Empty vector transfection. There was a decrease in the lytic band 
corresponding to MMP-9 in Myo-β6 cells transfected with MMP-8 WT 
compared to Empty vector controls (p=0.057, n=4) and MMP-8 EA carrying 
Myo-β6 cells (p=0.067, n=4), but this decrease was not significant (Figure 3-
15 B). There was no lytic band detected corresponding to MMP-2 activity 
(Figure 3-15 B). 
 
Recombinant MMP-9 was used as a control, however, bands generated from 
this were inconsistent. In the absence of a gelatinolytic band, the MW ladder 
was used to identify the size of the lytic bands from the samples.  
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Figure 3-12: Effect of MMP-8 over-expression on MMP-9 expression at 
mRNA level. QRT-PCR targeting MMP-9 mRNA showed that there was no 
significant difference in MMP-9 mRNA level in MMP-8 WT or MMP-8 EA 
transfected Myo-β6 cells compared to Empty vector transfected Myo-β6 cells 
24 hours after transfection. Error bars show means +/- SEM. n.s., not 
significant, A.U., arbitrary unit, representative for 3 independent experiments.   
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Figure 3-13: Effect of MMP-8 over-expression on gelatine degradation 
in in vitro zymography. MMP-8 WT, MMP-8 EA or EMPTY vector 
transfected Myo-β6 cells were seeded on rhodamine tagged (fluorescently 
red) gelatine and incubated for 24 hours, then fixed with 4%PFA and stained 
for FITC-tagged phalloidin as described in Section 2.14. Degraded gelatine 
appeared as black dots on red background. Bar, 50μm.  
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Figure 3-14: Quantification of the effect of MMP-8 over-expression on 
gelatine degradation in in vitro zymography. A; 10 pictures were taken 
per coverslip and gelatine degradation was quantified as the total area of 
black dots occupied per field. There was a significant reduction in fluorescent 
gelatine degradation in MMP-8 WT but not in MMP-8 EA when compared to 
Empty vector transfected control cells. B; the cell number per field was 
counted and no significant difference was observed among MMP-8 WT, 
MMP-8 EA or Empty vector transfected cells. *, P ≤ 0.05, **, P ≤ 0.01; 
(Student’s t test). Error bars show means +/- SEM. representative of 3 
independent experiments 
 
Figure 3-15: Effect of MMP-8 over-expression on gelatine degradation 
in gel zymography. A; CM were collected from modified and 24 hours 
serum starved Myo-β6 cells and gelatine zymography was run as described 
in Section 2.10. Degraded gelatine bands correspond to MMP-9 activity. No 
bands for MMP-2 were observed. B; Densitometric analysis was done with 
ImageJ and normalised to the Empty vector transfected control cells. There 
was a non-significant decrease in MMP-9 activity in MMP-8 WT carrying 
Myo-β6 cells compared to other transfection groups (p values, student’s t 
test). Error bars show means +/- SEM. A.U., arbitrary unit, representative for 
4 independent experiments. 
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3.2.11 MMP-8 Expression Knock-down in Myo-Puro Cells  
 
In order to study the loss-of-function effect of MMP-8 in a normal 
myoepithelial system, endogenous MMP-8 was knocked down using siRNA 
targeting MMP-8 mRNA in Myo-Puro cells as explained in Section 2.5, and 
siRNA targeting luciferase mRNA (siLUC) was used as a control. To 
evaluate MMP-8 expression after siRNA treatment, total RNA and protein 
was harvested 96 hours after transfection, then QRT-PCR and WB was run. 
QRT-PCR results showed a significant loss in MMP-8 expression upon 
MMP-8 siRNA treatment (p=0.0025, n=3) (Figure 3-17 A) compared to 
control siRNA transfected Myo-Puro cells. WB results confirmed a loss in 
MMP-8 expression after MMP-8 siRNA treatment (Figure 3-17 B).  
 
 
 
 
 
 
 
Figure 3-16: Knock-down of MMP-8 expression in Myo-Puro cells using 
MMP-8 siRNA. A; MMP-8 expression was knocked down by siRNA 
treatment as described in Section 2.5. MMP-8 expression was checked at 
RNA level and protein level 96 hours after transfection. QRT-PCR targeting 
MMP-8 mRNA was run, MMP-8 expression was significantly reduced at RNA 
level following siRNA transfection. B; Conditioned media was prepared for 
WB as described in Section 2.4 and subjected to WB. MMP-8 expression 
was lost at protein level. **, P ≤ 0.01; (Student’s t test). Error bars show 
means +/- SEM., representative for 3 independent experiments. 
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3.2.12 The Effect of MMP-8 Knock-down on Myo-Puro Proliferation 
 
To explore whether MMP-8 loss has an effect on Myo-Puro cell proliferation, 
proliferation rates were determined in modified Myo-Puro cells as described 
in Section 2.9. There was no difference in proliferation in siMMP-8 
transfected Myo-Puro cells in comparison to siLUC transfection (Figure 3-18) 
(p=0.4, n=3).   
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Figure 3-17: Effect of MMP-8 loss on Myo-Puro proliferation. Myo-Puro 
cells were grown for 24 hours and proliferation was analysed by MTS assay 
as described in Section 2.9. There was no significant difference in siMMP-8 
treated Myo-Puro cells when compared to control group. A.U., arbitrary unit, 
n.s., not significant, representative for 3 experiments. 
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3.2.13 Effect of MMP-8 Knock-down on Myo-Puro Adhesion  
 
To explore the impact of MMP-8 loss in the normal MEC system on cell-ECM 
interactions, myoepithelial adhesion to several ECM molecules was 
assessed. MMP-8 or control siRNA (siLUC) transfected Myo-Puro cells were 
seeded on ECM coated wells of a 96 well plate as described in Section 2.12. 
Experiments were repeated a minimum of 3 times. Myoepithelial adhesion to 
fibronectin (p=0.01), Collagen-I (p=1.1E-06), Collagen-IV (p=0.0003), laminin 
I-I-I (p=0.004) and tenascin-C (p=0.003) was significantly reduced in the 
absence of MMP-8 compared to control siRNA tranfected cells (Figure 3-19). 
Interestingly there was no significant difference in adhesion to the αvβ6 
ligand LAP (p=0.32).     
 
 
 
 
 
 
 
 
Figure 3-18: Effect of MMP-8 loss in normal Myo-Puro cell line on 
myoepithelial adhesion to several ECM molecules. Myoepithelial 
adhesion to ECM was evaluated as described in Section 2.12 and 
normalised to siLUC transfected control cells. Adhesion to fibronectin, 
Collagen-I, Collagen-IV, laminin-I-I-I and tenascin-C was significantly 
reduced in MMP-8 siRNA transfected cells. No significant difference in 
adhesion to LAP. **, P ≤ 0.01; (Student’s t test). Error bars show means +/- 
SEM. A.U., arbitrary unit, Fib., fibronectin, Col-I., Collagen-I, Col-IV., 
Collagen-IV, Lam-I., laminin-I-I-I, Ten-C., tenascin-C, representative for 3 
independent experiments.    
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3.2.14 Effect of MMP-8 Knock-down on Myo-Puro Migration 
 
MEC migration was studied using Boyden chamber assays in which MMP-8 
siRNA or control siRNA transfected Myo-Puro cells were separated from 
different ECM molecules by a transwell membrane and incubated for 8 hours 
as described in Section 2.15. All experiments were repeated a minimum of 3 
times. MMP-8 loss resulted in a significant increase in the percentage of cells 
migrating towards Collagen-IV (0.001), laminin-I-I-I (p=8.9E-5), tenascin-C 
(p=0.002) but not to fibronectin (p=0.64), Collagen-I (p=0.70) and LAP 
(p=0.81) (Figure 3-20).  
 
 
 
 
 
 
 
 
 
 
Figure 3-19: Effect of loss of MMP-8 expression in Myo-Puro cells on 
migratory behaviour. Transwell migration assays were performed and 
quantified as described in Section 2.15. There was a significant increase in 
percentage cell migration towards Collagen-IV, laminin-I-I-I, tenascin-C, no 
significant difference was determined for other ECM molecules.  ***, P ≤ 
0.001 (Student’s t test). Error bars show means +/- SEM. n.s. not significant, 
Fib., fibronectin, Col-I., Collagen-I, Col-IV., Collagen-IV, Lam-I., laminin-I-I-I, 
Ten-C., tenascin-C, representative for 3 independent experiments.  
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3.2.15 Effect of MMP-8 Knock-down on Myo-Puro Filopodia/Retraction 
Fibre Formation 
 
Investigation of filopodia/retraction fibre formation was performed as 
described in Section 2.18 and 3.3.7 by staining the modified Myo-Puro cells 
with α6β4 integrin and phalloidin after 24 hour incubation on fibronectin (n=3) 
(Figure 3-21 A). In each experiment at least 4 different fields containing at 
least 5 cells were quantified per condition. The quantification of 
filopodia/retraction fibre length (Figure 3-21 B) and number (Figure 3-21 C) 
was undertaken on α6β4 staining by ImageJ. There was a significant 
increase in filopodia/retraction fibre length (p=0.0009) and filopodia/retraction 
fibre number per cell (p=0.05) in MMP-8 knock-down Myo-Puro cells when 
compared to siLUC transfected Myo-Puro cells.   
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Figure 3-20: Effect of MMP-8 loss in Myo-Puro cells on 
filopodia/retraction fibre length and number. A; Filopodia/retraction fibre 
formation (arrows) analysis staining in modified Myo-Puro cells was done as 
described in 2.18 and 3.3.7. For each condition at least 4 different fields 
containing at least 5 cells were quantified by ImageJ. Bar 20μm. B; 
Filopodia/retraction fibre length and C; number was significantly increased in 
siMMP-8 transfected Myo-Puro cells compared to Myo-Puro cells transfected 
with siLUC. *, P ≤ 0.05, ***, P ≤ 0.001 (Student’s t test). Error bars show 
means +/- SEM., representative for 3 independent experiments.  
 
 
 
 
siLUC siMMP-8
0
20
40
60
80
***
L
e
n
g
th
 (
P
ix
e
ls
)
siLUC siMMP-8
0
5
10
15
*
N
u
m
b
e
r 
o
f 
fi
lo
p
o
d
ia
 p
e
r 
c
e
ll
siLUC siMMP-8
siLUC siMMP-8
0
5
10
15
p=0.05
F
il
o
p
o
d
ia
 n
u
m
b
e
r 
p
e
r 
c
e
ll
siLUC siMMP-8
0
20
40
60
80
p<0.001
L
e
n
g
th
 (
P
ix
e
ls
)
α6β4 integrin
Phalloidin
DAPI
B 
A
1 
C 
  
160 
 
3.2.16 Impact of MMP-8 Loss on MMP-9 Protease Function in Myo-Puro 
Cells 
 
To evaluate whether MMP-8 loss has an impact on MMP-9 activity; MMP-8 
or control siRNA transfected cells were seeded on rhodamine conjugated 
gelatine (red), incubated for 24 hours and stained for phalloidin (green) and 
DAPI (blue) (Figure 3-22 A). All experiments were done 3 times. The gelatine 
degradation was quantified as the total black (degraded) area on red 
background by ImageJ in at least 10 different fields per condition as 
described in Section 2.14. Gelatine degradation was significantly greater for 
MMP-8 knock-down Myo-Puro cells in comparison to the control cell group 
(p=0.007) (Figure 3-22 B). Cell number was counted for every field analysed 
and revealed no significant difference between MMP-8 knock-down or 
control siRNA treated groups indicating that enhanced gelatine degradation 
was not a result of increased cell number (p=0.65, n=3) (Figure 3-22 C). 
Furthermore, enhanced gelatinase activity could be inhibited by MMP-9 
siRNA or MMP-9 inhibitor (Section 3.2.9). 
 
The level of proteolytic activity was further studied by gel zymography, in 
which CM samples collected from modified Myo-Puro cell populations were 
run on a gelatine gel zymography (Figure 3-23 A). Cell counts of modified 
Myo-Puro cells were counted when CM was collected and showed no 
significant difference (data not shown), therefore equal volume of CM from 
each condition was loaded on the gel. Recombinant MMP-2 and recombinant 
MMP-9 were loaded as positive controls however inconsistent bands were 
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observed. In order to determine the MW, protein ladder was used (data not 
shown). Densitometric analysis of the lytic bands was done by ImageJ. 
MMP-2 levels did not differ (p=0.986, n=3). There was an increase in MMP-9 
activity in siMMP-8 treated Myo-Puro cells when compared to control group, 
however, this did not reach significance (p=0.060, n=3) (Figure 3-23 B).  
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Figure 3-21: Effect of MMP-8 knock-down on gelatine degradative 
activity of Myo-Puro cells in in vitro zymography.  A; siLUC or siMMP-8 
treated Myo-Puro cells were seeded on rhodamine tagged gelatine and 
incubated for 24 hours, fixed and stained for FITC-conjugated phalloidin 
described in Section 2.15. The total area of degraded gelatine (black dots on 
red gelatine) was analysed on 10 fields by using ImageJ and normalised to 
the degraded area found in Myo-Puro cells transfected with siLUC. Bar 
10μm. B; Degraded area was significantly increased in MMP-8 knocked 
down cells. C; Cell counts per each field revealed that there was no 
significant difference between siMMP-8 treated or control groups. **, P ≤ 
0.01; (Student’s t test). Error bars show means +/- SEM, n.s., not significant, 
representative for 3 independent experiments.      
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Figure 3-22: Effect of MMP-8 knock-down on MMP-9 and MMP-2 activity 
in gel zymography. A; CM were collected from modified Myo-Puro cells 
after 24 hours serum starvation and subjected to gelatine zymography as 
described in Section 2.10. Bands corresponding to MMP-9 and MMP-2 were 
observed. B; Quantification was done by the densitometric analysis of the 
degraded gelatine bands with ImageJ. There was an increase in MMP-9 
activity upon MMP-8 knock-down, but this was not significant. There was no 
significant alteration in MMP-2 levels (p values, student’s t test). Error bars 
show means +/- SEM. A.U., arbitrary unit, representative for 3 independent 
experiments.  
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3.2.17 The Effect of Inhibition of MMP-9 Activity on Gelatine 
Degradation of Modified Myo-Puro Cells 
 
In order to analyse whether MMP-9 activity is involved in enhanced gelatine 
degradation upon MMP-8 loss in Myo-Puro cells (Section 3.2.18), MMP-9 
was knocked down by siRNA treatment in the Myo-Puro cells transfected 
with MMP-8 siRNA (MMP-9 knock-down was verified by RT-PCR -data not 
shown) or the cells were treated with an MMP-9 inhibitor as described in 
Section 2.5. Figure 3.25 shows that the gelatine degradation was 
significantly down-regulated upon MMP-9 knock-down in siMMP-8 treated 
Myo-Puro cells (p=0.0003). In addition, there was a gradual decrease in 
degraded gelatine area, in relation to increasing concentrations of MMP-9 
inhibitor (50nm MMP-9 inhibitor, p=0.0005, 100nm inhibitor p=2.66E-05). 
There was no difference in DMSO vehicle only control in gelatine 
degradation compared to siMMP-8 treatment suggesting that the increased 
gelatine degradation is derived from increased MMP-9 activity after MMP-8 
knock-down. Unfortunately due to time constraints this experiment was 
performed only once, with analysis of 10 different fields from each condition. 
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3.3 Discussion  
 
3.3.1 Culturing of Myo-β6 and Myo-Puro Cells 
 
The cell lines used to model normal and DCIS-associated MEC were Myo-
Puro and Myo-β6, respectively. The parental cell line from which these were 
derived was an h-TERT immortalised MEC line (MEC 1089) [294] derived 
from reduction mammoplasty material. This cell line consists of a mixture of 
MECs which express high, intermediate or low levels of α6β4 integrin. These 
cells were subjected to a selection procedure with an α6β4 integrin antibody 
on magnetic beads to enrich the cells which have high α6β4 integrin 
expression. It was found that this sub-population exhibited expected 
characteristics of MECs including expression of P-cadherin, CK17 and Dsg3. 
Previous work in our lab has shown that DCIS-associated MECs exhibit an 
altered phenotype with the most consistent change being up-regulation of 
αvβ6 integrin. Experimental work demonstrated that this is a functionally 
relevant change, and alters MEC tumour suppressor function. Therefore in 
order to establish a DCIS model this α6β4 enriched myo-1089 population 
was transfected with a retroviral vector containing a β6 integrin insert and 
further sorted using αvβ6 integrin antibody-coated magnetic beads to select 
αvβ6 integrin over-expressing cells. The cell line generated here was called 
Myo-β6 cells and represents αvβ6 up-regulated DCIS MECs. A control 
retroviral system (Empty vector) was also used and these cells were used as 
a normal breast MEC model and called Myo-Puro.  
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Myo-β6 and Myo-Puro cells show a drift in their myoepithelial phenotype over 
time in vitro. Most notably, the α6β4 integrin expression is down-regulated. 
Therefore these cell lines are regularly selected for α6β4 integrin expression. 
In order to maintain the difference in αvβ6 expression between Myo-β6 and 
Myo-Puro cells, they are subjected to a routine re-sorting protocol in which 
Myo-β6 cells were positively selected for αvβ6 whereas Myo-Puro cells were 
negatively selected. The confluency of the cell lines also increases the αvβ6 
integrin expression. The cell lines were grown at no more than 70% 
confluency. By rigorously controlling culture conditions and regular selection, 
a consistent phenotype reflecting normal and DCIS-associated MEC was 
maintained throughout the study.  
 
Initial experiments carried out by a colleague (Dr M. Allen) compared 
behaviour of these cell lines to primary MEC population and, showed they 
exhibit similar behaviour in vitro (Prof. L. Jones personal communication).   
 
3.3.2 Source of MMP-8 in Normal and DCIS Breast 
 
MECs isolated from normal breast were confirmed to be the source of MMP-
8 and the loss of MMP-8 in DCIS associated MECs was demonstrated by 
QRT-PCR run on mRNA extracted from primary cells.  
 
In an earlier study investigating the expression of MMP-8 in breast tissue, we 
found on IHC that MMP-8 localised to the MEC-BM interface in normal 
breast ducts but was not detected in ducts containing DCIS [215]. 
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Unfortunately the antibody used in that study is no longer available. 
Therefore a series of other antibodies were tested for IHC staining on FFPE 
or frozen tissues using a number of antigen retrieval techniques; for frozen 
samples no antigen retrieval was done. For all antibodies used, high level of 
background staining was observed and no specific staining was present 
(data not shown), which implies that the MMP-8 antibodies available were 
not adequate for using in IHC staining. Whilst disappointing, there are 
limitations to using IHC to detect MMPs: IHC shows the localisation of the 
protein which may not reflect the cell type making the protein. MMPs are 
secreted proteins therefore, in order to detect MMP-8 at mRNA level in tissue 
samples, an in situ hybridization (ISH) approach was planned; a specific 
region in the MMP-8 mRNA sequence that would allow generation of an ISH 
probe was investigated. The great similarity shared between MMP family 
members made it difficult to identify an MMP-8-specific region. A region 
spanning exon 10 was identified as potentially specific for MMP-8; however 
PCR on normal MECs or Myo-Puro targeting this region did not generate a 
product (data not shown). This may be a result of alternative splicing, known 
to affect both exon 8 and exon 10 (Personal communication Prof. Dylan 
Edwards) and therefore this was not pursued further. Therefore primary 
normal breast and DCIS associated MECs, LECs and fibroblasts were 
purified and QRT-PCR was done. This technique is a powerful approach to 
investigate the source of a secreted protein since it allows discrimination of 
the cell group expressing the mRNA. The MMP-8 transcript has a low copy 
number therefore a nested PCR approach was taken. The total mRNA was 
isolated from freshly purified cells before passaging therefore these cells 
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provide conditions close to in vivo. This analysis confirmed the MEC 
population to be the source of MMP-8 in normal breast, with lack of 
expression in MEC isolated from DCIS. 
 
Having shown that normal MEC are the source of MMP-8, the expression 
levels of MMP-8 in cell line systems was further analysed. Since MMP-8 is a 
secreted protein CM collected from Myo-β6 or Myo-Puro cells were used. 
Cell lysate preparations were also used in WB but no specific signal was 
observed for MMP-8 (data not shown). The amount of protein in the CM is 
considerably lower than in the cell lysates therefore the CM were 
concentrated using centrifugal filters. The problems encountered with MMP-8 
antibodies in IHC also caused difficulties for WB. Two antibodies were found 
to give a signal for MMP-8 in WB. This signal was specific for MMP-8 since 
the band observed with these antibodies was no longer present in samples 
from siMMP-8 treated MECs. Using these approaches, the mRNA and 
protein levels of MMP-8 were found to be down-regulated in the DCIS 
associated system (Myo-β6) when compared to the normal system (Myo-
Puro), which recapitulates the alterations identified in vivo. Therefore these 
cell lines were considered to be good models to study the role of MMP-8 in 
normal breast versus DCIS. WT and a catalytically inactive mutant form of 
MMP-8 was over-expressed in Myo-β6 cells and MMP-8 activity was 
evaluated by Collagen-I zymography by adapting the analysis done by 
Palavalli et al [217], to qualitatively analyse the presence of MMP-8 activity. 
For specific detection and concentration of MMP-8; prior to Collagen-I 
zymography CM were immunoprecipitated for MMP-8 by adapting the 
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method shown by Palavalli et al [217] and these samples were added to 
gels. Addition of non-reducing loading buffer and incubating samples at RT 
for 15 minutes was sufficient to release the immunoprecipitates from the 
protein A beads as shown by the WB. 
 
Zymographic approaches allow monitoring of the enzymatic activity of 
proteases by exposure to a substrate in vitro [304, 305]. During the washing 
step after electrophoresis, non-ionic detergent Triton 100X substitutes for 
SDS which partially renaturates the triple helix structure and permits 
degradation by MMPs [305]. Collagen-I degradation was observed in MMP-8 
WT-carrying Myo-β6 cells as anticipated, however, although MMP-8 protein 
expression was confirmed in MMP-8 EA Myo-β6 cells, as shown by WB, 
Collagen-I degradation was absent, confirming the inactivity of the mutated 
EA vector. This approach therefore was appropriate to study the role of 
MMP-8 enzymatic activity in its biological function, as well as expression; 
furthermore this system will provide a tool to understand whether the action 
of MMP-8 is dependent on its proteolytic properties or influencing other 
proteins to exert its tumour suppressor role. Whilst β6 over-expressing MEC 
showed loss of MMP-8, αvβ6 levels were not altered on over-expression of 
MMP-8 WT or MMP-8 EA (data not shown). However in the Myo-β6 cell 
system, expression of αvβ6 is controlled by a potent retroviral promoter, 
therefore the over-expression of MMP-8 may not result in significant change. 
To address whether MMP-8 influences αvβ6 expression primary DCIS 
associated MECs could be analysed following transfection with MMP-8.   
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3.3.3 MMP-8 Down-regulates Migration but, Conversely Up-regulates 
Adhesion and Spread on ECM 
 
Having generated the tools to study the gain-of-function effects of MMP-8; 
firstly the effect of MMP-8 on MEC adhesion was analysed. The 
concentrations of ECM proteins used in this assay were determined by 
seeding Myo-β6 cells in SFM (growth factor deprived media) on serial 
dilutions of each ECM protein and monitoring cell behaviour after 1 hour. The 
cells showed rounded morphology in higher dilutions, rounded and spread 
cells were observed in intermediate dilutions and rounded morphology was 
detected again in lower dilutions. This response in cell spread has previously 
been explained by a ‘receptor saturation model’ by Gaudet and colleagues 
[306]. At low ligand concentration the integrin receptor ligand engagement 
(adhesion) is not enough to induce spreading or to create a traction force 
needed for migration. As the ligand concentration increases more integrins 
bind the ligand, therefore the cell spreads. At the highest matrix 
concentrations the receptors become saturated and more clustered therefore 
cells exhibit a rounded morphology which also blocks migration [306]. 
Therefore the matrix concentrations were selected from intermediate 
dilutions which allow optimum adhesion and migration [306-308]. It was 
found that MMP-8 significantly enhanced MEC adhesion to fibronectin, 
Collagen-I, laminin-I-I-I and tenascin-C, dependant on its protease activity. 
Conversely; adhesion to LAP, which is a well-established ligand of αvβ6 
during TGF-β activation, was down-regulated. It has previously been shown 
in our lab that Myo-β6 cells show significantly enhance adhesion to LAP 
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when compared to Myo-Puro cells [275]. Therefore this result may reflect 
decreased αvβ6 activity upon MMP-8 WT over-expression in Myo-β6 cells. 
However this evidence is limited, though the effect of MMP-8 on TGF-β 
signalling was further dissected, as described in result Section 5.  
 
Secondly, it was found that MEC migration in MMP-8 WT over-expressing 
but not in MMP-8 EA transfected Myo-β6 cells over fibronectin, Collagen-I, 
laminin-I-I-I, tenascin-C and LAP was significantly decreased. In the 
transwell migration assay, in which the underside of the transwell was coated 
with ECM, the cells were separated from ECM by a porous membrane 
therefore cells migrate towards a protein gradient. Since the ECM is 
insoluble and bound to a surface, and cells migrate towards a gradient, this 
migration is a model for haptotaxis. The cells were seeded in SFM and the 
outer chamber contained SFM therefore the only gradient established is for 
ECM [309]. Since the quantification was done on cell number after incubation 
this assay gives an end-point result. It was previously shown in our lab that 
Myo-β6 cells show a more migratory phenotype when compared to Myo-Puro 
cells [275]. It can be hypothesised that the stress from the uncontrolled 
growth of the tumour cells in the duct generated by physical forces may 
trigger a wound response in MECs and therefore acquisition of migratory 
properties may be considered as a DCIS related phenotype (Section 1.5.3).   
 
The down-regulation in migration towards ECM proteins seen in Myo-β6 cells 
over-expressing MMP-8 WT is in contrast to adhesion data which showed 
that MMP-8 WT enhances adhesion of Myo-β6 cells to ECM proteins. Thus 
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MMP-8 appears to mediate anchorage of MECs to their environment in a 
mechanism dependent upon its enzymatic properties since these changes 
were not seen in cells over-expressing mutant MMP-8 EA. Considering the 
central role of MECs in preserving normal tissue architecture, the disruption 
of which is characteristic of DCIS [59, 310], and the disruption of MEC layer 
integrity is a determining factor in the progression of pre-invasive to invasive 
disease, it may be hypothesised that MMP-8 can contribute to MEC tumour 
suppressor function by promoting maintenance of an intact cell layer through 
cell-matrix interactions. 
 
Based on these results the next aim was to analyse how MMP-8 may be 
involved in mediating stationary attachment. MEC share some characteristics 
with basal keratinocytes, forming an epithelial-BM interface, with generation 
of unique adhesive HD structures. Dissociation of HD in wound healing and 
migration is well studied in keratinocytes (Section 1.5.3). Given the effect of 
MMP-8 on MEC migration we postulated this might be mediated through 
modulation of HD. Therefore these structures were analysed in modified 
Myo-β6 cells and showed that HD formation is enhanced in MMP-8 WT when 
compared to MMP-8 EA or control cells. This was shown by co-localisation 
analysis of two components of HD; the α6β4 integrin and plectin. This 
analysis allows investigation of cellular structures while the cells are still 
under culture conditions. Immunoprecipitation analysis is an alternative 
approach to analyse physical contact between proteins, however, for this 
technique the cells need to be detached from the plate or ligand on which 
they are seeded, and possibly, to analyse a structure involved in cell 
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attachment, this approach might not be appropriate. The modified Myo-β6 
cells were also stained for MMP-8 (using the same antibody list as with the 
IHC Section 3.2.1), but no specific staining was observed. This is may be 
due to MMP-8 being secreted or due to failure of the antibodies. Staining for 
α6β4 revealed spike-like patterns at cell edges as well as the characteristic 
HD structures. These protrusions were stained with phalloidin. In the 
absence of dynamic information filopodial protrusions cannot be 
distinguished from retraction fibres, therefore these structures were referred 
as ‘filopodia/retraction fibres’. Further analysis of these structures showed 
that MMP-8 WT abrogates filopodia/retraction fibre formation, which is a 
characteristic of reduced migratory phenotype  [311]. This analysis was done 
on PFA-fixed cells which could affect cell protrusions. In order to investigate 
the motion of a cell group, time lapse microscopy is a better approach so the 
actual movement of the cells can be monitored, and the mode of migration 
(directed or random) as well as the speed of the cells could be quantified. To 
confirm the effect of secreted MMP-8, parental Myo-β6 cells were incubated 
with recombinant MMP-8 as described in Section 2.21. Recombinant MMP-8 
stimulation significantly down-regulated filopodia/retraction fibre number in 
Myo-β6 cells (Section 7.1), supporting the over-expression results. In parallel 
with filopodia/retraction fibre analysis, phalloidin staining also provided data 
on cell size. MMP-8 WT expressing Myo-β6 cells spread more on fibronectin. 
This is concomitant with the increased adhesion and decreased migration 
observed on fibronectin as described earlier. Taking these results together 
the conclusion can be drawn that MMP-8 promotes a more adhesive 
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phenotype with enhanced HD formation, and this may be one mechanism by 
which it contributes to MEC tumour suppressor phenotype.   
 
3.3.4 MMP-8 Reduces Matrix Degradation by MECs 
 
Primary invasion of breast cancer cells is accompanied by BM degradation.  
One distinct characteristic reported for DCIS-associated MECs by gene 
expression studies is the enhanced expression of proteases [12]. It has been 
postulated that this may contribute to the initiation of cancer cell invasion 
through BM. Concomitantly our lab has shown that Myo-β6 cells up-regulate 
MMP-9 expression compared to Myo-Puro cells via a TGF-β –dependent 
mechanism. Here, gelatine degradation analysis was done using an in vitro 
zymography assay which was originally developed for invadopodia analysis 
and permits visualisation of fluorescent gelatine [312]. The total degraded 
area per field was quantified, and in parallel the cell number per field was 
counted. MMP-8 WT but not EA over-expression led to a significant 
reduction in the gelatinolytic activity of Myo-β6 cells. MECs secrete the 
gelatinase MMP-2 in addition to MMP-9, therefore the proteolytic activity 
determined by this assay may not be fully attributed to MMP-9 activity. 
Therefore to discriminate between MMP-9 and MMP-2 activity, a substrate 
gel zymography in which gelatine was co-polymerised with acrylamide that 
allows separation of MMPs according to MW was done [305, 313, 314]. CM 
derived from MMP-8 WT but not from MMP-8 EA over-expressing Myo-β6 
cells showed evidence of reduced MMP-9 activity, however this reduction did 
not reach significance (MMP-8 WT vs empty p=0.057, MMP-8 WT vs MMP-8 
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EA p=0.067). Whilst a band for MMP-2 was seen with the positive control 
(data not shown), no bands were seen for Myo-β6 populations. There are 
certain limitations to be considered with gelatine zymography [313, 314]. The 
fact that the refolding of MMPs after electrophoresis is partially recovered 
might cause problems with insensitivity when a change in levels (reduction or 
induction) of an MMP is quantified [305]. It is also should be considered that 
during electrophoresis, SDS disassociates MMP-TIMP complexes which 
makes the inactive TIMP-bound MMP activity eligible for detection, thus the 
actual activity level in the CM might not be accurately reflected [305]. The 
pro-MMP forms can also be detected due to post electrophoresis treatment 
of Triton 100X and activation buffer, since they are covalenty bound to the 
pro-domain the pro-forms appear at a higher MW. Moreover, over-staining of 
gels with Coomassie blue might also introduce sensitivity problems. 
Therefore, there are several factors that interfere with the quantitative use of 
zymographic techniques and, limit the information about net proteolytic 
activity [313, 314]. It can be argued that MMP-8 activity might be detected by 
gelatine zymography, however this signal should be very weak since gelatine 
is not the preferential substrate of MMP-8. In this study, no bands 
corresponding to MMP-8 were observed on gelatine zymography. Also no 
proteolytic zone corresponding to MMP-9 was observed in Collagen-I 
zymography. In addition the recombinant MMP-9 and MMP-2 could not be 
consistently detected. This might be due to the low concentration of 
recombinant proteins or high concentration of gelatin in the gel, the 
recombinants might be visible if the gelatin concentration is reduced [313]. 
Different dilutions of MMP-9 and MMP-2 recombinants were run on gelatine 
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zymography but a consistent degraded gel area could not be observed. 
Alternatively, recombinant standards might include reducing agents which 
destroy the MMP activity [313].    
 
From the in vitro zymography and gel zymography there is some evidence, 
though not conclusive, that MMP-8 might exert an inhibitory role on MMP-9 
activity. PCR analysis showed no change in MMP-9 gene expression 
therefore based on previous reports that MMP-8 and MMP-9 could establish 
a complex [208], we hypothesised that MMP-8 might bind to MMP-9 and 
inhibit its action. In addition, MMP-9 is of particular interest since it has been 
shown that MMP-9 can bind to the extracellular domain of α6β4 and inhibit 
wound closure [315]. Therefore MMP-9 might interfere with the mechanism 
of MMP-8.    
 
3.3.5 Loss of MMP-8 Reduces Adhesion and Promotes Migration and 
BM Degradation by MECs 
 
To confirm the physiological relevance of the over-expression model, in 
parallel to this DCIS associated model, we generated a normal MEC system 
and demonstrated endogenous MMP-8 expression, confirming that the 
system is appropriate to work on MMP-8. Here it was shown that, MMP-8 
knock-down in Myo-Puro cells reduced adhesion but increased migration to 
several ECM components. However migration to fibronectin and Collagen-I 
did not alter with the loss of MMP-8. Considering the decrease in migration in 
MMP-8 WT expressing Myo-β6 cells, an increase in migration in Myo-Puro 
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cells lacking MMP-8 might be expected. Since in normal breast MECs are 
facing BM which is rich in Collagen-IV but not in fibronectin or Collagen-I it 
was hypothesised that normal MECs may not be conditioned to respond to 
these two ECM components. However we could not exclude the possibility 
that the variation between different experiments in migration towards 
fibronectin and Collagen-I (errors of mean) could mask the significant 
difference between siMMP-8 or siLUC transfected Myo-Puros. To evaluate 
whether the length of incubation could mask the significant effect of MMP-8 
loss over Collagen-I, migration assays incubated for 4 hours were 
conducted. However, no significant difference was observed (Section 7.1.2). 
Moreover in DCIS, fibronectin is up-regulated spatiotemporally concomitantly 
with αvβ6 expression probably through a TGF-β dependent mechanism 
(Personal communication Prof L. Jones). Interestingly there was also no 
significant change in response to LAP. This may reflect the absence of αvβ6 
dependent activity in Myo-Puro cells. Further investigation of the actin 
cytoskeleton revealed that filopodia/retraction fibre formation is enhanced in 
the absence of MMP-8. Preliminary data shows that MMP-8 knock-down also 
increased gelatinase activity, and this increase is MMP-9 dependent since 
when MMP-9 is inhibited with siRNA or inhibitor the enhanced gelatine 
degradation of MMP-8 knocked down Myo-Puro cells was abolished. This 
data requires confirmation but together the results suggest that MMP-8 loss 
promotes the gain of DCIS-related properties in normal MECs.  
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Chapter 4: Effect of MMP-8 on Myoepithelial 
Tumour Suppressor Functions 
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4 Effect of MMP-8 on Myoepithelial Tumour Suppressor 
Function 
 
4.1 Introduction and Aims 
 
The role of the microenvironment in promoting tumour cell invasion is now 
well established [64, 65]. Much of this work focuses on the role of tumour-
associated fibroblasts [67], but in the breast the MEC population also 
influences epithelial cell behaviour [58-60, 117, 275]. 
 
Normal MECs have been shown to exhibit tumour suppressor properties 
[117]. They establish a physical barrier around LECs and produce the BM 
[79]. MECs also secrete a number of tumour suppressor proteins, proteinase 
inhibitors and anti-angiogenic factors indicative of the paracrine mechanisms 
involved in this tumour suppressor function [114, 115]. In fact, normal MECs 
have been shown to inhibit breast cancer cell invasion in transwell invasion 
assays, in part, by down-regulating MMP expression and activity in breast 
cancer cells [117].    
 
In DCIS, MECs become altered and work in our laboratory has shown that 
certain changes, such as the up-regulation of αvβ6, lead to acquisition of 
tumour promoter properties [275]. In the current study, it is also evident that 
DCIS-associated MECs lose MMP-8 expression and this also impacts on 
MEC function.  
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Other studies also have demonstrated a tumour suppressor role for MMP-8. 
It was demonstrated that MMP-8 knockout mice show a higher incidence of 
skin tumours in a chemically induced carcinogenesis model compared to WT 
mice [208]. Similarly Gutierrez-Fernandez et al. showed that when B16F10 
melanoma cells were inoculated into MMP-8 knock out or WT mice via tail 
vein injection the number of lung metastasis was up-regulated in MMP-8 
knockout mice when compared to WT counterparts [215]. These studies 
underline the importance of host-derived MMP-8 on the behaviour of cancer 
cells.  
 
The aims of this chapter are: 
 
 To analyse the effect of MEC derived MMP-8 on breast cancer cell 
invasion in two dimensional (2D) and three dimensional (3D) systems. 
Specifically: 
o To co-culture modified Myo-β6 or Myo-Puro cells with breast 
cancer cells to analyse direct interactions between the two cell 
groups  
o To build organotypic cultures to analyse the MEC-cancer cell 
and stromal interactions in breast tissue context  
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4.2 Results  
 
4.2.1 Effect of MEC Derived MMP-8 on Breast Cancer Cell Invasion in 
Boyden Chamber Invasion Assays 
 
In order to analyse whether MMP-8 has a role in the paracrine interactions 
between MECs and breast cancer cells during primary breast cancer cell 
invasion; modified Myo-β6 cells and the breast cancer cell lines SUM159 or 
MDA MB 231 were co-cultured in a Boyden chamber invasion assay for 24 
hours. In this assay transwells were either coated with Matrigel to represent 
BM or the MMP-8 substrate Collagen-I, and the number of invaded breast 
cancer cells were quantified as described in Section 2.8. All experiments 
were repeated a minimum of 4 times. The number of breast cancer cells 
invading through Matrigel matrix was significantly reduced when co-cultured 
with MMP-8 WT (MDA MB 231 p=0.004, SUM159 p=0.04) but not with MMP-
8 EA over-expressing Myo-β6 cells (MDA MB 231 p=0.61, SUM159 p=0.64), 
in comparison to Empty vector transfected MEC (Figure 4-1). Addition of 
recombinant human MMP-8 also resulted in a significant reduction in 
invading breast cancer cells (p=0.001, n=2, data not shown).   
 
In order to exclude the possibility that the reduction in invasion identified in 
the presence of MMP-8 WT was a result of decreased proliferative activity; 
the proliferation of MDA MB 231 or SUM159 breast cancer cells was 
evaluated using the MTS assay, after 24 hours treatment with CM collected 
from MMP-8 WT, MMP-8 EA or Empty vector transfected Myo-β6 cells (as in 
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the invasion assay) as described in Section 2.9. There was no significant 
difference in proliferation rate between the different treatment groups for 
each cell line (Figure 4-2).  
 
 
 
 
 
 
 
 
Figure 4-1: Effect of MMP-8 over-expression in Myo-β6 cells on breast 
cancer cell invasion through Matrigel. A; Schematic representation of 
Boyden chamber invasion assay using Matrigel as a BM barrier. B; The 
number of breast cancer cells invading through the membrane was counted 
as described in Section 2.8, and normalised to the number of invading cells 
in the assays using Empty vector over-expressing Myo-β6 cells. There was a 
significant reduction in invasion by SUM159 and MDA MB 231 cells after 24 
hours in the presence of MMP-8 WT over-expressing Myo-β6 cells. The 
SUM159 and MDA MB 231 cell invasion did not change significantly after co-
cultured with MMP-8 EA over-expressing Myo-β6 cells for 24 hours.  *, P ≤ 
0.05, **, P ≤ 0.01 (Student’s t test). Error bars show means +/- SEM. A.U., 
arbitrary unit, n.s., not significant, representative for 4 independent 
experiments.  
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Figure 4-2: Effect of MMP-8 over-expression in Myo-β6 cells on breast 
cancer cell proliferation. MDA MB 231 or SUM159 breast cancer cells 
were treated with conditioned media collected from modified Myo-β6 cells as 
described in Section 2.9. MTS assay was done and the proliferation rate was 
normalised to the proliferation of breast cancer cells when treated with CM 
from Myo-β6 cells transfected with Empty vector. There was no significant 
change in proliferation under different co-culture conditions. Error bars show 
means +/- SEM. A.U., arbitrary unit, n.s., not significant, representative for 3 
independent experiments. 
 
 
Based on the observation that functioning WT but not the inactive EA form of 
MMP-8 reduced invasion of breast cancer cells in this 2D system, the effect 
of MMP-8 on breast cancer cell invasion through its ligand Collagen-I was 
analysed in a Boyden chamber invasion assay, set up by coating the 
transwells with Rat tail Collagen-I in place of Matrigel, as described in 
Section 2.8. There was a significant reduction in the number of SUM159 cells 
invading through Collagen-I when co-cultured with MMP-8 WT over-
expressing Myo-β6 cells compared to control Myo-β6 cells over-expressing 
Empty vector (p=0.001, n=2) (Figure 4-3). When SUM159 cells were co-
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cultured with MMP-8 EA over-expressing Myo-β6 cells, there was no 
significant difference in invasion (p=0.43, n=2).    
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Figure 4-3: Effect of MMP-8 over-expression in Myo-β6 cells on breast 
cancer cell invasion through Collagen-I. The number of invading breast 
cancer cells was analysed as described in Section 2.8 and normalised to the 
invading cell number in the presence of Myo-β6 cells over-expressing Empty 
vector. Invasion by SUM159 cells was significantly reduced in the presence 
of MMP-8 WT over-expressing Myo-β6 cells but not in the presence of MMP-
8 EA over-expressing Myo-β6 cells. **, P ≤ 0.01 (Student’s t test). Error bars 
show means +/- SEM. A.U., arbitrary unit, n.s., not significant, representative 
for 2 independent experiments. 
 
4.2.2 Effect of MEC Derived MMP-8 on Breast Cancer Cell Invasion in 
Organotypic Models 
 
To recapitulate the DCIS associated stromal microenvironment an 
organotypic culture model approach was taken. In this model organotypic 
gels were constructed from a Matrigel and Collagen-I mixture and embedded 
with MRC5 fibroblasts. Following 24 hours equilibration, modified Myo-β6 
cells and MDA MD 231 or SUM159 breast cancer cells were overlaid on top 
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of the gel then raised to air-liquid interface as described in Section 2.16 
(Figure 4-4 A).    
 
After 11 days incubation; gels were fixed, processed and sectioned then 
stained with H&E or specific antibodies as described in Section 2.19. 
Antibodies used were proliferation marker Ki67, MEC marker p63 and 
invasive breast cancer cell marker Neso which is the Neonatal splice variant 
of voltage gate channel Nav1.5 [317]. H&E stained sections are shown in the 
Figure 4-4 B and based on these; invasion was quantified as the combination 
of the number, depth and the area occupied by the invaded breast cancer 
cells to give an invasion index. At least 3 organotypic gels were prepared per 
condition in each experiment and the whole gel section was quantified 
except the edges. All experiments were done at least 4 times. As shown in 
the Figure 4-5 the invasion index was significantly reduced when MDA MB 
231 or SUM159 breast cancer cells were co-cultured with MMP-8 WT over-
expressing Myo-β6 cells (MDA MB 231 p=1.68E-13, SUM159 p=4.04E-04) 
but not when co-cultured with MMP-8 EA over-expressing Myo-β6 cells 
(MDA MB 231 p=0.15, SUM159 p=0.54) compared to the invasion in the 
presence of Empty vector transfected Myo-β6 cells. In order to consider the 
probability that this decrease in invasion index is because of a reduction in 
breast cancer cell proliferation in the presence of MMP-8 WT; gels were 
stained for Ki67 which is a proliferation marker. Proliferation index of cells 
invaded in the gel was quantified as the number of cells positive for Ki67 
divided by the total cell number (determined by the number of nuclei stained 
by DAPI) and normalised to the proliferation index when breast cancer cells 
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were co-cultured with Empty vector transfected Myo-β6 cells. There was no 
significant difference in the proliferation of breast cancer cells co-cultured 
with Myo-β6 cells transfected with either MMP-8 WT, MMP-8 EA or Empty 
vector (Figure 4-6) (n=3).  
 
 
Figure 4-4: Organotypic culture set up A; Schematic representation of 
organotypic cultures adapted from Froeling et al., 2008, Froeling et al., 2011, 
and Chioni and Grose, 2012 [297, 300, 316]. Bar 100μm. B; H&E staining of 
organotypic gels. After the incubation period organotypic gels were 
processed and sectioned as described in Section 2.16. Images are 
representative for 4 independent experiments.   
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Figure 4-5: Effect of MMP-8 over-expression in Myo-β6 on invasion of 
MDA MB 231 and SUM159 breast cancer cells in 3D organotypic 
systems. Based on H&E staining an invasion index was quantified as 
described in Section 2.16. The invasion index when MDA MB 231 or 
SUM159 were co-cultured with MMP-8 WT over-expressing Myo-β6 cells 
was significantly lower than when co-cultured with MMP-8 EA or Empty 
vector transfected cells. ***, P ≤ 0.001 (Student’s t test). Error bars show 
means +/- SEM. A.U., arbitrary unit, representative for 4 independent 
experiments 
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Figure 4-6: Effect of MMP-8 on proliferation of MDA MB 231 breast 
cancer cells in 3D organotypic systems. Gels were stained for Ki67 
proliferation marker as described in Section 2.16 and the proliferation index 
was quantified as the ratio of Ki67 positive cells to total cell number. There 
was no significant difference in proliferation index in breast cancer cells co-
cultured with MMP-8 WT, MMP-8 EA or Empty vector. Error bars show 
means +/- SEM., n.s., not significant, representative for 3 independent 
experiments. 
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Organotypic cultures were repeated incorporating primary normal breast 
fibroblasts in place of MRC5 fibroblasts. The fibroblasts were isolated from 
reduction mammoplasty tissue as described in Section 2.3. The invasion 
index of MDA MB 231 cells was significantly reduced when co-cultured with 
MMP-8 WT over-expressing Myo-β6 cells (Figure 4-7) (p=0.0002, n=2) but 
not with MMP-8 EA over-expressing group (p=0.64, n=2) when compared to 
control Empty vector co-cultures, reflecting the pattern of invasion seen in 
the presence of MRC5 fibroblasts.  
 
In order to confirm that the invaded cells counted in the organotypic gels are 
breast cancer cells, and to exclude the possibility that modified  Myo-β6 cells 
are also invading, gels were co-stained for the MEC marker p63 and an 
invasive breast cancer cell marker Neso [317]. The p63 staining revealed the 
layer of MEC on top of the gels and Neso staining selectively picked up the 
invading cells (Figure 4-7 B).  
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4.2.3 Effect of Loss of Myo-Puro Derived MMP-8 on Breast Cancer Cell 
Invasion in Boyden Chamber Invasion Assays  
 
In order to analyse the loss-of-function effect of endogenous MMP-8 
expression in a normal myoepithelial system on breast cancer cell invasion 
Myo-Puro cells were treated with MMP-8 siRNA or control siRNA. Knock-
down was confirmed by RT-PCR and WB (Section 3.3.9). The modified Myo-
Puro cells were then co-cultured with MDA MB 231 or SUM159 for 24 hours 
or with MCF-7 for 48 hours as described in Section 2.8. All experiments were 
repeated a minimum of 4 times. The number of MCF-7, MDA MB 231 or 
SUM159 cells invaded through Matrigel was significantly enhanced when co-
cultured with MMP-8 knock-down Myo-Puro cells compared to control siRNA 
treated Myo-Puro co-cultures (MCF-7 p=0.0003, MDA MB 231 p=0.001, 
SUM159 p=0.0003) (Figure 4-8). 
 
In order to examine the effect of loss of MMP-8 expression in normal MEC 
on breast cancer cell proliferation; MCF-7, MDA MB 231 and SUM159 cells 
were treated with CM collected from modified Myo-Puro cells (MDA MB 231 
and SUM159 for 24 hours or MCF-7 for 48 hours), followed by an MTS assay 
as described in Section 2.9. All experiments were repeated 3 times. As 
shown in Figure 4-9 there was no significant difference in proliferation rate of 
MCF-7, MDA MB 231 and SUM159PT cells under different CM treatments.     
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Figure 4-8: Effect of endogenous MMP-8 loss in Myo-Puro on breast 
cancer cell invasion through Matrigel. Modified Myo-Puro cells were co-
cultured with MCF-7, MDA MB 231 or SUM159PT cells as described in 2.8. 
After incubation the number of invaded breast cancer cells were counted and 
normalised to cell number in co-cultures with Myo-Puro transfected with 
control siRNA (siLUC). MCF-7, MDA MB 231 and SUM159 cell invasion 
through Matrigel was significantly up-regulated when co-cultured with 
siMMP-8 treated Myo-Puro cells. **, P ≤ 0.01; ***, P ≤ 0.001 (Student’s t 
test). Error bars show means +/- SEM. A.U., arbitrary unit, representative for 
4 independent experiments. 
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Figure 4-9: Effect of endogenous MMP-8 loss in Myo-Puro cells on 
breast cancer cell proliferation. MCF-7, MDA MB 231 and SUM159 cells 
were treated with CM from modified Myo-Puro cells as described in 2.9. 
MCF-7 cells were treated for 48 hours and MDA MB 231 and SUM159 cells 
were treated for 24 hours to reflect the invasion assays. An MTS assay was 
done to assess the proliferation. There was no significant difference in 
proliferation of the breast cancer cells under any of the assay conditions. 
Error bars show means +/- SEM. , n.s., not significant, representative for 3 
independent experiments. 
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4.2.4 Investigation of the Effect of MMP-8 Knock-down in Myo-Puro 
Cells on Breast Cancer Cell Invasion in 3D Culture  
 
In order to analyse whether the loss of Myo-Puro derived MMP-8 has an 
effect on breast cancer cell invasion in a 3D system, organotypic cultures 
were set up as described in Section 2.16 by co-culturing the MDA MB 231 
cells with modified Myo-Puro cells for 5 days. After that gels were processed 
and stained for H&E as described and the invasion index was calculated. All 
experiments were repeated a minimum of 3 times with at least 3 gels per 
condition (Figure 4-10 A). The invasion index of MDA MB 231 cells was 
significantly enhanced when co-cultured with siMMP-8 transfected Myo-Puro 
cells compared to the control system (p=0.007) (Figure 4-10 B).  
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Figure 4-10: Effect of MMP-8 knock-down in Myo-Puro cells on invasion 
of MDA MB 231 breast cancer cells in 3D organotypic systems. A; 3D 
organotypic systems were built as described in Section 2.16 in which MDA 
MB 231 cells were co-cultured with modified Myo-Puro cells and stained for 
H&E. Bar, 100μm. B; Breast cancer cell invasion was significantly up-
regulated when co-cultured with MMP-8 knock-down Myo-Puro compared to 
the control cell population. **, P ≤ 0.01; (Student’s t test). Error bars show 
means +/- SEM. A.U., arbitrary unit, representative for 3 independent 
experiments. 
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4.3 Discussion  
 
4.3.1 MEC Derived MMP-8 Can Down-regulate Breast Cancer Cell 
Invasion in 2D Invasion Assay Models 
 
The data presented here show that MEC derived MMP-8 can reduce breast 
cancer cell invasion through paracrine interations in 2D Boyden chamber 
invasion assays. Transwell invasion assays were constructed by coating the 
transwell (which possess a cell permeable membrane) with Matrigel, to 
mimic the BM barrier tumour cells encounter in vivo, and seeding breast 
cancer cells onto this matrix and MECs in the outer chamber of the assay. 
The cancer cells degrade Matrigel, cross the membrane and attach to the 
underside of the transwell, thus reflecting a process requiring matrix 
degradation and cell migration. The breast cancer cells selected for these 
this experiments are the highly invasive, ER- MDA MB 231 and SUM159 
cells because a “suppression effect” on invasion was being investigated. 
Matrigel is extracted from Englebreth-Holm Swarm (EHS) murine sarcoma 
and contains Collagen-IV, laminin, perlecan and various growth factors [318, 
319] and is considered therefore to resemble BM in vivo. As in the transwell 
assay assembly the different cell groups are not in contact; this system 
permits investigation of paracrine interactions of the two cell groups via 
secreted factors. This assay is quick, creates reproducible data, and can be 
prepared with low number of cells (20,000-30,000 per transwell). Despite the 
simple set up, Transwell invasion assays allow screening of the effect of an 
antibody, inhibitor, knock-down or over-expression of a particular protein 
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[320]. However this approach only produces an end-point result since the 
readout is the number of invaded cells after a particular incubation period. 
Moreover this system is certainly oversimplified, since the microenvironment 
is not represented and the 3D structural architecture of breast tissue is not 
reflected. Therefore this assay generates limited information about the full 
process of cancer cell invasion [309, 319, 320].  
 
Here it was shown that MMP-8 can play a role in modulating breast cancer 
cell invasion through a Matrigel barrier. This invasion suppressor role of 
MMP-8 was found to be dependent on its enzymatic activity since Myo-β6 
cells expressing inactive MMP-8 failed to show an effect when co-cultured 
with breast cancer cells. Since Matrigel resembles BM this system can be 
considered representative of primary invasion of breast cancer cells. MEC-
derived MMP-8 was shown not to have an effect on breast cancer cell 
proliferation. This is in agreement with the literature that MMP-8 does not 
influence primary tumour growth [215]. Thus it can be concluded that the 
higher cell counts reflect increased invasion rather than an absolute increase 
in cell number.   
 
Based on the observation that active but not inactive MMP-8 acts as an 
invasion suppressor, the next aim was to investigate invasion through the 
preferential MMP-8 ligand Collagen-I. Since Collagen-I is the major 
component of the interstitial matrix in breast, this approach also provides 
insights into the invasion into the ECM [107]. The Collagen-I invasion assay 
was an adaptation of the method used by Sheddin et al [107]. The Collagen-I 
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used here is acid-extracted from rat tail. At acidic pH Collagen fibril cross-
links are reversibly broken and the resultant (aldehyde-bearing) Collagen is 
soluble in acidic buffer. Collagen-I was reconstituted by adjusting to neutral 
pH, when cross-links are spontaneously reformed. This reconstituted 
Collagen-I has been widely used as a model of ECM [107, 309, 319, 320]. A 
similar pattern to Matrigel invasion was observed, with WT but not 
catalytically inactive MMP-8 leading to reduced breast cancer cell invasion 
through Collagen-I.  
 
4.3.2 MEC Derived MMP-8 Loss Promotes Breast Cancer Cell Invasion 
in 2D model 
 
MMP-8 deficient normal MECs (Myo-Puro) were found to enhance breast 
cancer cell invasion. This supports results from the over-expression system 
described above and implies physiological relevance. Having shown an 
increase in cell invasion in highly invasive breast cancer models, the less 
invasive ER positive breast cancer cell line MCF-7, was also included in the 
experiments to broaden the significance of the data. These cells also 
responded in same way and exhibited enhanced invasion in the presence of 
MMP-8 knocked down Myo-Puro cells. Similarly to the DCIS MEC model, 
loss of MMP-8 in Myo-Puro cells did not alter breast cancer cell proliferation; 
once again showing that MMP-8 is not involved in primary cancer cell growth 
but suppresses the invasive activity of the breast cancer cells.       
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4.3.3 MEC Derived MMP-8 Can Reduce Breast Cancer Cell Invasion in 
3D Organotypic Models 
 
The effect of MEC derived MMP-8 on breast cancer cell invasion was further 
analysed using 3D organotypic cell cultures which allow the co-culture of 
different cell populations; in this study MECs, breast cancer cells and 
fibroblasts, in juxta-position reflects the architecture of the tissue context thus 
recapitulating physiological conditions in vivo [309, 319, 320]. Here, 
organotypic gels were prepared with a Matrigel/Collagen-I mixture and 
fibroblasts embedded in the gel [17, 297-301]. The gels were then overlaid 
with MECs, then breast cancer cells were seeded on top of the MECs. This 
set up recapitulates the relationship of tumour cells with a MEC barrier to the 
stromal microenvironment.      
 
Breast cancer cell invasion was quantified by generating a numerical 
“invasion index” which combines the depth, number and sum of cell area 
invaded in the gel, as described by Nystrom et al [301]. This approach 
provides quantifiable, accurate and reproducible analysis however the 
pattern of invasion (single cell or collective) is not analysed.   
 
The results found in 3D cultures reflect the same pattern observed in 
Transwell assays. In the presence of Myo-β6 cells over-expressing MMP-8 
WT the invasion of breast cancer cells in 3D cultures was suppressed. This 
supports a role for MMP-8 in protecting against breast cancer cell invasion 
through the MEC layer. Considering that the organotypic gels are mainly 
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constructed from Collagen-I, which is the major target for MMP-8 
degradation, these findings raise the possibility of alternative functions for 
MMP-8, which could down-regulate breast cancer cell invasion.  
 
Conversely, knocking down endogenous MMP-8 in the normal MEC system 
enhanced cancer cell invasion. The effect observed here is moderate when 
compared to the over-expression system. This may be a result of the 
shortened incubation period for the cultures, necessary because of the 
transient siRNA knock-down system (5 days of incubation in comparison to 
11 days in the over-expression system). This incubation time might not be 
long enough to observe a substantial degree of invasion. In keeping with this, 
the tumour suppressor nature of MECs could down-regulate the invasion in 
organotypic gels [275]. In the future for better investigation of  the effect of 
loss of endogenous normal MEC derived MMP-8, Myo-Puro will be treated 
with shRNA targeting MMP-8 to generate stable knock-downs which will 
allow extended co-culturing incubation time.       
  
In the data presented, it was shown that MECs do not invade into the gel, but 
remain on the surface. This shows that the organotypic set up permits 
discrimination of non-invasive and invasive cell populations. MECs were 
identified with the established MEC marker p63 and the breast cancer cells 
were labelled with Neso. The latter antibody, which specifically detects 
neonatal isoform of Nav1.5 voltage-gated Na
+ channel was generated and 
used for identification of breast cancer during invasion [321]. The selective 
detection of invading MDA MB 231 breast cancer cells in organotypic 
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cultures by Neso staining was previously demonstrated by Chioni and co-
workers [322]. The fibroblasts are negative with this marker which makes this 
antibody a valuable tool to specifically identify invasive breast cancer cells 
[322].    
 
Here the use of invasive MDA MB 231 cells and normal fibroblasts in a DCIS 
model system might seem to be conflicting: in particular MDA MB 231 cells 
are certainly not pre-invasive breast cancer cells but derived from pleural 
metastasis. However gene expression studies comparing DCIS tumour cells 
and their invasive tumour cell counterparts repeatedly demonstrate the great 
similarity between the two cell groups; the DCIS tumour cells already show 
the spectrum of genetic alterations seen in invasive cells [12, 28, 323]. In 
regards to the fibroblast population previous studies have shown that when 
co-cultured with breast cancer cells, the normal fibroblasts are sufficient to 
promote invasion, tumour cells presumably inducing a myofibroblast 
phenotype [74, 117, 130]. Also co-injection of mice with normal fibroblasts 
together with the DCIS model MCF10ADCIS.com cells were sufficient to 
generate invasive tumours [130]. In keeping with normal fibroblasts being 
sufficient to enhance cancer cell invasion therefore being appropriate to use 
in DCIS system; CAFs show significant differences [66, 67]. Therefore in the 
future fibroblasts isolated from DCIS tissue will be used in organotypic 
cultures for better investigation of the cancer stroma and cancer cells.   
 
The organotypic cultures are fed from underneath by complete media which 
mimics the blood vessel. However, in vivo blood is continuously circulated 
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but in the organotypic system the nutrient source is stationary. In order to 
analyse the effect of blood flow and other features of the microenvironment, 
in the future, these organotypic gels will be transplanted in mice [297, 301].  
 
In summary, these experiments have shown that MEC derived MMP-8 
suppresses breast cancer cell invasion in a proteolytic-dependent 
mechanism, and loss of MMP-8 leads to enhanced invasion. The mechanism 
by which MMP-8 influences invasive behaviour is unclear, but will be further 
investigated in Chapter 5.  
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Chapter 5: Investigating the Mechanism 
Involved in MMP-8 Suppressor Function 
  
203 
 
5 Investigating the Mechanism Involved in MMP-8 
Suppressor Function 
 
5.1 Introduction and Aims 
 
The data from this study demonstrate that normal MEC are the major source 
of MMP-8 in the breast and that this is lost in DCIS. Using over-expression 
and knock-down systems it is evident that MMP-8 alters the adhesive and 
migratory capacity of MEC, appears to stabilise HD formation.  
 
Furthermore, co-culture systems demonstrate that MEC-derived MMP-8 
exerts an invasion suppressor effect and this is dependent on its proteolytic 
activity.  
 
Previous work in our lab has shown that the introduction of αvβ6 in MEC in 
DCIS increased adhesion to LAP, activation of TGF-β and TGF-β dependent 
up-regulation of MMP-9 leading to invasion promoting action [275]. Moreover 
it was recently shown that prolonged exposure of epithelial cells to TGF-β 
could result in a decrease in MMP-8 expression [324].  
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The aims of this chapter are: 
 To start to investigate how MMP-8 contributes to the tumour-
suppressor activity of MECs 
 Specifically to investigate whether MMP-8 can abrogate TGF-β 
activation and signalling in MEC since this appears to be an important 
mechanism leading to promotion of invasion by MEC  
 
5.2 Results  
 
5.2.1 Effect of MMP-8 Over-expression in Myo-β6 Cells on TGF-β 
Activation 
 
Two approaches were taken to dissect the TGF-β pathway: analysis of the 
ability of Myo-β6 cells to activate TGF-β, and assessment of the cellular 
response to exogenous TGF-β stimulation.  
 
Firstly, active TGF-β levels in modified Myo-β6 cells were analysed using a  
luciferase reporter assay by co-culturing MDA MB 231 cells carrying a TGF-β 
responsive luminescent vector (MDA MB 231-Luc) with MMP-8 WT, MMP-8 
EA or Empty control vector transfected Myo-β6 cells overnight as described 
in Section 2.22. The experiment was done 3 times using 1000pg/ml human 
active TGF-βI as a positive control. The luminescence observed from each 
co-culture system was used as a readout for active TGF-β levels in the 
system. No significant difference in luminescence levels was detected 
between different co-cultures (Figure 5-1).   
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Figure 5-1: Effect of MMP-8 over-expression in Myo-β6 on active TGF-β 
levels. The levels of active TGF-β was analysed as described in Section 
2.22. There was no significant difference in luminescence levels in co-
cultures with MMP-8 WT or inactive MMP-8 over-expressing Myo-β6 cells 
when compared to Empty vector control transfected cells. n.s., not 
significant; (Student’s t test). Error bars show means +/- SEM. A.U., arbitrary 
unit, representative for 3 independent experiments.  
 
Secondly, to analyse the effect of MMP-8 over-expression on response of 
MEC to active TGF-β, Myo-β6 cells were seeded on a 6 well plate and 
starved for 24 hours then treated with 5ng/ml active TGF-βI for 5, 10 and 15 
minutes as described in Section 2.20. As a readout for TGF-β signalling 
activity the phosphorylation levels of TGF-β downstream elements SMAD-2 
and SMAD-3 was evaluated by WB as described in Section 2.7. This 
experiment was repeated 3 times and results analysed by densitometry 
using ImageJ. The expression levels of total and phosphorylated forms of 
SMAD-2 and SMAD-3 were normalised to that of actin. Then the ratios of 
phosphorylated form to total protein levels were calculated.  
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The phosphorylation levels of SMAD-2 and SMAD-3 appeared to be 
decreased in MMP-8 WT over-expressing Myo-β6 cells when compared to 
Empty vector over-expressing control cells (Figure 5-2). There also was a 
reduction in phospho-SMAD-2 and SMAD-3 levels in MMP-8 EA over-
expressing Myo-β6 cells when compared to Empty vector transfected cells. 
These levels were higher than the phospho-SMAD-2 and SMAD-3 levels in 
MMP-8 WT. In the Myo-β6 cells over-expressing MMP-8 EA the 
phosphorylated SMAD-2 and SMAD-3 levels and the total SMAD-3 levels 
appeared to be higher than that of MMP-8 WT or Empty vector transfected 
Myo-β6 cells without TGF-β stimulation. In addition the total SMAD-3 levels 
appeared to decrease. The changes in phospho-SMAD-2 and SMAD-3 
levels did not reach significance due to the variation observed between 
experiments.  
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Figure 5-2: The effect of MMP-8 over-expression on response to TGF-β 
stimulation. MMP-8 WT, MMP-8 EA or Empty vector transfected Myo-β6 
cells were stimulated with 5 ng/ml TGF-β for 5,10 and 15 minutes after 24 
hours of serum starvation. A; Cell lysates were subjected to WB to check 
SMAD-2 and SMAD-3 phosphorylation. B; Phosphorylation levels of SMAD-2 
and SMAD-3 were examined by ImageJ. The expression level of each 
protein is normalised to actin loading control. In order to evaluate the 
changes in phosphorylated froms; the phosphorylated levels were divided by 
the total levels. These values were normalised to that of Empty vector for 
each time point. There was a decreased in phosphorylated SMAD-2 and 
SMAD-3 levels in MMP-8WT over-expressing group compared to inactive 
MMP-8 or Empty vector over-expressing Myo-β6 cells. pSMAD-2., 
phosphorylated SMAD-2 , pSMAD-3., phosphorylated SMAD-3, A.U., 
arbitrary unit, representative for 3 independent experiments (Result shown 
for 1 experiment).   
 
E
M
P
T
Y
M
M
P
-8
 W
T
M
M
P
-8
 E
A
E
M
P
T
Y
M
M
P
-8
 W
T
M
M
P
-8
 E
A
E
M
P
T
Y
M
M
P
-8
 W
T
M
M
P
-8
 E
A
E
M
P
T
Y
M
M
P
-8
 W
T
M
M
P
-8
 E
A
0 5 10 15 
pSMAD 2
pSMAD 3
70 kDa
55 kDa
70 kDa
55 kDa
55 kDa
55 kDa
55 kDa
40 kDa
TGF-β (mins)
SMAD 2
SMAD 3
Actin
5 10 15
0.0
0.5
1.0
1.5
EMPTY
MMP-8 WT
MMP-8 EA
TGF-
(mins):
p
S
M
A
D
2
/S
M
A
D
2
A 
B 
5 10 15
0.0
0.5
1.0
1.5
2.0
TGF-
(mins):
p
S
M
A
D
3
/S
M
A
D
3
  
208 
 
5.2.2 Effect of Lack of MMP-8 in Myo-Puro Cells on TGF-β Activation 
 
In order to analyse the effect of the loss of endogenous MMP-8 on active 
TGF-β levels in Myo-Puro cells; cells were treated with MMP-8 siRNA or 
siLUC control and co-cultured with TGF-β responsive MDA MB 231-Luc cells 
overnight as described in Section 2.22. This experiment was repeated 3 
times. The luminescence obtained when MDA MB 231-Luc cells were co-
cultured with siMMP-8 transfected Myo-Puro cells was normalised to the 
luminescence obtained in siLUC control co-cultures and no difference was 
observed in MMP-8 knocked down Myo-Puro cells in comparison to control 
cells (Figure 5-3).      
 
To investigate the effect of the loss of MMP-8 on TGF-β downstream 
signalling; modified Myo-Puro cells were treated with active TGF-βI as 
described in Section 2.20. This experiment was performed twice. The WB 
analysis of phosphorylation of SMAD-2 and SMAD-3 was done by ImageJ as 
described in Section 5.2.1 and revealed an increase in phosphorylated 
SMAD-2 and SMAD-3 in MMP-8 knock-down Myo-Puro cells compared to 
control siRNA transfected cells (Figure 5-4). The highest level of SMAD-2 
phosphorylation was observed at 10 minutes time point and the signal 
appeared to decrease at 15 minutes time point in siMMP-8 transfected Myo-
Puro cells. The SMAD-3 phosphorylation was observed only in Myo-Puro 
cells treated with siMMP-8 at 10 minutes and 15 minutes time point. This 
signal was also highest at 10 minutes time point.   
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Figure 5-3: Effect of MMP-8 loss in Myo-β6 on active TGF-β levels. The 
level of TGF-β activity was explored by luciferase reporter assay by co-
culturing modified Myo-Puro cells with MDA MB 231 cells carrying a TGF-β 
responsive vector as described in Section 2.22. There was no difference in 
luminescence observed levels in MMP-8 knock-down Myo-Puro cells when 
compared to control siRNA transfected cells. n.s., not significant; (Student’s t 
test). Error bars show means +/- SEM. A.U., arbitrary unit, representative for 
3 independent experiments (Result shown for 1 experiment).  
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Figure 5-4: The effect of lack of MMP-8 on response to TGF-β 
stimulation.  Modified Myo-Puro cells were activated with 5 ng/ml TGF-β, A; 
WB analysis and B; Densitometric quantification was done by ImageJ. Levels 
of phosphorylated forms of SMAD-2 and SMAD-3 were normalised to total 
SMAD-2 and SMAD-3 respectively for each time point. The phosphorylated 
SMAD-2 and SMAD-3 forms were up-regulated in MMP-8 knock-down Myo-
Puro cells in comparison to control siRNA transfected Myo-Puro cells. 
pSMAD-2., phosphorylated SMAD-2 , pSMAD-3., phosphorylated SMAD-3, 
A.U., arbitrary unit, representative for 2 independent experiments.    
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5.3 Discussion 
 
5.3.1 MMP-8 Expression does not Affect the Level of TGF-β Activity 
Potentially Down-regulates Downstream Signalling 
 
The preliminary data presented here showed that there was no significant 
difference in level of TGF-β activation upon MMP-8 WT or MMP-8 EA over-
expression in Myo-β6 cells. Similarly knock-down of MMP-8 in Myo-Puro did 
not result in a significant difference in TGF-β activity. The analysis of level of 
TGF-β activity was done using a TGF-β luciferase assay [325-327]. In this 
assay, modified MECs were co-cultured with the TGF-β responsive cell 
population MDA MB 231-Luc. The latter carries a TGF-β responsive PAI-
promoter fused with a renilla and a firefly luciferase gene [328, 329]. 
Therefore the level of active TGF-β in the test cell is reflected in the amount 
of luciferase activity of TGF-β responsive cells. In order to test the sensitivity 
of this assay TGF-β responsive cells were also treated with increased 
amounts (pg/ml levels) of active TGF-β and this resulted in a stepwise 
increase in luciferase activity as expected (data not shown). This Dual-
Luciferase reporter assay system allows quantification of the background 
luciferase activity created by background control renilla luciferase gene. 
Therefore this assay is sensitive and also carries an internal control. Myo-β6 
cells are over-expressing αvβ6 which is responsible for the activation of 
TGF-β by MECs. Therefore MMP-8 over-expression might not result in a 
significant difference in behaviour since Myo-β6 cells are engineered to 
express high levels of a TGF-β activator. Conversely in the Myo-Puro system 
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the levels of active TGF-β may be lower than the sensitivity level of the 
experiment [325]. In the future this assay will be repeated co-culturing a 
greater number of modified Myo-Puro cells with the responsive cell line. 
   
Further investigation of TGF-β downstream elements showed that MMP-8 
appears to have an inhibitory effect on TGF-β signalling. This analysis was 
done by checking phosphorylation levels of SMAD-2 and SMAD-3 after 
stimulating the MECs with active TGF-β. SMAD-2 and SMAD-3 
phosphorylation levels appear to decrease in cells following MMP-8 WT over 
expression. There also was a trend of reduced phospho SMAD-2 and 
SMAD-3 in MMP-8 EA over-expressing Myo-β6 cells. In addition there 
appears to be a change in total SMAD-2 or SMAD-3 levels after MMP-8 WT 
or MMP-8 EA over-expression. The variation in SMAD-2 and SMAD-3 
phosphorylation levels meant that a significant difference could not be 
determined, and these experiments need to be repeated. In MMP-8 knock 
out Myo-Puro system SMAD-2 and SMAD-3 appeared to increase. This 
assay was performed twice only due to time constraints therefore statistical 
analysis could not be run. In the future these experiments need to be 
repeated to obtain a significant result. This is of particular importance since it 
would provide insight into the mechanism of MMP-8 action.  
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6 Final Discussion and Future Work 
  
6.1 Overview of the Aims 
 
MECs of normal breast are robust tumour suppressor cells surrounding 
LECs and establishing the interface with BM [79, 117]. During breast cancer 
progression at the stage of DCIS stage they exhibit phenotypic alterations 
and eventually disruption of an intact MEC layer leads progression to 
invasion [58-60, 79]. One of the changes in DCIS MECs shown by our group 
was the apparent down-regulation of the tumour suppressor protein MMP-8 
[215]. In this study we aimed to study the functional significance of this 
change; whether MMP-8 contributes to the in tumour suppressor function of 
MECs in normal breast and whether its loss in DCIS is implicated in altered 
MEC phenotype which ultimately contributes to breast cancer cell invasion. 
 
6.2 MMP-8 Expression Influences Phenotype of DCIS MEC Model 
 
A consistent alteration observed in MECs of DCIS is the up-regulation of 
αvβ6 integrin, which we have shown to alter MEC suppressor function [275]. 
In the current study we established cell lines to study the re-introduction of 
MMP-8 expression in DCIS-associated MECs using a MEC line over-
expressing αvβ6, to recapitulate the in vivo phenotype. Investigation of MEC-
ECM interaction was analysed by means of MEC spread, adhesion and 
migration on several ECM proteins. This showed that MMP-8 can induce 
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spread and adhesion and reduces migration towards a number of ECM 
molecules. These results led to the hypothesis that MMP-8 could be involved 
in stationary anchorage of MECs to the ECM which implicates a role for 
MMP-8 in preserving the normal tissue architecture.  
 
It was previously shown by our lab that the DCIS-associated MEC model up-
regulates adhesion and migration to the αvβ6 ligand LAP [275] and this could 
be ablated by an αvβ6 blocking antibody. Adhesion and migration to LAP can 
be used as readout for αvβ6 activity. In the current study it was shown that 
MMP-8 over-expression down-regulates adhesion and migration to LAP 
therefore it can be hypothesised that MMP-8 over-expression might result in 
a reduction in αvβ6 activity. Since binding of αvβ6 to LAP triggers TGF-β 
activation; active TGF-β levels and TGF-β down-stream signalling was 
further studied.  
 
MECs are the basal cells of breast tissue and express the unique basal cell 
integrin α6β4 [234-237]. The extensive study on the role of this integrin in cell 
migration, especially in basal skin keratinocytes [244, 245], showed that 
shuttling of α6β4 from adhesive HDs to filopodial structures dictates whether 
cells will migrate [248, 253]. Here we showed that in the presence of MMP-8 
α6β4 localises more to HDs and filopodia/retraction fibre formation is down-
regulated, which corresponds to a reduced migratory phenotype. Together 
these results suggest a role for MMP-8 in modulating integrin activity.    
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The effect of MMP-8 appears to be dependent on its proteolytic function 
since over-expression of a catalytically dead mutant in DCIS associated 
MEC system did not result in significant effect on MEC phenotype. 
 
One of the striking differences found in DCIS associated MEC is the over-
expression of proteases. Considering the MEC layer establishes a barrier 
between LECs and BM in normal breast tissue it was speculated that 
enhanced protease expression by MEC could contribute to primary breast 
cancer cell invasion through BM. In fact it was shown by our lab that DCIS 
associated MECs up-regulate MMP-9 as a downstream response to TGF-β 
activity [275]. Intriguingly in the current study the gelatinase activity of DCIS 
associated MEC is down-regulated by MMP-8 expression.   
 
In our normal MEC model MMP-8 was knocked down and this showed that, 
conversely to the over-expression system, the loss of MMP-8 reduces 
adhesion but induces migration to several ECM proteins and enhanced 
gelatinase activity of Myo-Puro cells. Moreover in the absence of MMP-8 
formation of filopodia/retraction fibres were shown to be up-regulated which 
suggests an increased migratory phenotype in MECs.  
 
In the future, time lapse microscopy will be done to quantify the migratory 
phenotype of modified MECs. This would allow investigation of cell 
movement, speed and behaviour on different ECM proteins.  
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To gain a better understanding of the contribution of MMP-8 in preserving 
normal tissue architecture modified MECs and breast cancer cells will be 
embedded in organotypic gels to recapitulate the microenvironmental cues of 
cell-cell interactions. The generation of dual layered duct like formations in 
Collagen based gels have previously been developed in our lab [299].  
 
It was previously shown that MMP-8 and MMP-9 could establish a complex 
[209] but the functional significance of this complex is not known. In this 
study we showed that MMP-8 might have an inhibitory role on MMP-9 activity 
without changing MMP-9 expression levels. Therefore it was hypothesised 
that MMP-8 might bind and therefore inhibit MMP-9 action. For detailed 
analysis of MMP-8 interactor proteins, MMP-8 will be purified from modified 
MECs and a mass spectrometry approach will be taken to dissect the MMP-8 
complexes. Furthermore a microarray approach will be taken to analyse 
differentially expressed genes upon MMP-8 over-expression in Myo-β6 cells 
or MMP-8 knock-down in Myo-Puro cells. 
 
Taken together, these results lead to the hypothesis that MMP-8 contributes 
to reversion of the DCIS related MEC phenotype into a normal tumour 
suppressor phenotype, by modulating integrin activity and other members of 
MMP family (MMP-9). 
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6.3 MEC Derived MMP-8 Reduces Breast Cancer Cell Invasion 
 
The interaction of cancer cells with cells of the microenvironment is needed 
to generate an invasive phenotype [64, 65]. It was previously shown by our 
lab that DCIS associated MECs up-regulate breast cancer cell invasion 
compared to normal MECs [275]. Interestingly in the current study over-
expression of MMP-8 WT down-regulates breast cancer cell invasion in 2D 
and 3D organotypic systems. In contrast the loss of normal MEC derived 
MMP-8 resulted in up-regulation of breast cancer cell invasion. This result 
underlines the importance of microenvironmental control of breast cancer cell 
invasion and implicates a role for an MMP to suppress invasion. The results 
also emphasise the unique role of MECs in early stages of breast cancer.    
 
In the future the organotypic cultures will be implanted into the flanks of mice 
to determine whether any effects on breast cancer cell invasion in vitro 3D 
cultures are replicated in vivo. These assays will be repeated with primary 
MEC and fibroblast populations.  
 
For detailed investigation of how MEC-derived MMP-8 interacts in paracrine 
way with breast cancer cells, receptors such as chemokine receptors 
expressed by breast cancer cells will be studied. For example LIX was 
shown to be processed by MMP-8 [208]. In the future cleavage of this 
chemokine by MECs will be investigated.  
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6.4 MMP-8 might Modulate TGF-β Signalling 
 
In this study we present preliminary data to imply that MMP-8 could inhibit 
TGF-β activity. TGF-β is a protein involved in many stages of breast cancer 
and exhibit dual function dependent on disease stage (Section 1.6) [284-
286]. We are particularly interested in the involvement of TGF-β activity in 
crosstalk between MECs, breast cancer cells and the fibroblasts during 
primary breast cancer cell invasion. In the future the detailed analysis of 
MMP-8 and TGF-β interaction could provide information on mechanism of 
action of MMP-8.  
 
6.5 MMP-8 as an Anti-target for Cancer Therapy   
 
Here we presented data that microenvironmental derived MMP-8 can act as 
a tumour suppressor by influencing cell-ECM as well as cell-cell interactions, 
in part, by modulating integrin, growth factor and other MMP family members 
function. This further supports the growing evidence that the role of MMPs is 
much more complex than just ECM degradation.  
 
Based on the data presented in this study we proposed that MMP-8 is an 
anti-target for breast cancer therapy. It is of crucial importance to identify the 
anti-target proteins in order to tailor MMPI trials to spare anti-targets over 
tumour favouring MMPs [147]. Several other MMP family members have 
been shown to exert tumour suppressor roles, for example MMP-12 [135, 
174-176]. Moreover, according to disease stage some members could act as 
  
220 
 
tumour suppressor or promoter (MMP-9) [135, 165, 174-176]. Therefore 
spatiotemporal regulation of MMP function needs to be dissected carefully to 
create a detailed knowledge which is likely to be essential to develop 
successful inhibitor approaches.  
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7 Appendices 
 
7.1 Appendix 1 
 
7.1.1 The Effect of Recombinant MMP-8 Stimulation of Myo-β6 Cells on 
Filopodia/Retraction Fibre Formation 
 
In order to confirm the autocrine effect of MEC derived MMP-8, (parental) 
Myo-β6 cells were seeded on fibronectin and cultured overnight, then treated 
with 50ng/ml rhMMP-8 (prepared in SFM) for 24 hours. After that IF staining 
for α6β4 and phalloidin was done as described in Section 2.18. Control 
group was generating by treatment with vehicle only.  
 
There was a significant reduction in filopodia/retraction fibre number per cell 
(p=0.03, n=1) in recombinant MMP-8 treated group. This result corresponds 
to the observations in MMP-8 over-expression.  
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Figure 7-1: Effect of recombinant MMP-8 stimulation on Myo-β6 
filopodia/retraction fibre formation. A. Myo-β6 cells were stimulated with 
rMMP-8 for 24 hours and filopodia/retraction fibre number per cell was 
counted by using ImageJ. Bar 20 μm. B. A significant reduction in 
filopodia/retraction fibre number was observed in recombinant MMP-8 
treated group when compared to vehicle control.  rMMP-8., recombinant 
MMP-8, representative for 1 experiment.  
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7.1.2 Effect of MMP-8 Knock-down on Myo-Puro Migration Over 
Collagen-I in Short Incubation Period  
 
In order to investigate the effect of MMP-8 knock-down on Myo-Puro 
migration in short incubation to analyse whether the length of incubation time 
mask the significant effect of MMP-8, the migration assay was set up as 
described in Section 2.15, but incubated for 4 hours rather than 8 hours. 
MMP-8 loss showed no significant effect in Myo-Puro migration over 
Collagen-I after 4 hours incubation (p=0.55, n=1). This result is concomitant 
to observations after 8 hours incubation (Section 3.3.11).  
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Figure 7-2: Effect of MMP-8 knock-down in Myo-Puro cell migration 
over Collagen-I in short incubation. Migration assay was done as 
described in Section 2.18. Incubation was done for 4 hours. There was no 
significant difference in migration to Collagen-I between siMMP-8 treated 
Myo-Puro cells or control group. A.U., arbitrary unit, n.s., not significant, 
representative for 1 experiment. 
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7.2 Appendix 2  
7.2.1 List of MMP-9 Antibodies Used in WB 
 
Two MMP-9 antibodies were used in WB, however failed to reveal a specific 
band for MMP-9. 
 
Company  Host Cat no Outcome 
Santa Cruz Goat sc-6841 Unspecific bands  
Calbiochem Mouse IM09L No band 
Table 7-1: List of antibodies MMP-9 antibodies  
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7.3 Appendix 3 
 
7.3.1 Plasmid Digest  
 
To check the presence of MMP-8 WT insert in pcDNA4 vector, 4 clones of 
pcDNA4-MMP8 construct were digested as described in Section 2.4. MMP-8 
EA containing pcDNA4 vector was also analysed and digest generated 5000 
bp and 1400 bp expected bands (data not shown).   
 
Sequencing  
 
 
Figure 7-3: MMP-8 insert containing pcDNA4 digest result. Expected 5kb 
and 1.4kb bands were seen. Bp., base pair.  
 
7.3.2 Plasmid DNA Sequencing 
 
MMP-8 was sequenced using T7 primers and subsequent primers designed 
for the MMP-8 sequence. The sequencing reaction was carried out by 
genome centre using Big Dye Terminator v3.1 protocol. Resultant sequences 
were joined together using CLL sequence viewer (version:6) and the 
resultant sequence compared with the NCBI sequence for NM 002424.2. 
This analysis identified mutations in the sequence. This result in a T>I 
(translation frame position: 34) and K>E (translation frame position: 89) as 
shown on following pages.   
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Primer Sequence 5’-3’ 
Sequence-1 CACATTTTGATGCCGAAG 
Sequence-2 TAATCAACTATGCCTCCAGC 
Table 7-2: Primers used to check the presence of full length coding 
sequence of MMP-8 in pcDNA4 V5 His vector.  
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